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Abstract 
In eukaryotic organisms, regulation of gene expression at the transcriptional 
level is a fundamental mechanism which is evolutionary conserved in all cellular 
systems. It tightly regulates the diversification in expression patterns of genes and 
proteins required for biological complexity and function. Transcriptional regulation is 
mediated by the physical interaction between transcription factors and specific cis-
acting regulatory elements in gene promoter regions. Myocyte enhancer factor 2 
(MEF2) is a transcription factor highly conserved in eukaryotes involved in 
differentiation, proliferation, and survival/apoptosis. The MEF2 gene family (MEF2 
A-D) regulates development of various tissue types including muscle (skeletal, 
cardiac, and smooth muscle), bone, lymphocytes and neurons. The regulation of 
MEF2 activity is complex, and is coordinated at multiple levels including 
posttranslational modifications and protein-protein interaction, that together modulate 
MEF2's function. Conversely dysregulation of MEF2 activity underlies pathogenesis 
in muscle and neuronal cells. MEF2 is responsive to various signaling cascades which 
provide a way for distinct stimuli to differentially regulate MEF2-dependent gene 
expression. It is known that phosphorylation by kinases is an important process 
through which the activity of MEF2 is up- or down-regulated. Several kinases 
(p38MAPK, CDK5, PKC, and ERK.5) have been linked to muscle and neuronal 
development, as well as survival in part due to their modulation of MEF2 function. In 
addition MEF2 is known to be targeted by co-repressors, such as class Ila histone 
deacetylases (HDAC 4, 5, 7 and 9). This interaction contributes to repression of 
IV 
MEF2-dependent gene expression. Although MEF2 family members are critical 
regulators of skeletal muscle differentiation and cardiovascular function their 
individual roles within nervous system are less well characterized. 
In current studies, we attempted to investigate the posttranslational regulation of 
MEF2 both in myogenic and neurogenic cells. The cAMP/protein kinase A (PK.A) 
signaling pathway regulates a variety of cellular functions and numerous important 
biological processes. Many of the effects of cAMP /PKA are mediated via changes in 
gene expression. We have previously documented that cAMP/PKA signaling 
negatively regulates MEF2 activity and inhibits myogenes1s by direct 
phosphorylation of MEF2 proteins. MEF2 A-D are highly expressed in multiple 
regions of the brain, including cortex, cerebellum, and hippocampus. Distinct patterns 
of expression during pre- and postnatal development suggest specific functions for 
MEF2 proteins at different stages of neuronal maturation and survival. However, 
whether the cAMP /PK.A pathway inhibits MEF2 mediated gene expression in 
neurons was unclear. Recently, we evaluated whether cAMP/PKA signaling can 
inhibit MEF2-dependent gene expression directly or indirectly and survival role of 
MEF2D in hippocampal neurons. We performed survival assays to determine PKA 
effects in neuronal cells. We observed that experimental induction of cAMP /PKA 
signaling promotes apoptosis in primary hippocampal neurons as indicated by 
TUNEL and F ACS analysis. Luciferase reporter gene assays revealed that PK.A 
potently represses MEF2D trans-activation properties in neurons. Kriippel-like factor 
6 (KLF6) was identified as a key transcriptional target of MEF2 in hippocampal 
neurons and siRNA mediated knockdown of KLF6 expression promotes neuronal cell 
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death and also antagonizes the pro-survival role of MEF2D. In this study, we found 
that cAMP/PKA signaling represses KLF6 transcriptional activity and induce 
neuronal apoptosis by phosphorylating MEF2 and preventing HDAC4 export from 
the nucleus. These observations characterize a potent inhibitory effect of PKA on the 
transactivation properties of MEF2D leading to repression of KLF6 expression and 
compromising neuronal survival (Chapter III). 
Next, we were interested to determine how MEF2 controls diverse cellular 
processes in muscle development in the presence/absence of cofactors. Tandem 
Affinity Purification (TAP) combined with mass spectrometry analysis was employed 
in the current studies to identify MEF2 interacting cofactors. We identified 
Strawberry notch 1(Sbno1) as a novel interacting factor of MEF2D which is known to 
be downstream effecter of Notch signaling. Notch signaling is known to block the 
expression and activity of myogenic factors such as MEF2s. We therefore 
characterized the mechanism of myogenic inhibition by Notch-Sbnol signaling. 
C2C 12 myoblasts provide a useful in vitro model to study skeletal muscle 
differentiation. We determined the expression patterns, by western blot analysis, of 
muscle specific gene expression during myogenesis. Sbno 1 represses MEF2 
transactivation properties and plays a critical role in inhibition of skeletal muscle 
differentiation. Immunocytochemistry analysis suggests that Notch-Sbno 1 might be 
involved in maintaining the "reserve" cell population. Our data suggested that 
protein-protein interactions between Sbno 1 and MEF2D result in interference with 
the function of myogenic factors (Chapter IV). 
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MEF2D is a known transcriptional regulator of muscle differentiation. Current 
studies identified KLF6 as a novel MEF2D target gene which is involved in 
hippocampal neuronal survival. TGF~ has been reported as a potent inhibitor of 
myogenic differentiation by maintaining myoblasts in a proliferative state 
(undifferentiated myoblasts). Further, TGF~ and KLF6 regulate each other's 
expression in other cell types. We therefore sought to investigate the possible role of 
KLF6 in a myogenic context and assessed whether TGF~ activation regulates KLF6 
protein expression and function in a MEF2 dependent manner in C2C 12 myoblasts 
(Chapter V). 
Taken together, these studies indicate that differential activation of signaling 
cascades and co-factors regulate the MEF2 transcriptional complex which has 
profound effects on gene expression in myogenic and neurogenic cells. 
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Chapter I: Literature Review 
In higher eukaryotes, each cell type has a unique molecular organization that is 
ultimately controlled by a complex network of transcription factors, which activate 
or repress transcription of a multitude of downstream genes (Brivaniou & Darnell 
Jr., 2002). Transcription factors are DNA binding proteins that regulate gene 
expression by binding to promoter regions proximal to gene transcription start sites 
(TSSs) or to more distal enhancer regions that regulate expression through long-
range interactions (Farnham, 2009). The instructions for gene expression are started 
with the initiation of transcription process that involves the transcribing of genetic 
information from DNA to RNA. There are three major steps to the process of DNA 
transcription including binding of transcription machinery to DNA, elongation, and 
termination (Brivaniou & Darnell Jr., 2002). Transcription factor binding to DNA 
requires appropriate binding cis-elements which help to define regulatory elements 
initiation sites within the genome. Transcription factor binding depend upon cell 
types, and one major factor contributing to this cell type-specific binding is 
physiological function (Howard & Davidson, 2004). However, the binding of 
transcription factors to their cognate sites is often insufficient to account for the 
patterns of expression of their target genes (Figure 1 ). Many transcription factors 
are also relatively weak transcriptional activators and function by recruiting co-
activators/co-repressors that do not bind DNA directly but regulate transcription in 
a DNA sequence specific manner by associating with DNA-bound factors 
(Spiegelman & Heinrich, 2004). 
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Figure 1: Schematic of regulation of transcription initiation of a typical 
eukaryotic gene. 
The process of embryonic development, cell growth, differentiation, and 
survival are tightly connected with the regulation of gene expression that require 
extracellular and intracellular signals and subsequent activation of cascades of 
signalling machinery (McKinsey et al. 2002). The !!!)'Ocyte ~nhancer factor 
(MEF2), a family of transcription factor, have been shown to play critical role in 
transmitting extracellular signals to the genomic machinery and in the activation of 
the genetic programs that control critical cellular processes including cell 
proliferation, differentiation, morphogenesis, and survival of wide range of tissue 
types including muscle, T cells, and neurons (Matthew & Olson 2007). In adult 
tissues, . MEF2 also serves as a key regulator of stress responses and adaptive 
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programs m response to environmental signals, including fiber-type switch of 
skeletal muscle, cardiac hypertrophy, activity-dependent remodeling of neuronal 
synapses, and neuronal survival (Omatsky & McDermott, 1996; Flavell et al. 2006 
& 2008; Salma & McDermott, 2012; Akhtar et al. 2012). 
1. Evolution and origin of MEF2 genes 
Changes in genes encoding transcriptional regulators represent the most 
important determinants of morphological evolution in plants and animals (Degnan 
et al. 2009; Wu et al. 2011 ). A duplication event occurred more than a billion years 
ago in the MADS (MCMl, ~amous, geficiens, ~erum-response factor) box lineage 
before the divergence of plants from fungi and animals (Theissen et al. 1996; 
Alvarez-Buylla et al. 2000). The evolution of the MADS-box gene subfamilies 
based on the taxonomic distribution revealed that each family member comprises 
highly conserved putative orthologs and recent paralogs (Theissen et al. 1996; Wu 
et al. 2011 ). Phylogenetic analysis has shown that at least one ancestral MADS-box 
gene duplicated in the common ancestor of the major eukaryotic kingdoms to give 
rise to the distinct Type I (SRF-like) and Type II (MEF2-like) lineages found in 
plants, animals, and fungi (Alvarez-Buylla et al. 2000) (Figure 2). The defined 
species distribution, specific function, and strong evolutionary conservation of the 
MADS-box gene subfamilies suggest that establishment of different subfamilies 
occured during eukaryotic evolution by rapid fixation (Alvarez-Buylla et al. 2000). 
The evolution of MEF2 proteins is linked to their diverse role to the origin of 
3 
novelties in multicellular eukaryotes and function at the core of an ancient 
regulatory network for diverse tissue formations (Genikhovich & Technau, 2011). 
Type I 
Animals (SRF); Yeast (Mcm1) 
Plants (AGL) 
Animals (MEF2); Yeast (Rlm1) 
Plants (Agamous) 
Figure 2: Schematic representation of the protein domains of plant, animal, 
and fungal Type I (SRF-Iike) and Type II (MEF2-Iike) MADS-domain 
proteins. 
1.1. MADS-box proteins 
The MADS-box encodes a novel DNA-binding domain found in a diverse 
group of transcription factors from yeast, animals, and plants. Members of the 
MADS-box transcription factor family play essential roles in developmental process 
4 
in plants and animals (Shore & Sharrocks, 1995). Many MADS-box genes have 
conserved functions across the animals, but some have acquired novel functions in 
specific species during evolution. The analyses of MADS-domain protein 
interactions and target genes have provided new insights into their molecular 
functions (Shore & Sharrocks, 1995). The MADS- box genes encode for a family of 
highly conserved transcriptional regulators. The earliest members of MADS family 
identified as MCMl from yeast (Saccharomyces cerevisiae) (Passmore et al. 1989), 
AGAMOUS from plant (Arabidopsis thaliana) (Yanofsky et al. 1990), DEFICIENS 
from plant (Antirrhinum majus) (Sommer et al. 1990), and serum response factor 
(SRF) from human (Homo sapiens) (Norman et al. 1988). Plants contain a 
considerable number of MADS-box genes (e.g. 107 in A. thaliana). By contrast, 
only a few MADS-box genes are present in animals (two in Drosophila 
melanogaster, and five in human) and four in yeast, S. cerevisiae (Shore & 
Sharrocks, 1995). MADS- box proteins involves in a diverse range of important 
biological functions such as morphogenetic development in plants (Thakare et al. 
2008; Adamczyk & Fernandez, 2009), immediate early gene expression, 
differentiation and maintenance in animals (Black & Olson, 1998; Potthoff & 
Olson, 2007; Flavell et al. 2008), cell-type-specific transcription and pheromone 
response in yeast (Herskowitz, 1989; Shore & Sharrocks, 1995). These gene 
subfamilies may have been essential prerequisites for the establishment of several 
complex eukaryotic body structures, such as muscles in animals and certain 
reproductive structures in higher plants, and of some signal transduction pathways 
(Molkentin & Olson, 1996; Thakare et al. 2008; Adamczyk & Fernandez, 2009). 
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The MADS-box proteins are characterized by the MADS domain considered 
to consist of 55-60 amino acids in the N terminal region responsible for DNA 
binding, protein dimerization, and cofactor interactions (Pellegrini et al. 1995; 
Shore & Sharrocks, 1995; Ng & Yanofsky, 2001; Immink et al. 2002; Messenguy 
& Dubois 2003). The MADS domain folds into an N-terminal extension, followed 
by a long amphipathic a-helix and two antiparallel ~-strands. Most MADS proteins 
bind to A/T-rich DNA sequences in common. However, there are distinct consensus 
sequences: SRF binds as a homodimer specifically to a 10-bp consensus region 
CC(A/T)6GG, called the CArG-box or SRF site (Pollock & Treisman, 1990), 
whereas MEF2 proteins bind to another 10-bp consensus CT A(A/T)4 TAG, called 
MEF2 site (Pollock & Treisman, 1991; Andres et al. 1995). In general, MADS-box 
family members tend to share highly similar sequences, expression patterns, and 
related functions. Previous analyses revealed that the highly conserved MADS-box 
domain, in SRF and MEF2 proteins, is highly critical for maintaining the 
configuration of the DNA binding and for protein dimerization (Shore & Sharrocks, 
1995). There are few striking differences between SRF- and MEF2-type MADS 
domains. SRF-type MADS domains has a highly conserved basic residue Lysine 
(K), whereas the corresponding position of MEF2-type MADS domains has a 
conserved acidic amino acid, which cannot interact with the DNA phosphate, as the 
basic residue (K) of SRF-type does. Despite the absence of C-terminal, the MADS 
domains of SRF and MEF2 remain sufficient to mediate the correct DNA-binding 
specificity (Nurrish & Treisman, 1995; West et al. 1997; Santelli & Richmond, 
2000). In addition, the analysis of MADS domains in bacteria and phage showed 
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that these MADS domains are more similar to MEF2-type MADS domains than to 
SRF-type MADS domains. In mammals, there is only one SRF and four members 
of the MEF2 family, in addition with their greater diversity by alternative splicing 
variants, belonging to the MADS-box superfamily (Theissen et al. 1996). The 
binding sites for these factors are similar to each other containing A/T-rich DNA 
sequences. However, there are many different properties between SRF- and MEF2-
binding sites in line with the differences between the SRF- and MEF2-type MADS 
domains (Chambers et al. 1992). 
1.2. MEF2 proteins 
MEF2 are evolutionary conserved proteins among all family members and act 
as a key determinant factor in both muscle and neuronal development in vertebrates 
and invertebrates (Potthoff & Olson, 2007). The N-terminus of MEF2 proteins 
share about 50% identity overall and 95% similarity in the highly conserved 
MADS-box (consists of 58 amino acids) and an adjacent MEF2 domain (consists of 
29 amino acids) (Shore & Sharrocks, 1995; Black & Olson, 1998). The MADS-box 
domain mediates dimerization of MADS-box proteins and DNA-binding to an A/T 
rich sequence in gene regulatory region, whereas MEF2 domain binds preferentially 
to the consensus sequence CTA(A/T)4 TA(G/A), found in the control region of most 
muscle specific genes (Gossett et al. 1989; Pollock & Treisman, 1991). The MEF2 
domain is specific to MEF2 family of proteins require for high affinity DNA-
binding, co-factor interaction and dimerization (McDermott et al. 1993; McKinsey 
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et al. 2002). The MADS-box and MEF2 domain are mandatory and sufficient for 
DNA binding but lack transcriptional activity on their own (Omatsky et al. 1996) 
(Figure 3A). Interestingly, previous studies revealed that MEF2 domain are not 
required for DNA binding but are essential for site-specific transcription, suggesting 
a functional relationship between MEF2 domain and transcriptional activation 
domain (TAD) (Molkentin et al. 1996). Mutation of MEF2 binding sites severely 
diminishes its expression and MEF2 mediated target genes (Molkentin et al. 1996; 
Potthoff & Olson, 2007). The organization of the MEF2 genes is identical within 
conserved regions, from Drosophila to Homo sapiens, indicate that they evolved 
from a common ancestral MEF2 gene present in invertebrates (Breitbart et al. 1993; 
Lilly et al. 1994). 
N 
Figure 3A: Schematic of MEF2 protein. The MADS and MEF2 domains are 
shown at the N-terminus and transcriptional activation domain locates at C-
terminus. 
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The C-terminus of MEF2 proteins is more divergent amongst the MEF2 
members and acts as a transcriptional activation domain (TAD), as revealed by 
sequence analysis. This region is subject to extensive alternative splicing, multiple 
post-translational modifications, and interactions with a number of other proteins 
which regulate the ability of MEF2 to activate transcription (Black & Olson, 1998) 
(Figure 3A). Recent studies have demonstrated that structure-function relationship 
of the C-terminus of MEF2 is very important in several tissue types (Han & 
Molkentin, 2000; Potthoff & Olson, 2007). MEF2A has been shown to contain a 
nuclear localization §equence (NLS) at its extreme C-terminus, which is conserved 
in MEF2 family members. When the NLS is deleted, MEF2 fails to localize to the 
nucleus (Yu et al, 1992). 
1.2.1. MEF2 isoforms 
In vertebrate, MEF2 proteins are encoded by four genes MEF2 A, -B, -C, and 
-D, which are expressed in distinct but overlapping temporal and spatial expression 
patterns during embryogenesis and in adult tissues, with highest expression in 
mature skeletal, cardiac and smooth muscle cells, as well as in neurons and at lower 
levels in several other cell types. (Pollock & Treisman, 1991; Yu et al. 1992; 
Breitbart et al. 1993; McDermott et al. 1993; Leifer et al. 1993; Martin et al. 1993, 
Martin et al. 1994; Edmondson et al. 1994; Lyons et al. 1995; Ticho et al. 1996). 
MEF2 A, -C, and -D bind the MEF2 consensus sequence with high affinity as a 
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homo/heterodimer whereas MEF2B fails to bind as a homodimer in vivo or in vitro 
(Pollock & Treisman, 1991; Yu et al. 1992) (Figure 3B). 
hMEF2A 
hMEF2B 
hMEF2C 
hMEF2D 
Yeast 
MEF2 
Drosophila 
MEF2 
C.elegans 
MEF2 
DNA Binding/ 
Dimerization 
Domain 
Transcriptional Activation 
Domain 
~---'-"~--........ ..-----------'-" ,- ~r' ...... ---------~~ 
1 57 88 507 
MADS MEF2 
Figure 3B. Schematic of Myocyte Enhancer Factor2 in diverse species. 
Vertebrates have four MEF2 (MEF2 A, B, C, and D) whereas, Yeast 
Drosophila and C. elegans possess a single MEF2 gene. The conserved N-
terminal contains the MADS box and MEF2 regions, which together mediate 
DNA binding, dimerization, and co-factor interactions. The C-terminal regions 
are divergent among family members that mediate transcriptional activities, 
interactions with other proteins and subject to complex patterns of alternative 
splicing and posttranslational modifications. This figure is adapted from the 
article by Potthoff & Olson 2007. 
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In contrast, in Drosophila, Caenorhabditis elegans, and S. cerevisiae, there is 
a single MEF2 gene (Potthoff & Olson, 2007). In yeast (S. cerevisiae), the MEF2 
homo log Rlm 1 binds the same DNA sequence as the vertebrate MEF2 proteins, 
regulated specific gene expression in response to mitogen-activated protein (MAP) 
kinase activation (Dodou & Treisman, 1997). The number of MEF2 genes in 
primitive vertebrates is not yet evident, but invertebrate chordates, including a 
Urochordate (sea squirt, Ciona sp) and a Cephalochordate (amphioxus, B floridae), 
have but one. All established mammalian genomes have four MEF2 gene isotypes 
(Wu et al. 2011). By contrast, metazoa ranging from Porifera (sponges) and 
Cnidaria (coral, hydra, and jellyfish) through Arthropoda (insects and crustaceans) 
and Echiniodermata (sea urchin) have a single MEF2 gene (Genikhovich & 
Technau, 2011). 
A cnidarian MEF2 homologue, PcMej2, was first reported in the hydrozoan 
Podocoryne carnea (Spring et al. 2002). Nvmej2 was identified in the sea anemone, 
Nematostella vectensis, and mentioned as an ectodermally expressed gene 
(Martindale et al. 2004). The Nvmef2 transcript was found in single cells throughout 
embryonic and larval development (Martindale et al. 2004; Govich & Technau 
2011 ). These cells are considered to be precursors of neurons or sensory stinging 
cells (cnidarian-specific nematocytes) (Watanabe et al. 2009). 
11 
1.2.2. Alternative Splicing 
Alternative splicing is a major mechanism of generating protein diversity in 
higher eukaryotes. Recent genome-wide studies suggest that more than 50% 
mammalian genes, including many therapeutic target genes, produce multiple 
protein isoforms through alternative splicing and alternative usage of transcription 
initiation and/or termination (Caceres & Kornblihtt, 2002; Pan et al. 2008; Luco et 
al. 2011 ). The role of alternative promoter is particularly critical in transcriptional 
regulation, since their precise utilization allows the balanced expression of 
corresponding transcript variants in different tissues and developmental contexts 
(Genikhovich & Technau, 2011). Altered expression of transcript variants and 
protein isoforms for numerous genes is linked with diseases (Singh & Cooper, 
2012). MEF2 mRNAs, proteins, and sequence-specific DNA-binding activities are 
widely expressed, but target gene activation is highly restricted among tissues and 
cell types but additional condition may also be pertinent, including regulated 
expression of splicing isoforms with distinct functions (Zhu et al. 2005). 
The C-terminal region of each vertebrate MEF2 transcripts is capable of 
generating multiple isoforms through a complex pattern of alternative splicing that 
are conserved among vertebrates. These splicing patterns use alternative exons and 
splice versus no-splice options that include or exclude a short domain (Zhu et al. 
2005). Several splicing variants of the four MEF2 transcripts were identified in the 
original cDNA cloning work (Zhu et al. 2005). MEF2A was the first MEF2 to be 
identified (Yu et al. 1992; Pollock & Treisman, 1991), and four splicing variants are 
encoded by the MEF2A gene of all vertebrates (Zhu et al. 2005). Three additional 
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vertebrate MEF2 isoforms, MEF2B, -C, and -D, were subsequently identified 
(Black & Olson, 1998). There are four alternatively spliced exons/domains, termed 
al, a2, ~' and y, which give rise to numerous tissue-restricted MEF2 isoforms 
(Figure 4). 
MEF2A 
MEF2B 
MEF2C 
MEF2D 
DNA Binding 
Domain 
~ ~~ 
al 
a2 
Transcriptional Activation 
Domain 
349aa 
507aa 
465aa 
514aa 
Figure 4: Major forms and splice variants of MEF2. Four vertebrate MEF2 
isoforms with indicated alternative splicing exons within the C-terminal 
transcriptional activation domain labelled as al/a2, p and y. The MADS and 
MEF2 domains are shown at the N-terminus of each isoform. This figure is 
adapted from the article by Black & Olson 1998. 
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MEF2D contains an acidic exon (TEDHLDL), which is present only in 
skeletal muscle, heart and brain (Breitbart et al. 1993; Martin et al. 1994). MEF2D 
alternatively spliced exon al (isoform la) is expressed ubiquitously in kidney, 
heart, stomach, PC 12 cells, and neuronal cells, whereas the other exon a2 (isoform 
1 b) expression is restricted in skeletal muscles, a good example of tissue specific 
splice (Martin et al. 1994). MEF2 ~+ isoforms are more robust than~- isoforms in 
activating MEF2-responsive gene expression. ~ function is position-independent 
and exists in all MEF2 splicing variant contexts. MEF2A mRNAs containing an 
acidic ~-exon (SEEEELEL) are expressed predominantly in striated muscle and 
brain, the corresponding region in MEF2C (SEDVDLLL) is present only in skeletal 
muscle and brain (McDermott et al. 1993) and MEF2D (TEDHLDL) is restricted to 
skeletal muscle, heart and brain (Breitbart et al. 1993, Martin et al. 1994). 
MEF2A spliced transcripts that include the ~ exon, are induced during 
.myocyte differentiation (Yu et al. 1992). Studies has shown that MEF2s with the~+ 
exon seem to be more potent in activating MEF2 responsive reporter gene 
expression than MEF2 without the ~ exon, suggesting that alternative splicing 
variants may possess distinct regulatory capabilities in vivo (Zhu et al. 2005). The 
third exon (y) is unique to MEF2C genes. This y domain is constitutive in other 
MEF2 isoforms, but y- variants of MEF2C have distinctive function within this 
family (Zhu & Gulick, 2004). The MEF2C y- isoforms are expressed exclusively in 
heart tissue with no evidence of y+ isoforms, however y- isoforms are expressed 
predominantly in other adult tissues such as skeletal muscle and brain (Zhu & 
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Gulick, 2004). MEF2C y- isoforms are much more robust than y+ forms m 
activating MEF2-responsive reporter gene expression (Zhu & Gulick, 2004). 
Expression patterns of the various vertebrate MEF2 isoforms demonstrate a 
conserved pattern of alternative splicing that involve in distinct functions in diverse 
tissue types. However, the expression of the different splice variants is mostly 
overlapping, and there might be some redundancy in function. Alternative splicing 
emerges as critical regulators of MEF2 function that interferes with almost every 
biological function such as proliferation, differentiation, and survival of myogenic 
and neurogenic cells. 
1.3. MEF2 expression in diverse tissue 
The MEF2 family of proteins was originally identified as a regulator of muscle 
specific gene expression that recognized with an A/T rich cis element in the muscle 
creatine kinase (MCK) enhancer (Gossett et al. 1989; Black et al. 1995). MEF2 
binding sites have subsequently been identified in the promoter or enhancer regions 
of the skeletal, cardiac and smooth muscle genes (Braun et al. 1989; Iannello et al. 
1991; Nakatsuji et al. 1992; Molkentin & Markham, 1993; Wong et al. 1994; Katoh 
et al. 1994; Kolodziejczyk et al. 1999; Anderson et al. 2004; Creemers et al. 2006a). 
However, unlike skeletal muscle restricted transcription factors, MRFs, MEF2 
proteins are extensively expressed in many tissues types, including lymphocytes, 
neural crest, endothelium, bone and neurons (Leifer et al. 1993; McDermott et al. 
1993; Leifer et al. 1994; Dodou et al. 1995, Ikeshima et al. 1995; Lyons et al. 1995; 
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Omatsky & McDermott, 1996; Lin et al. 1996; Arnold et al. 2007; Lam & Chawla, 
2007). Several reports have also provided evidence that expression of MEF2 
proteins are ubiquitous (Pollock & Treisman, 1991; Yu et al. 1992; Breitbart et al., 
1993; McDermott et al. 1993; Martin et al. 1994). MEF2 expressed in different 
tissues appear to have distinct preferences for sequences flanking the core region, 
but such selectivity is depending on specific role of MEF2 in diverse tissue types 
(Andres et al. 1995). 
1.3.1. Expression of MEF2 in muscle 
During embryogenesis, the MEF2 transcripts are highly enriched both in 
vertebrates and invertebrates developing muscle cell lineages (Black & Olson, 
1998; Naya et al. 1999). MEF2C is the first member of MEF2 family to be 
expressed during mouse and chick embryo development (Edmondson et al. 1994 ), 
appearing in the cells of precardiac mesoderm at 7.5 dpc that give rise to the heart 
(Edmondson et al. 1994) Soon thereafter, transcripts for MEF2A, MEF2C and 
MEF2D were detected in the developing myocardium at 8.5 dpc. In the skeletal 
muscle, expression of MEF2C appears in the somite myotomes few hours after 
Myf5 and myogenin expression at 9.0 dpc which implicate the critical role ofMEF2 
required for the myoblats differentiation/for the activation of myogenin gene 
expression during the process of myogenesis (Edmondson et al. 1994). MEF2A 
and MEF2D expression are found at lower level than MEF2C in the myotome at 9 .5 
dpc. However, MEF2A, -D are detected more in embryonic tissues than MEF2C 
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transcript. Throughout the embryo development of mouse, MEF2 transcripts are 
expressed in the smooth muscle cells where it precedes the expression of muscle 
structural genes (Anderson et al. 2004). After 12.5 dpc, MEF2 transcripts are 
detected at high levels in various regions of the brain (Lyons et al. 1995). By 14 
dpc, MEF2A, -B,· and -D transcripts begin to be transcribed in a wide range of 
tissue types of vertebrates. In addition, after birth, MEF2A, -B, and -D transcripts 
are also detected ubiquitously in various tissues, except in the brain, where they 
display highly localized expression pattern (Pollock & Treisman, 1991; Edmondson 
et al. 1994; Dodou et al. 1995; Lyons et al. 1995). Only MEF2C transcript is 
restricted to skeletal, cardiac muscle, spleen and brain tissues (Lyons et al. 1995; 
Black & Olson, 1998). 
In cultured skeletal muscle cells, the expression pattern of MEF2 genes during 
differentiation follows a sequentially timing of appearance. MEF2D has been 
reported to be expressed in proliferating myoblasts prior to the onset of 
differentiation, but in fact it does not activate muscle target genes until myoblasts 
exit from the cell cycle (Breitbart et al. 1993; Martin et al. 1994). MEF2A proteins 
start to express as cells enter the differentiation pathway after serum withdraw! and 
MEF2C appears later in the differentiation program (McDermott et al. 1993; Martin 
et al. 1993). It is clear that MEF2 protein is regulated at multiple levels during 
development and differentiation which allow the cells to maintain tight control of 
MEF2 levels in a precise temporospatial pattern (Black & Olson, 1998). 
MEF2 mRNA accumulation appears in a wide range of tissue types but MEF2 
transcriptional activity and protein expression has been reported to be highly 
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restricted to muscle specific cells and neuronal cell lineages (N aya et al. 1999). The 
possible explanation of this disparity may be the repression of posttranscriptional 
and translation regulatory mechanism which limits the MEF2 transcriptional 
activity. Furthermore, MEF2 proteins, particularly MEF2D, demonstrate a 
considerable role in regulating serum induced gene expression in non-muscle cells. 
Previously, it has been found that HeLa cells and NIH3T3 fibroblasts contain 
MEF2 binding activity and considerable expression of MEF2 proteins but MEF2 
lack transcriptional activity in these non-muscle cells (Pollock & Treisman, 1991; 
Ornatsky & McDermott, 1996). This suggests that MEF2 activity is tissue-specific 
and depends on posttranslationally regulated mechanisms (Yu et al. 1992; Breitbart 
et al. 1993). For example, while both muscle (C2Cl2) and non muscle cells (HeLa, 
Schneider, and L6E9) contain considerable MEF2 expression, only C2Cl2 muscle 
cells demonstrate a MEF2 dependent transcriptional activation of muscle specific 
reporter gene (Ornatsky & McDermott, 1996). These observations are also 
supported by in vivo data where MEF2 is restricted to the specific cell lineages in 
the MEF2 sensor mouse during embryo development (Naya et al. 1999). MEF2-
dependent expression was observed in developing myogenic cell lines of the MEF2 
sensor embryo but not in other cell types that also contain MEF2 (Naya et al. 1999). 
In certain conditions MEF2 remain silent and transcriptional activity of MEF2 
proteins can be regulated independent of DNA binding in various cell types (Black 
& Olson, 1998). 
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1.3.2. Expression of MEF2 in neurons 
MEF2 family members are highly expressed in postmitotic neurons throughout 
the central nervous system (CNS) during embryogenesis, as well as in the adult 
(Leifer et al. 1993; McDermott et al. 1993; Leifer et al. 1994; Lyons et al. 1995; 
Ikeshima et al. 1995; Black et al. 1996). In vertebrates, each MEF2 isoform shows a 
unique temporal expression pattern in different regions of the brain. The timing of 
MEF2 expression in the CNS is consistent with a role for MEF2 factors in neuronal 
differentiation and survival (Lam et al. 2007). In human brain, MEF2C transcripts 
are preferentially expressed in certain neuronal layers of the postnatal cerebral 
cortex in a temporal manner declining from postnatal day 2 to adult (Leifer et al. 
1993; Lyons et al. 1995). During brain development the level of MEF2 expression 
increases significantly following withdrawal from the cell cycle in differentiating 
neurons, which suggests the possible contribution to development and function of 
the nervous system (NS) by MEF2 (lkeshima et al. 1995). In an invertebrate NS, 
MEF2 expression has been found in neurons of C. elegans and in mushroom bodies 
of D. melanogaster, and these studies concluded that MEF2 plays a functional role 
in neurogenesis (Schulz et al. 1996; Dichoso et al. 2000). 
In the vertebrate brain, each MEF2 genes shows a unique expression pattern in 
different regions of the brain. All MEF2 isoforms are highly expressed in the 
olfactory bulb, cortex, thalamus, cerebellum, and hippocampus (Leifer et al. 1993; 
Lyons et al. 1995; Lin et al. 1996). The expression pattern of MEF2 correlates 
directly with neuronal maturation during development of the brain (Leifer et al. 
1994). MEF2C is the most extensively characterized of the four MEF2 proteins in 
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the CNS. Indeed, MEF2C was initially cloned on the basis of its enrichment in the 
brain. MEF2C regulates the laminar differentiation of central neurons but absence 
in dividing neurons in the subventricular zones (Leifer et al. 1993; Speliotes et al. 
1996). An alternative splice variant of MEF2C is found exclusively in the brain and 
contains a unique SEDVDLLL peptide sequence in the transactivation domain that 
may serve to mediate tissue specific protein-protein interactions (Leifer et al. 1994). 
In the developing rat cerebral cortex, a high level of MEF2C protein is expressed at 
embryonic day 1 7 to 21 in the cortical plate where postmitotic neurons further 
differentiate and become mature (Mao & Wiedmann, 1999). Cortical cells 
expressing MEF2C also express beta-tubulin type III, but not glial fibrillary acidic 
protein (GFAP), indicate that MEF2C expression is restricted to neurons. More 
importantly, antibody against MEF2C does not stain proliferating neuronal 
precursors identified in primary culture by BrDU, suggesting that MEF2C positive 
neurons are postmitotic. Again, the pattern of expression of MEF2C protein in 
central cortex correlates with the pattern of expression of MEF2C mRNA. 
Interestingly MEF2C is expressed in the adult brain, but not in the developing 
neurons in the cerebral cortex (McDermott et al. 1993; Leifer et al. 1993; Allen et 
al. 2002; Zhu & Gulick, 2004). In contrast, the other MEF2 family members show a 
more restricted expression pattern. MEF2A expressed in the hippocampus, 
thalamus, and internal granular layer of the cerebellum (Lin et al. 1996). The 
pattern of MEF2B expression largely follows that of MEF2A developmentally, but 
it is undetectable outside the olfactory bulb, cortex, and dentate gyrus by adulthood 
(Lyons et al. 1995). MEF2D is highly enriched throughout the developing CNS 
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through adulthood. In the cerebellum and hippocampus, MEF2A and -D proteins 
appear to be the dominant forms, although MEF2C is also expressed (Leifer et al. 
1993; Lyons et al. 1995). In postnatal brain, all four MEF2 transcripts are present in 
the dentate gyms. This dynamic pattern of MEF2 expression during pre- and 
postnatal development suggests that different MEF2 isoforms may perform unique 
roles at different stages of neuronal development. 
In the mouse brain, MEF2C mRNA is first detected in the telencephalon at 
postnatal day 11.5. This region of the brain is one of the first to begin neuronal 
differentiation. At postnatal day 13.5, MEF2C is expressed in a layer of cells in the 
intermediate zone of the frontal cortex and in the olfactory bulb (Lyons et al. 1995). 
At this time MEF2 transcripts are also localized in different regions of the neural 
tube. MEF2A is distributed in a gradient with highest levels in the dorsal portion 
and lowest levels in the ventral portion. MEF2C is expressed only in the dorsal 
region, whereas, MEF2D is distributed throughout the neural tube. At postnatal day 
14.5, MEF2C and MEF2D are detected in frontal cortex, hippocampus, amygdala, 
midbrain, olfactory bulb, and cerebellum. MEF2B is abundant in frontal cortex, 
present at lower levels in the hippocampus, midbrain, and amygdala, and absent in 
the cerebellum (Lin et al. 1996). At postnatal day 16.5, low levels of MEF2A 
overlap with high levels of MEF2C in the hippocampus, midbrain, and frontal 
cortex and midbrain cortex. MEF2D is the most widely distributed of the four genes 
at this time. At birth, the expression pattern of MEF2B and MEF2C overlap in 
frontal cortex and olfactory bulbs (Lyons et al. 1995). MEF2B transcripts appear in 
the cerebellum. In the two weeks postnatal brain, all four genes transcripts are 
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present in dentate gyrus. MEF2A, -C, and -D appear in neurons of the horn of 
Ammon. MEF2C and MEF2D are expressed equally throughout the layers of the 
frontal cortex. Between 2-6 weeks after birth, MEF2 transcripts show a striking 
pattern of differential expression in the mature cerebellum. MEF2A and MEF2D 
are found predominantly in the granule layer of the cerebellum. MEF2C is 
expressed primarily in the Purkinje neurons and MEF2B is very low or absent. This 
dynamic pattern of MEF2A expression during pre- and post-natal development in 
the mouse suggests that different MEF2 isoforms may perform unique roles at 
different stages of neuronal maturation (Lyons et al. 1995; Lin et al. 1996). 
The immunocytochemistry and in-situ hybridization studies indicate that 
MEF2 transcription factors are primarily expressed in differentiating neurons but 
not in dividing neuronal precursors. To date, the extensive immunocytochemical 
studies have not been performed to identifiy the detailed localization of specific 
MEF2 proteins in the brain partly due to the insufficiency of high affinity isoform-
specific antibodies. The data so far indicate that MEF2 protein expression in the 
brain correlates with mRNA expression (Lin et al. 1996). Together, these studies 
suggest distinct MEF2 isoforms may mediate similar functions in different 
populations of neurons, but because of their structural variations they might be 
regulated in MEF2 isoform-specific and cell-type specific manners. Consider the 
possible role of MEF2, sub family of MADS proteins, in neuronal differentiation. 
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1.3.3. Role of null MEF2 isoforms in diverse tissue types 
Functions of MEF2 isoforms are observed partially overlap, but distinct roles 
for the diverse tissue types. Therefore, assessing MEF2 function of specific isoform 
has been complicated and challenging due to their overlapping expression patterns 
during development. However, recent studies identified numerous MEF2 target 
genes, indicating their diverse role during the myogenesis and neuronal survival 
(Sandmann et al. 2006; Flavell et al. 2008). Murine gene mutation/deletion studies 
provide genetic evidence in support of discrete MEF2 isoforms-specific functions in 
vertebrates (Bult et al. 2008). For example, the phenotypes of mef2 null mice 
showed distinct role of MEF2 in skeletal and cardiac muscle. Targeted inactivation 
of mef2 isoforms in mice results in embryonic lethality (Lin et al. 1998; Naya et al. 
2002), and a failure of normal bone development (Arnold et al. 2007). 
The essential role of MEF2 in muscle development was first observed in 
Drosophila (Bour et al. 1995). Deletion of single D-mef2 gene in Drosophila leads 
to complete loss of MEF2 function result in block differentiation of all muscle cell 
types like somatic, cardiac, and visceral muscle throughout embryonic and larval 
development (Nguyen et al. 1994; Bour et al. 1995; Lilly et al. 1995; 
Ranganayakulu et al. 1995). This indicates the absolute requirement of MEF2 for 
myogenesis and morphogenesis (Bour et al. 1995). During embryogenesis, MEF2C 
is expressed at the onset of differentiation of the cardiac and skeletal muscle 
lineages and is followed by expression of the other MEF2 genes in vertebrates 
(Edmondson et al. 1994). The Mej2c null mice die at embryonic day 9.5 due to 
cardiovascular defects, and these mice also exhibit vascular defects such as heart 
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tube fails to undergo looping morphogenesis, the malformation of the right 
ventricle, and inhibition of subsets of cardiac muscle gene expression (Lin et al. 
1997; Phan et al. 2005). The other Mej2 isoforms are expressed at normal or 
supraphysiological levels in the Meflc null mice but lack of compensation by other 
isoforms indicating the unique role of Meflc in cardiac development in vivo (Lin et 
al. 1998). Recent report has been documented about skeletal muscle specific 
deletion of Meflc leads to disorganized sacromeres and the loss of integrity of the 
Sacromere M-line (Potthoff et al. 2007). 
The Mefla null mice survive to the neonatal period, but subsequently develop 
severe myocardial mitochondrial deficiency, pronounced dilation of the right 
ventricle and sudden cardiac death (Naya et al. 2002). Only a few Mefla-null mice 
survive to adulthood with marked reduction in size and number of cardiac 
mitochondria and disorganization of myofibrillar and susceptibility to unexpected 
death (Naya et al. 2002). A loss of Mefla transcriptional regulation is account for 
the lack of compensation by the up-regulated mef2 isoforms in these mice. This 
Mefla-null mice phenotype, together with the fact that meflc null embryos do not 
exhibit mitochondrial defects (Lin et al. 1997), indicates that MEF2A plays a 
specific role in mitochondrial biogenesis. The Meflb null mice are also viable, and 
do not display any obvious phenotypic defects in skeletal and cardiac muscles 
(Black & Olson, 1998) Because expression of the other Mej2 isoforms is also up-
regulated in these mice and Meflb have possible functional redundancy with other 
Mej2 isoforms, indicating lack of compensation in vivo for selective MEF2 gene 
loss (Black & Olson, 1998). The alternative splicing of Meflb transcripts is altered 
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in Mej2 b null embryos (Vong et al. 2006) and a significant upregulation of Mef2 b 
expression was also observed in Mef2b null mice (Lin et al. 1997). Mice 
homozygous for deletions in Mef2a or Mej2b are viable, whereas the mej2d null 
mice die prior to gastrulation (Lin et al. 1997; Phan et al. 2005; Kim et al. 2008). 
Several lines of evidence have implicated MEF2 functional role in myogenesis, 
progenitor cell specification and mature myotubes formations (Black & Olson, 
1998). MEF2s are also reported to be involved in cardiac hypertrophy 
(Kolodziejczyk et al. 1999). Mej2d null mice shows no abnormalities in skeletal 
muscle development however, these mice are resistant to cardiac hypertrophy 
invoked by cardiac stress or chronic ~-adrenergic stimulation (Kim et al. 2008). 
Mej2d isoform is thus thought to play a crucial role in mediating stress-dependent 
gene expression in the adult heart (Kim et al. 2008). 
Since the phenotype of mej2a, mej2b, mej2c and mej2d null mice are distinct 
from each other, considering that the four members share similar DNA binding 
activities and overlapping expression pattern, suggests that they have distinct as 
well as partially redundant functions (Black et al. 1996; Lin et al 1996; Han et al. 
1997; Blaeser et al. 2000; Gaudilliere et al. 2002; Butts et al. 2003; Heidenreich & 
Linseman, 2004). Despite all MEF2 isoforms demonstrated the importance of 
MEF2s in muscle development, but to-date it is not clear whether Mef2 isoforms 
selective functions relate solely to distinctions in temporospatial expression, or to 
unique features of the MEF2 forms encoded by the different genes. None of the 
aforementioned genetic deletions of MEF2s shows a specific effect in vertebrate 
skeletal muscle development in vivo. In this regard future studies will likely focus 
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on tissue-specific gene deletion of MEF2s in skeletal muscle and in other tissue 
abnormalities specifically cardiac related phenotypes. Generation of double and 
triple knockout mutant mice may be a valuable methodology to further ascertain the 
role of MEF2 proteins. This also lessens concern about MEF2s redundant functions 
among family members while analyzing MEF2 null mice. Hence conditional 
mutagenesis approaches may be very practical and applicable in future. Taken 
together, these observations suggest that differential expression of MEF2 isoforms 
is a mechanism of transcriptional specificity for MEF2-dependent gene expression. 
1.4. Regulation of MEF2 activity: 
Regulation of gene expression is crucial to cell proliferation, differentiation 
and survival. Context specific and signal dependent regulation of gene expression is 
achieved to a large part by transcription factor regulation. The MEF2, family of 
transcription factors are crucial regulators controlling muscle-specific gene 
expression during myogenesis. MEF2 also plays pivotal roles in neuronal survival 
and synaptic formation, and in lymphocyte selection and activation (Potthoff & 
Olson, 2007). 
The structural organization of MEF2 proteins allows it to receive and respond 
to multiple inputs from various intracellular signaling pathways and thus MEF2 
function is profoundly influenced by developmental cues and signals from the 
extracellular environment (McKinsey et al. 2002). The post-translational 
modifications are integral components of signalling cascades that enable cells to 
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efficiently, rapidly and reversibly respond to extracellular stimuli (Black & Olson, 
1998). As a critical regulator in many cell types, MEF2 activity is tightly regulated 
by a multitude of posttranslational modifications that control and modulate 
signalling responses and gene expression such as phosphorylation, acetylation and 
sumoylation (Yang et al. 1998; Ornatsky et al. 1999; Han & Molkentin, 2000; 
Sterner & Berger, 2000; Cox et al. 2003; Gregoire & Yang 2005; Ma et al. 2005; 
Shalizi et al. 2006). As such well-defined posttranslational modification patterns 
also dictate the functions and protein-protein interactions of MEF2 (Black & Olson 
1998). 
1.4.1. Phosphorylation of MEF2 
Protein Phosphorylation is one of the important mechanisms for regulation of 
proteins in a mammalian cell (Graves & Krebs, 1999). The phosphorylation 
mechanism was initially identified by Fisher & Krebs in 1955, as a regulatory 
mechanism from muscle tissues. In humans, more than 500 different protein kinases 
are documented so far and identification of their biological targets is still a very 
challenging and active research field (Pearce et al. 2010). 
The mechanism of phosphorylation is regulated by two types of enzymes, 
protein kinases and protein phosphatases (Graves & Krebs, 1999). Kinases transfer 
a phosphate group from the nucleotide donor ATP and more seldom GTP to 
specific amino acid residues where as phosphatases catalyze the removal of the 
phosphate group to control activity of protein (Krebs & Beavo, 1979). In 
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eukaryotes, serine/threonine residues are more common target by one of specific 
protein kinases, and tyrosine residue by another kinase (Figure 5). The overall 
phosphoserine/phosphothreonine events are ,...,90% and ,..., 10% respectively in 
contrast to phosphotyrosine which is only "'0.05% in proteins (Pearce et al. 2010). 
Each protein may contain multiple phospho-sites, which might be targeted by 
different kinases/phosphatases at different time and upon different extracellular or 
intracellular stimuli, and thus subsequent biological functions such as, cell cycle, 
proliferation, differentiation, metabolism, neurotransmission and neuronal survival 
(Kim et al. 2002; Bossis & Stratakis, 2004; Insel et al. 2012). Protein kinases/ 
phosphatases also play a major role in human diseases such as inflammation and 
cancer; therefore they become a prime target for therapeutic intervention (Pearce et 
al. 201 O; Insel et al. 2012). 
In general, transcription factors are substrates of a number of protein kinases 
that phosphorylate serine and theronine as well as tyrosine residues. Protein 
phosphorylation and dephosphorylation of transcription factors is the most widely 
described regulation process affecting their structure, subcellular localization, 
transcriptional activity and DNA binding, leading to regulation of specific target 
genes (Pearce et al. 2010). Phosphorylation plays an imperative role in the 
regulation of MEF2 functions in myogenic and neurogenic cells (Zhao et al. 1999; 
Mckinsey et al. 2002; Cox et al. 2005). 
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Figure 5: Schematic of Phosphorylation process. Protein phosphorylation is a 
reversible process which catalyzed by protein kinases and phosphatases. 
Phosphorylation affects the substrates by modification of their activity, 
localization and stabilization resulting in regulation of different biological 
processes such as cell proliferation, differentiation, survival, and apoptosis. 
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To date, many phosphorylation sites have been identified in the transactivation 
domain of MEF2A and numerous studies reported that the activity of MEF2 factors 
is tightly modulated by phosphorylation (Ornatsky et al. 1999; Yang et al. 1998; 
Cox et al. 2003; Gong et al. 2003). It is known that phosphorylation by kinases is an 
important regulatory mechanism through which the MEF2 activity is up/down-
regulated leading to modulate MEF2 functions. Multiple kinases can target MEF2 
proteins including p38MAPK, PKC (Han et al. 1997; Ornatsky et al. 1999), 
ERK5/BMK (Kato et al. 1997; Yang et al. 1998), CKII (Molkentin et al. 1996), and 
CDK5 (Gong et al. 2003) depending on the external and internal stimuli (Kato et al. 
2000; Mckinsey et al. 2002) in a positive or negative manner. 
N 
Figure 6: Schematic of posttranslational modifications of MEF2 
30 
The majority of phosphorylation sites consist of proline directed serine/theronine 
residues, which are more often targeted by MAPK and CDK families of protein 
kinases. The post-translational modification of MEF2 by various signaling enzymes 
may provide a way for distinct stimuli to differentially regulate MEF2-dependent 
transcriptional programs in various tissue types (Figure 6). 
1.4.1.1. cAMP-dependent Protein Kinase (PKA) signaling pathway 
Cyclic adenosine 3',5'-monophosphate (cAMP) is produced as an intracellular 
second messenger in response to a variety of extracellular signals, including 
hormones, growth factors, and neurotransmitters (Tasken et al. 1997). The effect of 
cAMP on certain cellular functions has been shown to be dependent on cell-type 
and biological responses (Skalhegg & Tasken, 2000; Bossis & Stratakis, 2004; 
Pearce et al. 2010). cAMP regulates the effects of differentiation and gene 
expression, and stimulates cell metabolism through cell division, growth and 
promotes the G1 to S phase transition in the cell cycle (Kim et al. 2002; Insel et al. 
2012). Major intracellular effects of cAMP in mammalian cells are believed to be 
mediated by cAMP-dependent protein kinase (PKA), discovered as an active kinase 
in early 1950s (Taylor et al. 1990). In addition, cAMP has a PKA independent 
effect including interaction with cyclic nucleotide-gated ion channels, cAMP-
guanine nucleotide exchange factors and cyclic nucleotide phosphodiesterases (Kim 
et al. 2007). 
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1.4.1.1.1. Protein Kinase A (PKA) 
PKA is a well-defined kinase which plays fundamental roles in a variety of 
biological processes (Taylor et al. 1990). PKA, a serine/theronine kinase, is the 
main mediator of cAMP signaling, a ubiquitous signaling pathway that is conserved 
in all eukaryotes (Tasken et al. 1997; Skalhegg & Tasken, 2000; Pearce et al. 2010). 
The most common consensus sequences of PKA, RRX(S/T), (R/K)X(S/T), and 
(R/K)XX(S/T), were determined in various substrates (Shabb, 2001 ). PKA mediates 
acute as well as long-term responses to environmental changes through 
phosphorylation of wide range of substrates in almost all mammalian tissues 
(Bossis & Stratakis, 2004). PKA substrates include enzymes, ion channels, 
structural proteins and transcription factors. PKA must have appropriate substrate 
specificity to ensure correct transmission of appropriate signals (Shabb, 2001 ). 
Structure of PKA: 
The PKA holoenzyme is a hetero-tetramer composed of two catalytic subunits 
(C) associated with two regulatory subunits homodimer (RI and RII) (Skalhegg & 
Tasken, 2000). Multiple regulatory (Ria, RIP, Rlla, and RIIP) and catalytic (Ca, 
cp, and Cy) subunit isoforms have been identified in mammalian tissues. The type I 
PKA contains either regulatory subunit Ria or RIP in its structure and type II PKA 
contains either regulatory subunit Rlla or RIIP (Uhler & McKnight, 1987; Tasken 
et al. 1993; Kim et al. 2007) (Figure 7A). 
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Figure 7 A: Structure and Mechanism of Adenylyl Cyclase and cAMP-
dependant Protein Kinase A (PKA). Adenylyl cyclase is a membrane 
glycoprotein possessing a total of 12 transmembrane domains (depicted as lines 
passing through the membrane) and two catalytic domains (CAT) within the 
cytoplasm. This enzyme converts ATP to cAMP upon stimulation by subunits 
of Gs generating pools of cAMP. In the inactive state, PKA is a complex of two 
catalytic subunits (C) bound to two regulatory subunits (R) that inhibit 
catalytic activity. When two molecules of cAMP binds to each of the regulatory 
subunits of PKA resulting in conformational changes and dissociation of the 
holoenzyme into a regulatory R-subunit dimer and two active catalytic C-
subunits. 
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The type I PK.A is generally associated with proliferation and is often 
overexpressed in human cancer cell lines and in primary tumors. On the other hand, 
preferential expression of type II PKA is found in normal nonproliferating tissues 
and in growth-arrested cells (Uhler & McKnight, 1987). The amino acid sequences 
of Ca and CBI within a given species are 91 % identical. However, the amino acid 
identity of Ca proteins from different species is significantly greater, 98-100% 
(Uhler & McKnight, 1987), suggesting that each kinase plays a distinct role(s) in 
cellular functions (Skalhegg & Tasken, 2000). Furthermore, Ca is ubiquitously 
expressed in mammalian tissues, whereas CB 1 is highly expressed in brain tissues 
(Cadd & McKnight, 1989). The diversity of cellular responses to cAMP is the 
presence of multiple isoforms of PK.A in different tissues (Skalhegg & Tasken, 
2000; Kim et al. 2002). The regulation of PK.A is achieved via unique signaling 
events, phosphorylation of Thr197 in the activation loop of the C- subunit is 
necessary for the maturation and optimal catalytic activity of PK.A. Once C-
subunits are phosphorylated, PK.A become fully active in its catalytic potential and 
the Thr197 phosphate does not tum over (Uhler & McKnight, 1987). 
The four regulatory subunits isoforms of PK.A are similar in molecular mass 
and domain organization. The regulatory subunits contain N-terminal docking 
domain that mediates both dimerization and localization, a hinge region that 
interacts with the catalytic subunit and two cAMP binding domains in the C-
terminus (Scott, 1991; Tasken et al. 1993) (Figure 7 A). The regulatory subunits 
have multiple functions. First, they interact with the catalytic subunits and inhibit 
their catalytic activity. Second, the regulatory subunits serve to target AK.AP (A-
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Kinase Anchoring Proteins) scaffolding proteins (Wong & Scott, 2004 ). The 
regulatory subunits serve as a primary receptor of cAMP. Two stable regulatory 
subunits were found in vivo, the dissociated cAMP-bound form and the cAMP-free 
holoenzyme (Skalhegg & Tasken, 2000). 
Regulation of PKA: 
The activation of PKA is achieved by binding of the second messenger cAMP 
(Sands & Palmer, 2008). cAMP action starts as a response to a complex array of 
extracellular stimuli after agonist binding (hormones, neurotransmitters, and growth 
factors) to their specific G protein coupled receptors (~2-adrenergic receptor) in the 
plasma membrane results in activation of heterotrimeric G proteins (Woo & Xiao, 
2012), which in tum stimulate adenylate cyclase to increase the intracellular level of 
cAMP (Skalhegg & Tasken, 2000). cAMP binding to the Rla subunits of PKA 
which consequently induces a conformational change in the R- subunit and leads to 
the dissociation of the holoenzyme into regulatory R-subunit dimer and two active 
catalytic C-subunits. The free active C-subunit can then affect a range of diverse 
cellular events by phosphorylating an array of cytoplasmic and nuclear protein 
substrates, including enzymes and transcription factors (Francis & Corbin, 1999; 
Shabb, 2001; Sands & Palmer, 2008) (Figure 7B). The PKA subunits perform a 
substantial capacity of self-regulation. In cell culture model, over-expression of Ca 
or C~ results in significant compensation by an increase in Rla protein (Uhler & 
McKnight, 1987). 
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Figure 7B: Regulation of gene expression by cAMP-PKA signaling pathway. 
Ligand binding to a G-protein coupled receptor activates adenylyl cyclase 
generating pools of cAMP. PKA is activated as described in figure 6A. After 
dissociating from the regulatory subunits (R), the catalytic subunits (C) are 
translocated into the cell nucleus, where they phosphorylate transcription 
factor MEF2 and inhibit transcription of target gene expression. 
36 
Role of PKA: 
PK.A has been described to be involved in regulation of diverse biological 
processes including proliferation (Graves et al. 1993; Sirotkin et al. 2004; Sirotkin 
& Grossmann 2006), muscle differentiation (Li et al. 1992; Winter et al. 1993; 
Chen et al. 2005), chromatin condensation (Ueda et al. 1995), DNA replication 
(Costanzo et al. 1999), the immune system, and neuronal survival/apoptosis (Rydel 
& Greene, 1988; Hanson et al. 1998; Li et al. 2000; Jiang et al. 2009). The cellular 
localization and differential expression of PK.A has a pivotal role in regulation of 
gene expression through regulation of a wide variety of transcription factors such as 
CREB (cAMP response element binding protein) (Chen et al. 2005; Sands & 
Palmer, 2008). Activation of CREB by PK.A is one of the best studied transcription 
factor in diverse tissue types (Chen et al. 2005; Belfield et al. 2006; Pearce et al. 
2010). Previous studies has shown that cAMP-dependent PKA signaling potently 
inhibit skeletal muscle differentiation but the precise molecular mechanism of 
inhibition was unknown (Li et al. 1992; Winter et al. 1993). Previously, it is 
revealed that MRF family member, myogenin, contain two conservered PK.A 
phosphorylation sites in the basic region and repression of its transcriptional 
activation by PKA is an indirect mechanism. It is possible that repression of other 
myogenic regulators by PKA could involve inhibition of differentiation of skeletal 
muscle cells (Li et al 1992). Interestingly, in silico analysis reveals multiple 
consensus phosphoacceptor sites of PKA on MEF2 proteins. MEF2 is known as an 
obligatory partner for the MRFs in the myogenic program and our group was able 
to identify the missing link between MRFs and MEF2 (Du et al. 2008). In addition, 
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it has been documented that PKA is involved in development of somites in the early 
phase of myogenic induction by targeting CREB (Chen et al 2005). Stimulation of 
intracellular cAMP levels can induce to CREB phosphorylation via PKA. 
Phosphorylation of Serl 33 is a critical event in CREB activation and induces an 
increase in CREB transactivation potential by allowing the recruitment and binding 
to co-activators such as CREB-binding proteins (CBP) and MEF2 (Belfield et al. 
2006). As such PKA acts as a major physiological kinase responsible for Ser133 
phosphorylation. 
In the CNS, CREB family members have been shown to be essential for 
neuronal survival and are thought to modulate both synaptic and intrinsic plasticity 
in response to neuronal activity (Benito & Barco, 2010; Lonze & Ginty, 2002). 
Differentiation of neural progenitor cells is regulated by a coordinated change in 
expression of specific target genes involved in different intracellular signaling 
pathways. cAMP-dependent PKA signaling has also shown to be involved in 
neuronal differentiation during brain development (Martinez et al. 1999). PKA 
phosphorylate CREB leading to regulation of neuronal differentiation, neurite out-
growth and neuronal plasticity (Belfield et al. 2006). All stimuli that activate 
neuronal CREB-dependent transcription (e.g., receptor tyrosine kinases, calcium 
signaling pathways, cAMP) do so by inducing phosphorylation of CREB at serine 
133 (Shaywitz & Greenberg, 1999). In addition to phosphorylation of Ser133, 
activation of neuronal calcium signaling pathways induces phosphorylation of 
CREB at Ser142 and Ser143 (Kornhauser et al. 2002). These phosphorylation 
events occur concurrently with activation of CREB-dependent transcription, and 
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mutation of these sermes to non-phosphorylatable alanine residues selectively 
inhibits calcium-regulated CREB activity in a reporter gene assay, while leaving 
cAMP-dependent transcription unaffected (Kornhauser et al. 2002). cAMP-
dependent PKA promotes mitochondrial-dependent apoptosis in lymphoma cells 
(Zhang et al. 2008). Neuronal apoptosis is mediated by caspase-dependent 
pathways via cAMP-dependent PKA activation in hippocampal neurons (Zhao et al. 
2008). 
1.4.1.1.2. MEF2 and PKA 
PKA functions as a negative regulator that phosphorylates a specific region of 
MEF2 factor, thereby inducing proteolytic modification to generate the repressor 
forms and inhibit muscle differentiation. The functional role of the identified PKA 
phosphorylation sites in the MEF2 factors has been characterized previously by our 
group (Du et al. 2008). Theoretical mapping shows multiple possible PK.A sites 
residing in C-terminus region of all three MEF2 isoforms. PKA is known to 
phosphorylate two consensus sites: RRX(S/T) or RXS/T. (Figure 8). Sequence 
analysis of MEF2 isoforms identified four PKA sites in MEF2A at 8235, 8494, 
8302, and T415, two PKA sites in MEF2C at 8181 and 8228. Three possible PKA 
sites were detected in MEF2D at 8121, 8190, and 8231. Interestingly, the 8121 site 
of MEF2D is conserved and ubiquitously expressed isoform located in the 
alternatively spliced exon a-1 which is highly expressed in C2C 12 myobalsts, PC 12 
cells, kidney, stomach, heart, and brain, whereas exon a-2 is restricted as striated 
muscle- isoforms (Martin et al. 1994 ). MEF2D is potently phosphorylated by PKA 
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whereas, MEF2A and C are moderately phosphorylated and it was concluded that 
they are not directly targeted by PKA (Du et al. 2008). Moreover our group did not 
find any PKA sites at the N-terminus of all MEF2 isoforms and these observations 
contradict the previous study which showed PKA phosphorylates the conserved 
T20 residue present in the N-terminus region (Wang et al. 2005). 
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Figure 8: Theoretical mapping of PKA consensus sites (RRXS/T or RXS/T) are 
found on MEF2A, -C, and -D. 
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Mutation analysis of PK.A phospho-residues in MEF2D, 8121A and 8190A, 
attenuate the PK.A effect in skeletal muscle (Du et al. 2008). This demonstrates that 
PK.A directly phosphorylates MEF2D at 8121 and 8190 to inhibit skeletal muscle 
differentiation, and mutation of these residues to neutral alanine residues rescues 
this inhibition (Du et al. 2008). In addition, previous studies have identified other 
mechanism that is involved in MEF2 inhibition by PK.A phosphorylation of MEF2. 
PK.A activation also results in an enhanced nuclear accumulation of HDAC4 and a 
subsequent increase in a MEF2-HDAC4 repressor complex (Backs et al. 2011) 
(Figure 9). Neutralizing mutations of 8121 and 8190 confers PK.A-resistance to 
MEF2D and efficiently rescues myogenesis from PK.A-mediated repression (Du et 
al. 2008; Gordon et al. 2009). Whereas, calcium and cAMP cooperate to activate 
the transcription factor CREB, cAMP can either prevents/inhibits MEF2 activation 
by blocking HDAC export from the nucleus and by inhibiting import of the MEF2 
co-activator, NFATc3/c4 (Nuclear factor of activated T cells) (Belfield et al. 2006). 
41 
.~ 
ActlvePKA ) 
Figure 9: Regulation of gene expression by cAMP-PKA signaling pathway. 
Ligand binding to a G-protein coupled receptor activates adenylyl cyclase 
generating pools of cAMP. PKA activation results in an enhanced nuclear 
accumulation of HDAC4 and prevents its export from the nucleus following 
increase in a MEF2-HDACs repressor complex and inhibit transcription of 
target gene expression. 
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1.4.1.2. Mitogen activated protein kinase (MAPK) signaling 
The mitogen-activated protein kinases (MAP Ks) play an imperative role in 
diverse cellular programs by regulating transcription factors leading to gene 
expression upon receiving extracellular and intracellular signals (Cuenda & 
Rousseau, 2007). In eukaryotic cells, MAPKs are among the most evolutionary 
conserved signaling pathways ranging from yeast to human that coordinately 
regulate many physiological processes (Cuenda & Rousseau, 2007). MAPKs are 
members of a ubiquitous praline-directed proteins serine/threonine kinase family 
responsible for signal transduction cascades. 
The major kinase cascades of the MAPK family include extracellular signal-
regulated protein kinase (ERK), c-jun N-terminal kinase (JNK), and p38 MAPKs 
pathways. In general, ERKs are preferentially activated in response to growth 
factors and phorbol esters, while the JNK and p38 kinases are more responsive to 
stress stimuli ranging from osmotic shock and ionizing radiation to cytokine 
stimulations (Pearson et al. 2001 ). Each family of MAPKs is composed of a set of 
three evolutionary conserved and sequentially acting kinases: a MAPK, a MAPK 
kinase (MAPKK), and a MAPKK kinase (MAPKKK). The MAPKKKs are often 
activated through phosphorylation in response to extracellular mitogen stimuli or a 
wide range of cellular stress signals (Cuadrado & Nebreda, 2010). MAPKKK 
activation leads to the phosphorylation and activation of a MAPKK, which then 
stimulates MAPK activity through dual phosphorylation on threonine and tyrosine 
residues (Chang & Karin, 2001) (Figure 10). Once activated, MAPKs 
phosphorylate downstream target substrates (Cuadrado & Nebreda, 2010) and able 
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to modify the functions of specific transcription factors in response to specific 
stimuli (Chang & Karin, 2001). Previous studies documented that ERK and p38 
MAPK are the key regulators of MEF2 function in wide range of tissue types 
including muscle and brain. These signaling cascades commonly affect MEF2 
activation involved in cell proliferation, differentiation, and survival (Han et al. 
1997; Yang et al. 1998; Zhao et al. 1999; Thomas & Huganir 2004). 
1.4.1.2.1. The p38 MAPK 
The p38 MAPKs are strongly activated by a wide range of cellular stresses but 
also involve in a variety of biological processes including inflammation, immune 
response as well as in the regulation of cell differentiation and survival/apoptosis 
(Han et al. 1994; Raingeaud et al. 1995; Han et al. 1997; New et al. 1998; Pearson 
et al. 2001; Cuadrado & Nebreda, 2010). The p38MAPK family consists of four 
different but functionally overlapping isoforms: p38a (MAPK14), p38~ 
(MAPKl 1), p38y [SAPK (stress-activated protein kinase) 3, ERK (extracellular-
signal-regulated kinase) 6 or MAPK12], and p388 (SAPK4 or MAPK13) (Lechner 
et al. 1996; Cuenda & Rousseau, 2007; Cuadrado & Nebreda, 2010). These isomers 
are approximately 60% identical in their amino acid sequence but differ in their 
expression patterns, substrate specificities and sensitivities to chemical inhibitors 
(Bain et al. 2007; Bae et al. 2009; Cuadrado & Nebreda, 2010). The first p38MAPK 
family member was identified during endotoxin-induced cell activation, which 
showed that p38 was rapidly phosphorylated on tyrosine residue in response to 
extracellular changes (Han et al. 1994; Enslen et al. 1998). 
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Based on their expression pattern, substrate specificity and sensitivity to 
pharmacological inhibitors, p38 isoforms can be divided into two groups: p38a and 
p38~ (group 1) while p38y and p388 (group2) (Jiang et al. 1996; Bae et al. 2009). 
Group 1 (p38a and p38~) is ubiquitously expressed in many tissues. Whereas group 
2 (p3 8y and p3 88) appear to have a more tissue specific expression pattern. p3 8y is 
most abundant in skeletal muscle and p38~ in brain (Lee et al. 2000; Bae et al, 
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2009), while p388 is highly expressed in testes, pancreas, kidney, small intestine, 
and in endocrine glands (Cuenda & Rousseau, 2007; Bae et al. 2009). In the adult 
mouse brain, all four isoforms of p38 (a, ~' y, 8) are expressed in tissues such as the 
whole brain, cerebellum, and cortex, however p38a and p38~ isoforms are reported 
to be highly localized in specific regions of the adult mouse brain including cerebral 
cortex and hippocampus (Lee et al. 2000). In general, throughout the brain, p38a is 
predominately expressed in neurons whereas p38~ is highly expressed in both 
neuronal and glial cells (Lee et al. 2000). All isoforms phosphorylate the Serine-
Proline or Thronine-Proline MAPK consensus motifs, but some substrate selectivity 
has been reported (Han et al. 1994; Jiang et al. 1996; Cuenda & Rousseau, 2007). 
The commonly used p38MAPK inhibitor SB203580 specifically inhibits p38a and 
p38~, but does not inhibit p38y and p388 activities (Bain et al. 2007; Cuenda & 
Rousseau, 2007). p38MAPK is present in both the nucleus and cytoplasm of 
quiescent cells, but upon cell stimulation p3 8 translocates from the cytoplasm to the 
nucleus (Raingeaud et al. 1995) but another research group shown that activated 
p38MAPK is also present in the cytoplasm of stimulated cells (Ben-Levy et al. 
1998). The four p38 isoforms are strongly activated by various environmental 
stresses and inflammatory cytokines, including oxidative stress, UV irradiation, 
hypoxia, ischemia, interleukin-I (IL-1), and tumor necrosis factor alpha (TNF-a) 
(Cuenda & Rousseau, 2007). A major function of p38 isoforms is the production of 
proinflammatory cytokines. p3 8MAPK can regulate cytokine expression by 
modulating transcription factors, or at the mRNA level by modulating their stability 
and translation (Jiang et al. 1996; Han et al. 1997). 
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In mammalian cells the functional role of the p3 8MAPK signaling cascade 
were identified in 1994. This provided the first step towards identification of several 
other substrates of p38MAPK and provides the first insight into the molecular 
mechanism involved in the activation ofp38MAPK cascades (Freshney et al. 1994; 
Rouse et al. 1994). Several substrates of p38MAPK have been identified and 
characterized, for example transcription factors that are involved in cell 
development, myocyte differentiation and regulation of neuronal processes such as 
synaptic plasticity and neurodegenerative diseases (Perdiguero & Muiioz-Canoves, 
2008; Correa, 2012). The role of p38 MAPK has been defined as a tumor 
suppressor, as p38a negatively regulates cell cycle progression at both the G1/S and 
G2/M transitions by number of mechanisms, including downregulation of cyclins 
and upregulation of CDK (Cyclin Dependent Kinase) inhibitors (Jiang et al. 1996; 
Thornton & Rincon, 2009). Some studies have reported prosurvival functions of 
p38a, however under cellular stresses cause the induction of apoptosis. These 
effects can be mediated by transcriptional and posttranscriptional mechanisms, 
which affect death receptors, survival pathways or pro- and antiapoptotic proteins 
(Thornton & Rincon, 2009). Classical example of transcription factors are A TF 
(activating transcription factor), SRF (serum response factor), p53 (tumor 
suppressor protein) and MEF2s. These transcription factors are directly 
phosphorylated and activated by p38 MAPKs in response to wide range of stimuli 
in mammalian cells (Perdiguero & Muiioz-Canoves, 2008). 
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1.4.1.2.1.J. p38 MAPK and MEF2 
The p38MAPK is a major regulator of MEF2 phosphorylation and MEF2-
dependent gene expression in a variety of cell types (Yang et al. 1998; Zetser et al. 
1999; Cox et al. 2003). It promotes skeletal muscle differentiation, neuronal 
survival and also mediates the pathological effects of MEF2 in cardiac hypertrophy 
(Kolodziejczyk et al. 1999; Zhao et al. 1999; Okamoto et al. 2000). A two-hybrid 
screening with p3 8 kinase as bait was first revealed by researchers that p3 8MAPK 
directly phosphorylates MEF2C (Han et al. 1997; Han & Molkentin, 2000). 
Phosphorylation of the transactivation domain of MEF2 transcription factors has 
been shown to increase MEF2 activity. Previous studies have documented that p38 
MAPK phosphorylate several residues in the transcriptional activation domain of 
MEF2A and MEF2C (but not MEF2B and MEF2D) and considerably increase 
MEF2 activity without affecting DNA binding (Han et al. 1997; Omatsky et al. 
1999; Cox et al. 2003). Previously it was shown that MEF2D is not phosphorylated 
by p38 (Zhao et al. 1999). But recently, it has been documented that MEF2D 
transcriptional activity is also regulated by p38 signaling-supported by other 
cofactors like Ash2L which is selectively recruited to muscle specific promoters 
through p38-dependent phosphrylation of MEF2D (Rampalli et al. 2007). In vitro 
studies in muscle cells and in fibroblasts showed that inhibition of p38 markedly 
reduces MEF2D activity and downstream MEF2 target genes (Penn et al. 2004; 
Rampalli et al. 2007). The efficient target of MEF2A and -C by p38 is mediated by 
conserved docking domain (D-domain) present between amino acids 266 to 282 in 
MEF2A and between amino acids 249 to 264 in MEF2C located in their 
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transactivation domain (Yang et al. 1999). The "D-domain" is sufficient to target 
p38MAPK to heterologous substrates (Enslen & Davis, 2001; Fantz et al. 2001). 
Interestingly MEF2D lacks p3 8 docking domain. Since MEF2D can dimerize with 
MEF2A, it may be possible that phosphorylation of MEF2A by p38 can potentially 
up-regulate MEF2D-dependent gene expression (Omatsky et al. 1999; Yang et al. 
1999; Zhao et al. 1999). Deletion of the docking site prevents MEF2A from being 
targeted by p38. Moreover, alteration of the docking domain from MEF2s to other 
proteins which are not p38 substrates confers p38-responsiveness (Yang et al. 1999) 
(Figure 11 ). 
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Figure 11. Schematic of multiple kinase phosphoacceptor sites of MEF2 
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Phosphorylation of MEF2A and MEF2C by p38MAPK enhances their 
transcriptional activity. Among four isoforms of p38MAPK (a, ~' y and o), at least 
two of the isoforms, p38a and p38~, are well known to activate MEF2A and 
MEF2C by phosphorylating residues located in their transactivation domain (Yang 
et al. 1999; Zhao et al. 1999). Three major sites of p38-induced phosphorylation 
contribute to the transcriptional activity of the MEF2s (Thr312, Thr319, and 
8er453). It is well documented that MEF2A can be phosphorylated at T312 and 
T319 residues within the transactivation domain, especially for transcriptional 
activation in muscle cells (Yang et al. 1999; Zhao et al. 1999; Wu et al. 2000). 
Additional serine residues including 8355, 8453, and 8479 are phosphorylated 
in vitro by p38 but their relevance to transcriptional activation is still unknown 
(Yang et al. 1999; Zhao et al. 1999; Omatsky et al. 1999). Interestingly, these sites 
are conserved in MEF2s, however they are contained within an alternatively spliced 
region of MEF2C (the y domain) that is only present in a fraction of the MEF2C 
protein expressed in brain (Zhu et ai'. 2005). Activation of MEF2C by p38 seems 
more complex than MEF2A and is subjected to tissue specific regulation. In 
response to physical-chemical stresses and proinflammatory cytokines, three 
prominent residues, T293, T300, and 8387, in the transactivation domain of 
MEF2C are phosphorylated by p38 identified during in vitro studies (Raingeaud et 
al. 1995; Han et al. 1997; Zhao et al. 1999). Phosphorylation of these residues has 
been shown to be important for MEF2C activation by p38 in T-cells (Han et al. 
1997). However, only phosphorylation of T293 is induced in differentiating 
myocytes and is required for MEF2C activation by p38 during muscle 
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differentiation, suggesting activity of p38MAPK is necessary for muscle formation 
(Wu et al. 2000). Mutation of these primary phospho-sites in the transactivation 
domain of MEF2A or MEF2C is sufficient to block myogenesis (Zetser et al. 1999; 
Puri et al. 2000; Penn et al. 2004). p38 also mediates pathological effects of MEF2 
in cardiac hypertrophy and some forms of myotonia (Kolodziejczyk et al. 1999; Wu 
& Olson, 2002). 
Previously it is reported that p38MAPK has also been shown to play a crucial 
role in somatic myogenesis. Indeed, a critical interaction between p38 and MEF2 
occurs in the somites myotome during development (de Angelis et al. 2005). In vivo 
model, abrogation of p38MAPK blocks MEF2 activation in somites, and 
concurrently inhibits myogenic differentiation (Wu et al. 2000; Keren et al. 2006; 
Lluis et al. 2006; Bae et al. 2009). p38 is involved in myogenesis with expression 
of muscle-specific genes (Zetser et al. 1999; Puri et al. 2000; Penn et al. 2004; Lluis 
et al. 2006). As mentioned before among four isoforms of p38MAP kinase, p38a 
and p38~ plays a prominent role in myogenesis. There is a persistent rise in p38a/~ 
activity during myoblast differentiation. However, blocking of p38 inhibits 
induction of selective muscle-specific genes and myogenic differentiation (Wu et al. 
2000; Lluis et al. 2006). p38 phosphorylates MEF2 that drive muscle-specific gene 
expression at several levels such as dimerization of MyoD with E-proteins, 
chromatin remodeling at muscle-specific genes, and stability of myogenic mRNAs 
(Wu et al. 2000; Simone et al. 2004; de Angelis et al. 2005). Differentiation of 
skeletal muscle is coordinated by MEF2 transcription factors and MyoD family, and 
p38 promotes myogenesis through phosphorylation ofMEF2s that stimulate MyoD-
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dependent muscle-specific gene expressions (Wu et al. 2000; de Angelis et al. 
2005). 
In past decade several studies started to focus on the role of p3 8MAPK in 
neurons and presented evidence that p38MAPK-mediated neuronal survival 
requires phosphorylation and activation of MEF2. Blocking the p38 signaling by 
p3 8 inhibitors promotes apoptosis of differentiating cerebellar granule neurons 
(Mao et al. 1999; Okamoto et al. 2000). Interestingly, MEF2-dependent 
transcription activity was inhibited by introducing dominant-interfering mutants of 
p38 in primary cerebellar granule neurons and differentiating P19 cells (Mao et al. 
1999; Okamoto et al. 2000). This suggests a direct involvement of p38 in promoting 
neuronal survival via activation of MEF2 in neurons. Overexpression of MEF2s 
mutants, which cannot be phosphorylated by p38, blocked membrane depolarization 
and p38MAPK induced neuronal survival. The role of p38MAPK mediated 
neuronal survival through MEF2 was confirmed by earlier studies and later 
confirmed in the neurogenesis model of P19 cells (Okamoto et al. 2000). Calcium 
signaling, a second messenger, involve in wide range of cellular responses in 
neuronal cells (Ghosh & Greenberg, 1995). The importance of p38MAPK-mediated 
regulation of MEF2 in neurons was first observed in calcium signaling dependent 
neuronal survival model (Mao et al. 1999). Previously, it was shown that calcium 
influx triggered by extracellular stimuli induces p38MAPK activity in cerebellar 
granule neurons, leading to direct phosphorylation of MEF2C at Ser 387 by p38 
kinase (Han et al. 1997; Mao et al. 1999). These findings indicate that calcium 
influx into neuronal cells results in induction of p38 cascade and phosphorylation 
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and activation of MEF2 by p3 8 which protects neurons from apoptosis in a p3 8 
pathway-dependent manner (Mao et al. 1999). Observations from these studies 
contribute to our understanding regarding MEF2 regulation in neuronal cells and its 
requirement for survival leading to confirmation of importance of postranslational 
modifications of MEF2 for normal cellular functions (Okamoto et al. 2000). 
1.4.1.2.2. ERK5 
Another important mediator of MAPK signaling is ERK.5, the extracellular 
signal-regulated protein kinase 5. ERK.5 (also known as BMKl, for big mitogen-
activated protein kinase-I) is a member of MAPK family (Lee et al. 1995; Zhou et 
al. 1995). ERK.5 is twice the size of other MAPK family members ( ~ 100 kDa), and 
its N-terminal contains a kinase domain similar to that of ERK.1/2. ERK.5 has a 
relatively large C-terminal with unique structure that contains a nuclear localization 
signal (NLS) and a proline-rich region which makes it distinct from other family 
members. Three isoforms of ERK.5 have been reported (ERK.Sa, -b, and -c) (Zhou 
et al. 1995). ERK.5 was initially reported as a MAPK family member that is 
activated by stress stimuli. ERK.5 activity is increased in response to oxidative 
stress and hyperosmolarity (Wang et al. 2006). Another study showed that ERK.5 
can be activated in response to serum (Kato et al. 1997), and nerve growth factor 
(NGF) (Encinas et al. 1999; Chang et al. 2004). ERK.5 activation is correlated with 
the dual phosphorylation of Thr and Tyr residues within a conserved Thr-Glu-Tyr 
(TEY) motif in the activation loop of the kinase domain (Kasler et al. 2000). Upon 
stimulation, MEKK2 and MEKK3, members of the MAPKKK family, activate 
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MEK5, a specific MAPKK for ERK.5. Subsequently, MEK5 phosphorylates and 
activates ERK.5, and then the activated ERK.5 phosphorylates substrates including 
MEF2 (Kato et al. 1997). Interestingly, PD98059 and U0126 were identified as 
MEKl/2-specific inhibitors, also known to efficiently inhibit the MEK5-ERK5 
pathway (Kamakura et al. 1999; Mody et al. 2001). However, MEK5 is less 
sensitive to PD184352 and is also known as a MEKl/2 inhibitor (Mody et al. 2001). 
ERK.5 is ubiquitously expressed in several tissues, including heart and skeletal 
muscle and particularly expressed in high levels in the brain, thymus, and spleen 
(Kondoh et al. 2006). ERK.5 is essential for early embryonic muscle and normal 
vascular development as well as neuronal survival (Dinev et al. 2001; Regan et al. 
2002; Finegan et al. 2009). Targeted deletion of ERK.5 in mice has revealed the 
critical role of ERK.5 in cardiovascular development and maintenance of vascular 
integrity (Regan et al. 2002). Regarding localization, endogenous ERK.5 found in 
cytoplasm and in nucleus, depending on the cell types (Buschbeck & Ullrich, 2005; 
Kondoh et al. 2006). In resting cells, ERK.5 localizes in cytoplasm and translocates 
to the nucleus when co-expressed with constitutively active MEK5 or upon 
stimulation (Kato et al. 1997). Endogenous inactive ERK.5 localizes either in the 
cytoplasm or diffusively throughout the whole cell, and translocates to the nucleus 
on stimulation in myoblast C2C12 cells (Kondoh et al. 2006). It has been shown 
that when ERK.5 translocate to the nucleus, where it directly interacts with, or 
phosphorylates and activates several transcription factors including c-Myc, c-Fos, 
Fra-1, and MEF2 family members to control cellular functions (Kato et al. 1997; 
Terasawa et al. 2003; Kondoh et al. 2006). As such activation of ERK5-MEF2 
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signaling is important for promoting cell proliferation (Kato et al. 1998), 
differentiation (Dinev et al. 2001), and neuronal survival (Shalizi et al. 2003). 
1.4.1.2.2.1. ERK5 and MEF2 
In addition to p3 8 MAPK, the serine/theronine kinase ERK.5 is capable of 
directly phosphorylating the transactivation domain of MEF2 family members 
including MEF2A,-C, and -D, resulting in an increased transcriptional activity. 
However, ERK.5 does not phosphorylate MEF2B (Kato et al.1997; Yang et al. 
1998; Marinissen et al. 1999; Kato et al. 2000). Phosphorylation of MEF2D at S 179 
by ERK.5 is required for enhanced transcriptional activity upon Epidermal Growth 
Factor (EGF) stimulation in transfected Hela cells. However, other group reported 
that phosphorylation at S 179 did not induce ERK.5-mediated enhancement of 
MEF2D transcription potential in response to ionomycin treatment in hybridomas. 
Additional studies reported that ectopically express ERK.5 specifically up-regulates 
the activity of MEF2A and -C, but not of MEF2D in COS cells, suggesting the 
regulation of MEF2D by ERK.5 may depend on cellular context (Pazyra-Murphy et 
al. 2009). 
ERK.5 was initially found to interact with the N-terminus of MEF2D in a 
yeast-two-hybrid screen (Yang et al. 1998). The regulation of MEF2 by ERK.5 was 
first shown in Chinese hamster ovary (CHO) cells. ERK.5 possesses a unique C-
terminal transactivation domain, which mediates protein-protein interactions with 
MEF2 transcription factors and provides a potent coactivator function toward 
MEF2-driven transcription. Interestingly, ectopic expression of the C-terminal 
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coactivator domain of ERK.5 is sufficient on its own to induce MEF2-dependent 
transcription (Kasler et al. 2000). Disruption of ERK.5 causes cardiac 
developmental defects, observed in MEF2C knockout mice (Dinev et al. 2001; 
Regan et al. 2002). In T-cells, activation of ERK.5 induces immediate-early 
transcription of the nur77 orphan steroid receptor gene via MEF2 proteins (Kasler 
et al. 2000). 
In non-neuronal cells, growth factor activation of ERK.5 has been reported to 
contribute to cell proliferation, and differentiation. However ERK.5 is activated by 
neurotrophic factors in primary neuronal cells and plays an important role in 
neurotrophin mediated neuronal survival (Shalizi et al. 2003). ERK.5 is highly 
expressed in the brain during early embryonic development but declines as the brain 
matures (Liu et al. 2003). MEF2C is activated by neurotrophins, and the ERK.5 
signaling is required for neurotrophin stimulation · of MEF2C transcription. 
Mechanism of ERK.5-mediated survival involves MEF2 transcriptional regulation 
(Wang et al. 2009). ERK.5 enhances the transcriptional activity of MEF2C by 
phosphorylating at S387, which is located in the transactivation domain of the 
protein (Kato et al. 1997; Yoon et al. 2005). Different studies have addressed the 
issue of whether ERK.5 regulates MEF2 in neurons (Pazyra-Murphy et al. 2009). 
Using a brain-derived neurotrophic factor (BDNF) mediated survival model, it was 
shown that ERK.5 protection of E 1 7 cortical neurons may be mediated through 
MEF2 induced gene expression. ERK.5 is activated by BDNF and regulates 
MEF2C-mediated gene expression in embryonic cortical neurons. Blocking MEF2 
function also attenuated BDNF-induced ERK.5 dependent survival. Overexpression 
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of a dominant-negative ERK5 mutant block the BDNF protection against trophic 
withdrawal in primary cortical neurons cultured from embryonic day (E 1 7) but not 
P 19 (Liu et al. 2003 ). Likewise the temporal survival effects of BDNF in cerebellar 
granule neurons seems to be mediated by an ERK5/MEF2 signaling pathway that 
induces transcription of neurotrophin (Shalizi et al. 2003). Overexpression of a 
constitutively active form of MEF2, MEF2C-VP 16, attenuated the neuronal death 
induced by the dominant-negative ERK5. Together, these studies demonstrated that 
ERK.5-mediated survival effect of BDNF requires the activity of its downstream 
target MEF2. Both ERK5 and MEF2 have been associated with neuronal cell 
survival following activation of neurotrophin (Cavanaugh et al. 2001; Pazyra-
Murphy et al. 2009). 
1.4.1.2.3. CDKS and MEF2 
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine 
cyclin-dependent kinase family member. It is highly expressed in the central 
nervous system (CNS) but activity of Cdk5 is largely restricted to post-mitotic 
neurons and requires its activator proteins p35/p39 or particular truncated forms, 
p25/p29 (Dhavan & Tsai 2001, Smith et al. 2003 & 2006). CdkS shares 60% 
homology with other members of cell cycle kinase family. However, Cdk5 is not 
directly involved in the cell cycle (Hellmich et al. 1992; Lew et al. 1992; Meyerson 
et al. 1992; Dhavan & Tsai, 2001). Cdk5 plays an essential role in the development 
of the CNS such as regulation of neuronal migration, axon growth, 
neurotransmission, and synaptic plasticity through phosphorylation of a large 
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number of substrates (Tang et al. 1995; Dhavan & Tsai, 2001; Gong et al. 2003; 
Tang et al. 2005; Qu et al. 2007; Ikiz & Przedborski, 2008; Lagace et al. 2008). 
During the past years, Cdk5 has received substantial attention as a result of its 
unique contribution in the neuronal apoptosis. Under pathological conditions, Cdk5 
is strongly and consistently activated in vivo, while defects of Cdk5 is highly 
destructive in neurons after breakdown by Cdk5p35/Cdk5p25, which change 
cellular localization of Cdk5 that induces neuronal cell death eventually (Gong et al. 
2003; Tang et al. 2005). The positive regulation of MEF2 has been well known in 
the CNS where it plays a critical role in neuronal survival. In contrast, oxidative 
stress appears to inhibit the pro-survival function of MEF2 in cortical neurons. 
Previous studies identified Cdk5 as a negative regulator of MEF2, phosphorylates 
and inactivates MEF2 in cerebellar neurons undergo neuronal apoptosis (Gong et al. 
2003; Tang et al. 2005). 
The Cdk5 phosphorylate conserved site in MEF2A, -C, and -D but this site is 
not found in MEF2B. Previous studies documented that Cdk5 phosphorylate at a 
conserved serine residue present in the transcriptional activation domain (Ser-408 
of MEF2A and Ser-444 of MEF2D) (Gong et al. 2003). Oxidative stress and 
excitotoxic concentrations of glutamate escalate Cdk5 activity leading to Cdk5-
dependent phosphorylation of MEF2 and inhibition of survival function. Moreover, 
MEF2 mutants that are resistant to Cdk5-mediated phosphorylation rescue MEF2-
dependent transcriptional activity and prevent neurons from neurotoxin-induced 
apoptosis caused by excitotoxicity/oxidative stress (Gong et al. 2003). Recent study 
has provided evidence that neuronal activity withdrawal or neurotoxin stress 
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involve in gradual decline of MEF2 protein level in cerebellar granule neurons, 
which leads to neuronal apoptosis (Tang et al. 2005). 
The complete mechanism by which Cdk5 phosphorylate MEF2 and inhibits 
MEF2 function is still unclear. But studies from different groups presented the 
possibilities that p?osphorylation by Cdk5 may targeting MEF2 for cleavage and 
degradation in neuronal cells. When cortical neurons treated with N-methyl-D-
aspartate (NMDA), a potent apoptosis-inducing reagent, led to caspase-dependent 
cleavage of MEF2A, C, and D (Okamoto et al. 2002). This data correlated to 
previous observations with activity withdrawal, caspase-cleaved fragments of 
MEF2 blocked MEF2-VP 16-dependent transcriptional activation. Further, 
constitutively active form of MEF2 (MEF2-VP 16) was neuroprotective against 
NDMA-stimulated apoptosis, however this effect was completely abolished by co-
expression of caspase-cleaved fragments of MEF2 (Okamoto et al. 2002). 
Observations from one study identified a mechanism related to the caspase cleavage 
of MEF2 proteins. It appears that for MEF2 to be cleaved in fragments by caspase-
3, and must be phosphorylated by Cdk5 (Tang et al. 2005). Studies in primary 
cerebellar granule neurons have shown that phosphorylation of MEF2A and -D by 
CDK5 inhibits MEF2 transcriptional activity, which also facilitates caspase-
mediated cleavage and degradation of MEF2. Blocking Cdk5 activity by using 
either a dominant-negative Cdk5 or specific pharmacological inhibitor attenuated 
MEF2A and -D degradation. These observations suggest that Cdk5 and caspase 
dependent signaling are coordinated together to regulate MEF2 protein stability in 
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neurons, eventually controlling the neuronal survival upon neurotoxin stimuli (Tang 
et al. 2005). 
MEF2C is neither phosphorylated nor cleaved by Cdk5 in granule neurons in 
response to excitotoxicity (Zhu & Gulick, 2004). Beside the Cdk5 role in neurons, 
another study on non-neuronal cells (COS7 and C2C12 cells) identified the Cdk5 
site location within a transcriptional activation domain encoded by an alternative 
exon" y domain" only exist in MEF2C, which is highly expressed in muscle, brain, 
and spleen. Furthermore, y domain defines as an independent repressive domain 
which is phosphorylation-dependent neuronal and non-neuronal cells. Mutation of 
phospho-residue serine with alanine leads to profound induction of MEF2-
dependent transcription, despite having no effect on MEF2 DNA-binding activity or 
stability. Interestingly, substantial portions of the y-domain beyond the 
phosphorylation site are conserved in both MEF2A and -D isoforms, and 
demonstrate similar repressive effects on the transcriptional activities (Zhu & 
Gulick, 2004 ). These observation suggests that phosphorylation site of Cdk5 may 
influence the interaction of MEF2 with transcriptional regulators, most likely 
through recruitment of co-repressors class Ila HDACs. 
It is worth noting that Cdk5 site in MEF2D is adjacent to the already identified 
sumoylation site (Gregoire & Yang, 2005). Phosphorylation-dependent regulation 
of MEF2 protein stability is certainly not restricted to neurons. Experiments 
performed in non-neuronal cells, showed that CDK5 acts in association with 
HDAC4 to stimulate MEF2D sumoylation at K439 residue by phosphorylating 
S444 (Gregoire et al. 2006). Opposing the activation of CDK5, calcineurin 
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dephosphorylates S444 and prevents sumoylation of K439, thus acting as modifier 
of MEF2' s phosphorylation status, selectively removing inhibitory phosphatases 
(Gregoire et al. 2006). In cerebellar granule neurons, calcineurin (calcium-sensitive 
protein phosphatase) seems to be required to maintain MEF2 in a hypo-
phosphorylated and active state. The interplay of K439 sumoylation and S444 
phosphorylation consequently regulates MEF2 activity in certain contexts. Because 
of Cdk5 profound effects on MEF2 function in diverse tissue types, understanding 
the role of this novel phosphorylation site controlling MEF2 function in the nervous 
system may, in fact, provide insight into the regulation of MEF2 in tissue types 
other than neurons. 
Biochemical studies have shown that phosphorylation of MEF2 at sites distinct 
from the Cdk5 site by unknown kinase (s) also regulates MEF2 stability in non-
neuronal cells. For example S255 of MEF2A becomes phosphorylated when 
p38MAPK activity is enhanced. Mutation of S255 to aspartic acid destabilizes 
MEF2A and leads to its degradation in COS7 cells (Cox et al. 2003). It is not clear 
yet under what conditions, S255 is phosphorylated in neurons and degradation. In 
light of accumulating evidence that Cdk5 activity is observed in number of 
neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, 
Huntington's disease, and amyotrophic lateral sclerosis (Takahashi et al. 2000; 
Grant et al. 2001 ). These observations raise the possibility that decreased function 
of the survival-inducing transcription factor, MEF2, Cdk5 contributes to the 
neuronal loss causing neurodegenerative diseases. These findings provide a novel 
regulatory mechanism of MEF2 activity by Cdk5-induced phosphorylation and 
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caspase-dependent degradation, suggesting regulation of MEF2 protein as more 
delicate and conspicuous process. 
1.4.1.2.4. Casein Kinase 2 (CK2) and MEF2· 
Protein kinase CK2, also known as casein kinase II, is a highly conserved, 
multifunctional serine/threonine kinase. It is critically important for the regulation 
of variety of signaling cascades in eukaryotes that involve in cell proliferation, 
differentiation and survival/apoptosis (Montenarh, 2010). CK2 ubiquitously express 
in all tissues, particularly its amount and activity are highly elevated in tumor cells. 
In mammals, there are two paralog catalytic subunits, CK2a (Al) and CK2a' (A2), 
and one CK2~ dimer, which together form the heterotetrameric holoenzyme and 
absolutely mandatory for embryonic development (Mazzorana et al. 2008; 
Dominguez et al. 2011 ). The catalytic subunits are distantly related to the CMGC 
subfamily of protein kinases, such as the cyclin-dependent kinases (CDKs). The 
CK2 is unique enzyme with some peculiarities, which are not found with most of 
the other protein kinases. CK2 is constitutively active and it can use ATP and GTP 
as phosphoryl donors (Mazzorana et al. 2008). 
Protein kinase CK2 constitutively phosphorylates all MEF2 isoforms at a 
conserved serine 59 residue in the MADS-box domain (Molkentin et al. 1996). In in 
vivo, phosphorylation of this site by CK2 enhances DNA-binding and MEF2 
transcriptional activity leading to enhance MEF2-dependent gene expression 
(Molkentin et al. 1996). Previously, there was another putative CK2 site detected in 
the alternative spliced exons of MEF2 isoforms, MEF2A,-C, and -D (Cox et al. 
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2003). But no evidence is observed in CK2-dependent direct regulation of MEF2 
suggesting some crosstalk between CK2 and other signaling cascades. Interestingly, 
it has been shown that MEF2A to be phosphorylated at a consensus CK2 site, 8289, 
in response to p38 MAPK signaling (Cox et al. 2003). This suggests a possible 
tissue-specific functional role of CK2 phosphorylation for this site which is located 
in alternately spliced exons of MEF2s. This also indicates the connection between 
p38MAPK signaling and the phosphorylation ofMEF2A by CK2 (Cox et al. 2003). 
CK2 is capable of regulating cell survival at multiple levels including DNA 
repair, activation of anti-apoptotic proteins and inhibition of pro-apoptotic proteins. 
This crosstalk with survival signaling cascades such as Wnt and PI3K/AKT/PKB 
signaling occurs in variety of tissue types (Ponce et al. 2011 ). Another recent study 
has indicated the important role CK2 in regulation of p3 8MAPK in keratinocytes 
differentiation (lsaeva & Mitev, 2011). Since p38MAPK mediated neuronal 
survival through MEF2 is well documented, it may be possible that CK2 involve in 
indirect regulation of MEF2 through p38MAPK in neurons and muscles. Further 
understanding of the regulation of MEF2 by CK2 may provide greater insight in 
identifying a mechanism of cell survival and CK2-dependent survival which makes 
this enzyme an important target for therapy. 
1.4.1.2.5. Protein Kinase C (PKC) and MEF2 
Protein kinase C (PKC) is a family of multifunctional isoenzymes, activated 
by ligand stimulation of transmembrane tyrosine kinase receptors. PKC play an 
essential role in signal transduction and intracellular crosstalk by phosphorylating at 
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serine/threonine residues as an array of substrates, including cell-surface receptors, 
enzymes, contractile proteins, transcription factors and other kinases (Omatsky et 
al. 1999; Kang et al. 2012). PK Cs regulate proteins indirectly by phosphorylating 
positive and negative co-regulators of protein expression or function. There are 
multiple PKC isoforms that are classified as conventional cPKCs (a,~ and y), novel 
nPKCs (11, e, 8, and 9) and typical aPKCs (t ands) (Mellor & Parker, 1998). Each of 
the isozyme is different in their pattern of specific tissue and subcellular 
distribution, function and Ca2+ /phospholipid cofactor requirements (Mellor & 
Parker, 1998). The novel Protein Kinase C (nPKCs) has been implicated in a wide 
range of important cellular processes such as regulating cell growth, homeostasis, 
and programmed cell death (Mackay & Mochly-Rosen, 2001). The nPKCs 
isozymes 8 and e have been shown to phosphorylate the transcriptional activation 
domain of MEF2A in cultured cells. The transcriptional activity of MEF2A 
enhances after phosphorylation by nPKC. However the exact phosphoacceptor sites 
targeted by PKC remain unknown (Omatsky et al. 1999). 
1.4.2. Acetylation 
A well-characterized post-translational modification is acetylation, which 
involves the covalent linkage of an acetyl group from acetyl-coenzyme A to thee-
amino groups of lysine residues within the N-terminal tails of histones. The 
modification is regulated by two opposing families of proteins, histone 
acetyltransferase (HAT) and histone deacetylases (HDACs). Acetylation has 
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typically been associated with active transcription, whereas deacetylation of 
histones confers a repressed state. It is thought that acetylation facilitates 
transcription by opening up the chromatin structure through weakened histone-
DNA interactions (Gregoire et al. 2007). The level of protein acetylation is 
balanced by lysine transferases and the complementary reversal is accomplished by 
histone deacetylases. This balance is perturbed in many tissues including muscle 
and brain (Mao & Wiedmann, 1999; Wu et al. 2001 ). 
Protein phosphorylation is a key regulatory post-transcriptional modification 
necessary for normal cellular signaling and, therefore, of many cellular functions by 
regulating MEF2 in several tissue types. Beyond phosphorylation of serine and 
tyrosine residues, lysine acetylation has recently emerged as a critical modification 
regulating MEF2 functions (Kang et al. 2006; Gregoire et al. 2007; Angelelli et al. 
2008). HDAC3, belong to class I HDAC, deacetylates MEF2 in vivo, represses 
MEF2 transcriptional activity and inhibits myogenesis. In contrast, the class Ila 
HDACs, HDAC4 and 5, repress MEF2-dependent transcription however, they 
cannot directly deacetylate MEF2 (Gregoire et al. 2007). 
Previously, it has shown that p300 acetylates six lysine residues in the 
transactivation domain of MEF2C, both in vivo and in vitro (Ma et al. 2005). 
Acetylase p300 interacts with MEF2 and enhances MEF2 function by acetylation 
lysine residues at its C-terminal transcription domain. Mutation of these lysines 
affects MEF2 transcriptional activity and its synergistic effect with other 
transcription factors that ultimately inhibits myogenic differentiation (Ma et al. 
2005). It is noteworthy that four major acetylatable lysines (K234/239/252/264) in 
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human MEF2C are also fully conserved in MEF2A, MEF2C, and MEF2D in 
variety of species. This suggests that MEF2 acetylation by p300 at these sites is a 
general mechanism conserved in vertebrates. These sites are functionally important, 
while overexpression of MEF2 mutants (non-acetylated) inhibit myogenic 
differentiation (Ma et al. 2005) (Figure 12). 
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Figure 12. Schematic of model of HAT and HDACs. In the unphosphorylated 
state, class II HDACs are localized in the nucleus and associated with MEF2, 
resulting in repression of target genes. Phosphorylation of two conserved 
serines that flank the NLS of HDACs results in recruitment of 14-3-3 and 
dissociation from MEF2. Binding of 14-3-3 masks the NLS and activates a 
cryptic NES at the carboxyl terminus of HD A Cs leading nuclear export. 
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Calcium-dependent activation of calcineurin leads to dephosphorylation of Ser 
and Thr residues on MEF2 in neurons and muscle cells (Mao & Wiedmann, 1999; 
Wu et al. 2001 ). Dephosphorylation at S408 is particularly important for the ability 
to switch MEF2 from repressor to activator and is also required for activity to 
induce the switch at K403 from sumoylation to acetylation (Gregoire et al. 2006; 
Shalizi et al. 2006). It is conceivable that the MEF2 isoforms are similarly regulated 
by acetylation and play a key role in biological processes of T-cell development, 
cardiogenesis and neurogenesis. 
1.4.3. Sumoylation of MEF2 
Sumoylation is a novel post-translational mechanism where ~mall !!biquitin-
like modifier (SUMO) proteins are covalently attached to the lysine residues of 
target proteins through an amide bond (Gill, 2005; Hay, 2005). The SUMO is 
approximately 10 kDa in size, which is structurally related to ubiquitin and linked 
to histones. In vertebrates, there are at least three paralogues of SUMO proteins 
(SUMOl, -2, and -3). SUM02 and -3 share greater than 90% sequence identity, and 
both are --50% identical to SUMOl (Gill, 2005; Hay, 2005). SUMO modifies many 
proteins that contribute in diverse cellular processes including cell cycle 
progression, subcellular transport, maintenance of DNA integrity, transcriptional 
regulation, and signal transduction (Bossis & Melchior, 2006). The growing 
number of extranuclear functions of neuronal sumoylation is reported to have 
critical implications in neurological disorders (Martin et al. 2007; Scheschonka et 
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al. 2007). Similar to acetylation, sumoylation targets lysine residues, but within a 
unique consensus sequence: ':PKxE ('I', large hydrophobic residue and x, any amino 
acid) which catalyze by a three set of enzymes, including EI-activating enzyme 
(Aosl/Uba2), E2 conjugating enzyme [Ubc9 (ubiquitin-conjugating enzyme 9], and 
E3 ligases. Further there are three types of SUMO E3 ligases identified as RanBP2, 
the PIAS (Protein Inhibitor of Activated STAT) proteins, and Pc2 (Gill, 2005; Hay, 
2005). They exhibit different subcellular localization patterns and might enhance 
sumoylation of specific subsets of SUMO substrates in vivo. Like ubiquitination, 
sumoylation is a dynamic process and is actively reversed by SUMO-specific 
proteases, including SENPl, -2, -3 and -6, and is controlled by an enzymatic 
pathway (Gill, 2005; Hay, 2005; Bossis & Melchior, 2006). The functional 
consequences of SUMO attachment differ in great extent from substrate to 
substrate. Frequently SUMO alters interactions of substrates with other proteins or 
with DNA. SUMO can also act by increasing proteins stability through 
antagonizing ubiquitination The reversible covalent attachment of these small 
peptides modifies the target protein (Hay, 2005; Bossis & Melchior, 2006; Geiss-
Friedlander & Melchior, 2007). 
Sumoylation has emerged as an important regulatory mechanism for 
transcription factors and cofactors and, in general, inhibits their transcriptional 
activity in variety of tissue types (Riquelme et al. 2006). Series of studies suggest 
that sumoylation could play a pivotal role in controlling MEF2 transcriptional 
activity in muscle and neurons (Gregoire & Yang, 2005; Gregoire et al. 2006; 
Riquelme et al. 2006; Shalizi et al. 2006). Sumoylation of MEF2 is enhanced by 
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class Ila HDACs and by SIRTl-mediated deacetylation of the lysine acceptor for 
SUMO (Gregoire & Yang, 2005, Zhao et al. 2005). HDAC4 has a novel SUMO E3 
ligase activity that regulates MEF2 sumoylation. Previous study has shown that 
HDAC4 binds the SUMO-conjugating enzyme Ubc9 and potently stimulates MEF2 
sumoylation in both cultured cells and an in vitro reconstituted system (Gregoire & 
Yang, 2005, Zhao et al. 2005). In addition, C-terminal domain of MEF2C and 
MEF2D has been shown to be modified by SUM02 and SUM03 on a single lysine 
residue located at a consensus sumoylation motif which is conserved among MEF2 
proteins. Sumoylation inhibits MEF2 transcriptional activity. SUMO protease 
SENP3 reverses this inhibitory effects and augments the myogenic activity of 
MEF2 (Gregoire & Yang, 2005). MEF2A also undergoes sumoylation primarily at 
a single lysine residue (K395) both under in vitro and in vivo condition. Mutation of 
K395 to arginine abolishes MEF2A sumoylation and enhances MEF2 
transcriptional activity (Riquelme et al. 2006). Furthermore, sumoylation of 
MEF2C at K391 inhibits its transcriptional activity but does not block its DNA-
binding activity (Kang et al. 2006). Interestingly, phosphorylation of S396 in 
MEF2C, a residue in close proximity to the major sumoylation site (K391), is 
known to be phosphorylated in vivo but enhances sumoylation of delta-N2-MEF2C 
in vitro. The S396A mutation reduces sumoylation of MEF2C in vivo and enhances 
the transcription activity of MEF2C in reporter assays (Kang et al. 2006). 
Previously, it has been documented that cdk5-induced phosphorylation at conserved 
S444 ( 4 amino acid downstream of a SUMO-targeted lysine residue) is required for 
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MEF2 sumoylation, and dephosphorylation of S444 by calcineurin reversed 
sumoylation of K439 (Gregoire et al. 2006, Kang et al. 2006). 
Neuronal activity regulates the strength and number of synapses that are 
formed during neuronal development, and synapse formation involves contact 
between pre- and post-synaptic neurons (Shalizi et al. 2006). Recently, MEF2s have 
been identified as critical regulators of dendritic claw formation (Flavell et al. 
2006). In developing hippocampal neurons MEF2 suppresses the number of 
excitatory synapses in a neuronal-activity and calcineurin-dependent manner. 
Neuronal activation leads to calcineurin activation and dephosphorylation of MEF2. 
Dephosphorylated MEF2 then leads to regulate various genes that restrict synapse 
number, such as activity-regulated cytoskeleton-associated protein (Arc) and 
synaptic Ras GTPase activating proteinl homolog (synGAP) (Flavell et al. 2006). 
Sumoylation of MEF2A strongly influences synapse formation through a phospho-
regulated sumo-acetyl switch (Shalizi et al. 2006). 
PIASx has been identified as an E3 for MEF2A sumoylation during synapse 
development in vivo. PIASx is a SUMO E3 ligase that represses MEF2-dependent 
transcriptional activity in neurons. Over-expression or knockdown of PIASx was 
shown to significantly enhance or inhibit dendritic claw formation respectively. 
This suggests a role for SUMO E3 ligases in brain development and neuronal 
plasticity (Shalizi et al. 2007). Previously, it has been reported that class Ila HDACs 
(HDAC4,5, 7 and 9) also promote sumoylation of the transactivation domain of 
MEF2D in neuronal cells (Shalizi et al. 2007) The ability of class II HDACs to 
promote MEF2D sumoylation depends on the N-terminal repressor domain and it is 
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independent of the deacetylase motif (Lemercier et al. 2000; Gregoire & Yang, 
2005). This may contribute repression of MEF2-dependent transcription by 
reducing the acetylation of histones at MEF2 target gene promoters and by 
deacetylating K403, a key SUMO residue in MEF2s. Deacetylation of K403 is 
correlated with modification of this residue by the SUMO moiety, which appears to 
stabilize MEF2 in the repressor state (Shalizi et al. 2006; Zhao et al. 2005). 
On the other hand, during brain development, sumoylation at K403 residue 
represses MEF2A, and promotes postsynaptic neuronal differentiation. Activity-
dependent calcium signaling leads to the activation of calcineurin and 
dephosphorylation of MEF2A at S408. This favours de-sumoylation of K403 and 
the subsequent acetylation of this residue, leading to MEF2A activation and 
inhibition of synapse formation (Shalizi et al. 2006). Thus, phosphorylation 
dependent switch between sumoylation (an inhibitory modification) and acetylation 
(an activating modification) comprise a novel regulatory mechanism to regulate the 
MEF2 activity which provides an understanding of the interplay between multiple 
post-translational modifications tightly regulating complex cellular processes. 
1.5. Protein-protein Interaction 
In all organisms, proper development, growth and function requires precise 
and integrated regulation of the gene expression. Often, regulation depends on the 
appropriate binding of proteins to DNA and upon protein-protein interactions. The 
function of MEF2 proteins is also regulated by their direct physical interaction with 
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diverse array of co-factors including activators/repressors, and adaptor/chaperone 
proteins that synergistically regulate MEF2 target gene expression in a variety of 
tissue types (Black & Olson 1998) (Figure 13). 
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Figure 13: The schematic of MEF2 interacting partners (co-activators/co-
repressors ). The regulation of MEF2 is achieved through its interaction with 
diverse array of these co-factors in variety of tissues. 
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1.5.1. MEF2:MEF2 interactions 
MEF2 members can homo- and heterodimerize with each other, but they 
cannot interact with other MADS-box containing factors, suggesting that specific 
amino acids residues within the MADS-box that establish dimerization interface are 
not conserved outside the MEF2 family (Black & Olson, 1998). In non-muscle cells 
MEF2A:MEF2D heterodimers are predominantly found to be transcriptionally 
inactive (lkeshima et al. 1995; Black & Olson, 1998). In contrast, MEF2A:MEF2A 
homodimers are commonly formed in muscle cells and robustly activate muscle-
specific gene transcription (Dodou et al. 1995; Omatsky & McDermott, 1996; 
Black & Olson, 1998). Interactions between MEF2 members are mediated through 
the MADS-MEF2 domain of MEF2 factor. However the TAD domain of MEF2 is 
dispensable for the interaction with most of the known MEF2 coactivators. A 
truncated form of MEF2 containing only MADS and MEF2 domains acts as a 
dominant-negative transcription factor (Omatsky et al. 1997), suggesting that gene 
expression requires more than DNA binding and dimerization of MEF2. The 
selection of genes regulated by MEF2 is normally determined by MEF2 interaction 
with other co-factors in various tissue types. 
1.5.2. MEF2: HDACs & HATs interactions 
MEF2 activity is tightly regulated by two families of chromatin-remodeling 
enzymes (HA Ts and HD A Cs). Histone acetylation by histone acetyltransferases 
(HATs) relaxes the structure of nucleosomes (Gregoire et al. 2007) whereas histone 
deacetylations by histone deacetylases (HD A Cs) promotes chromatin condensation, 
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and thereby act as transcriptional activators and repressors, respectively (McKinsey 
et al. 2001 b; Grozinger & Schreiber, 2002; Verdin et al. 2003 ). HD A Cs regulate 
cellular processes in variety of tissue types, including skeletal muscle and cardiac 
growth, bone development, and neuronal survival by controlling gene expressions 
(Grozinger & Schreiber, 2002). The HAT p300, for example, has been shown to 
interact with the MADS domain of MEF2C, and to potentiate MEF2-mediated 
transactivation (Sartorelli et al. 1997). In mammals, there are four major classes of 
HDACs based on their homology to distinct yeast HDACs. Class I HDACs 
(HDACl, 2, 3, and 8) are widely expressed and consist mainly of a catalytic 
domain, and are nuclear, believed to act predominantly at the chromatin level. Class 
II HDACs are divided into two sub-classes, Ila (HDAC4, 5, 7, and 9) and Ilb 
(HDAC6 and 10). Class III HD A Cs are referred to as sirtuins (SIRT 1-7) and class 
IV (HDAC 11 ). Members of Class I, II and IV HD A Cs share a common feature 
such as the dependence on zinc for their enzymatic activity, whereas class III 
HDACs are NAD+-dependent and members of class III HDACs are related to yeast 
Sir2, and are SirTl-7 (Wang et al. 1999). In addition, there is a truncated form of 
HDAC9, also called MEF2 interacting transcriptional repressor (MITR) that lacks 
intrinsic deacetylase activity, but it can recruit other HDACs or CtBP to MEF2 
proteins (Sparrow et al. 1999; Bertos et al. 2001; Zhang et al. 2001 a; Verdin et al. 
2003). Growing evidence supports a therapeutic potential for HDACs against 
diseases such as neurodegenerative disorders and cardiac hypertrophy (Zhang et al. 
2001a; Yang & Gregoire, 2005; Bolger et al. 2007) (Figure 14A). 
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Figure 14A: The schematic diagram of class II HDAC family members. 
Members of class II HDACs have a bipartite structure, with a C-terminal 
catalytic (HDAC) domain and an N-terminal extension with a MEF2 binding 
domain. Conserved phosphorylation sites flank the nuclear localization 
sequence (NLS) and a nuclear export sequence (NES) is near the C terminus. 
MITR is a splice variant of HDAC9 that lacks an HDAC domain. 
All class Ila HDACs (HDACs 4, 5, 7, and 9) are distinguished from other 
classes of HDACs. Class Ila HDACs exhibit three unique features. First, they are 
expressed in a tissue-specific manner and exert their transcriptional repressive 
function in diverse tissue types (Martin et al. 2009). Second, members of Ila 
HDACs contain a highly conserved 18 amino acid extension domain (MEF2 
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binding domain) at their N-termini that mediates binding to MEF2 proteins and 
regulating nuclear-cytoplasmic shuttling, while other classes of HDACs do not 
contain this domain and fail to directly interact with MEF2s (McKinsey et al. 
2001a; Chan et al. 2003) (Figure 14B). 
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Figure 14B: The schematic structure of class II HDAC (histone deacetylase) 
protein. Class II HDACs have a bipartite structure, with a C-terminal catalytic 
(HDAC) domain and an N-terminal extension with a MEF2 binding domain. 
Conserved phosphorylation sites flank the nuclear localization sequence (NLS) 
and a nuclear export sequence (NES) is near the C terminus. Phosphorylation 
of two conserved serines that flank the NLS results in recruitment of 14-3-3. 
Binding of 14-3-3 masks the NLS and activates a cryptic NES at the carboxyl 
terminus. 
MEF2 activity in muscle is inhibited under basal conditions by class Ila 
HDACs, which repress cellular gene expression by binding directly to MEF2 
proteins in the nucleus (Miska et al. 1999). Third, phosphorylation of class Ila 
HDACs is a crucial event that determines whether they are localized in the nucleus 
or cytoplasm and, therefore, their ability to act as transcriptional co-repressors in 
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the nuclear compartment. The cellular trafficking class Ila HDACs are regulated by 
intrinsic nuclear import and export signals as well as binding sites for 14-3-3 
proteins (Grozinger & Schreiber, 2000). HDAC4, 5, 7, and 9 contain series of 
conserved 14-3-3 binding sites located in the regulatory N-terminal domain. 
Binding of the 14-3-3 proteins stimulate the cytoplasmic retention or nuclear export 
of the class Ila HDACs in a phosphorylation dependent manner, which in turn 
regulates the activity of transcription factors such as MEF2, that regulates muscle, 
stress-responsive and survival genes (McKinsey et al. 2000a; Bertos et al. 2001; 
Verdin et al. 2003) (Figure 15). 
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Figure 15. Schematic of model of HAT and HD A Cs in the control of muscle 
gene expression. In undifferentiated myoblasts, the activity of MEF2 is 
repressed by association with a variety of HDACs, resulting in deacetylation of 
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histones and transcriptional repression of muscle target genes. Initiation of 
differentiation, CaMK and possibly other kinases phosphorylates HDACs 
results in dissociation of HDACs from MEF2. Hyperphosphorylated Rb binds 
to HDACl in a competitive manner to dissociate HDACs from MEF2 leading 
histone acetylation. p300/PCAF and other coactivators with HAT activity are 
then recruited to muscle gene control regions through association with MEF2, 
with resulting activation of muscle transcription and myotubes formation 
(adapted from McKinsey et al. 2001). 
Several signaling pathways, including Ca2+/calmodulin-dependent kinases 
(CaMKs) (McKinsey et al. 2000a), protein kinase D (PKD) (Vega et al. 2004), 
microtubule affinity-regulating kinases (Chang et al. 2005), and salt-inducible 
kinases (SIK) (Berdeaux et al. 2007) regulate phosphorylation of these 14-3-3 
binding sites. Majority of class Ila HDACs demonstrate cell-type-restricted 
expression patterns and target selected physiological programmes (Bertos et al. 
2001; Verdin et al. 2003, Majdzadeh et al. 2008) (Figure 16). 
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Figure 16. Model of class Ila HDACs activity regulated by multiple 
kinases/phosphatases in variety of tissue types. Class Ila HDACs have a C-
terminal catalytic (HDAC) domain and' an N-terminal regulatory domain. The 
phosphorylation sites are located in the N-terminal. Kinases/phosphatases that 
phosphorylate/dephosphorylate class Ila HDACs are shown with a description 
of the biological functions in diverse tissue types. 
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The interaction between MEF2 and HDACs was originally identified by yeast 
two hybrid screening (Sparrow et al. 1999; Lu et al. 2000a). Class Ila HDAC4 and -
5 are predominantly expressed in· the skeletal, cardiac, and smooth muscle, and the 
brain, within the same tissues where MEF2s expression are also found in highest 
levels. Interestingly, number of studies documented that HDAC4, 5, and 7 directly 
interacts with MEF2 and act as potent inhibitors of MEF2 dependent transcriptional 
activity (Lemercier et al. 2000; Lu et al. 2000b ). Overexpression of both HDAC4 
and HDAC5 suppresses skeletal muscle cell differentiation in vitro (McKinsey et al. 
2000b ), while expression of HDAC4 in muscle fibers is sufficient to induce muscle 
damage in mice (Miska et al. 1999). Previous studies in knockout mice have 
identified class Ila HDACs as key regulators of tissue growth and development. 
Mice lacking HDAC5 and HDAC9 show exaggerated hypertrophic growth of the 
myocardium in response to diverse stress stimuli (Backs & Olson, 2006). Mice 
deficient in HDAC4 show premature bone calcification, and mice lacking HDAC7 
show embryonic lethality resulting from a failure to form tight junctions in the 
developing circulatory system (Martin et al. 2009). Both HDAC4 and HDAC5 
show many similarities in control class Ila HDAC activity but differential 
localization of HDAC4 and HDAC5 has also been observed during differentiation 
of myoblasts into myotubes. HDAC4 is cytoplasmic in undifferentiated myoblasts 
and shuttle into the nucleus after myoblast fusion during differentiation (Miska et 
al. 2001; Zhao et al. 2001 ). However, HDAC5 localization exhibits an inverse 
pattern: it is nuclear in myoblasts and is exported to the cytoplasm during 
differentiation (McKinsey et al. 2001 a; Zhao et al. 2001 ). The functional 
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significance of this difference is not clear. It is possible that HDAC4 and HDAC5 
target different MEF2-dependent genes during the transition of myoblasts to 
differentiating myotubes. Previously, it has been shown that MEF2 proteins 
associate with histone deacetylase5 (HDAC5) in myoblasts, resulting in repression 
of muscle genes controlled by MEF2 sites (McKinsey et al. 2000a). The repression 
of particular MEF2 dependent genes by HDAC4 is required at the later stages of 
muscle differentiation/ or to maintain a terminally differentiated state of myotubes 
(Lu et al. 2000b). Association of class Ila HDACs and other co-factors with MEF2 
promotes the formation of multi-protein repressive complexes on MEF2-dependent 
muscle genes such as myogenin (Potthoff & Olson, 2007). Previously, it was shown 
that HDAC4 and related members bind to MEF2 via the MITR homology domain 
and potently repress MEF2-induced gene transcription (Sparrow et al. 1999; Zhang 
et al. 2001 b ). Another study identified activation of HDAC4 in response to 
chronically reduced neural activity suppresses MEF2-dependent gene expression 
and contributes to progressive muscle dysfunction and also observed in 
neuromuscular diseases (Cohen et al. 2009). Previously, it was thought that 
inhibition of MEF2 transcriptional activity, through direct interaction with HDACs, 
prevents the myogenic genes expression prior to cells receiving appropriate 
differentiation cues. In proliferating myoblasts, MEF2 is present but 
transcriptionally silent. When cells are induce to differentiate, calcium-regulated 
protein kinases, such as PKD and various CaMKs convey signals from G protein-
coupled receptors to the regulatory phosphorylation sites in class Ila HDACs in a 
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variety of tissue types, rescue MEF2-dependent target genes from HDACs 
inhibitory effects (Verdin et al. 2003; Paroni et al. 2004). 
The interaction between MEF2 and HD A Cs ( 4 and 5) and its regulation by the 
CaMKs, has been well characterized in skeletal, cardiac muscle and in neuronal 
cells (McKinsey et al. 2002; Linseman et al. 2003a; Backs et al. 2006; Potthoff et 
al. 2007; Cohen et al. 2009). Activation of CaMK results in dissociation of MEF2 
from these HDACs and unmasking of MEF2 transcriptional activity (Ginnan et al. 
2012). Repression of MEF2 activity is specific for HDACs 4 and 5, but, it is not 
observed for other HDACs that lack the MEF2-interacting region. However, this 
repression can be relieved by over-expression of active CaMKs, whereas the 
transcriptional activity of MEF2 proteins can also be inhibited by CaMK inhibitors, 
such as KN-62 and KN-93 (Lu et al. 2000a; Linseman et al. 2003a). MEF2 can then 
associates with HA Ts and other positive regulators of muscle differentiation and 
activate myogenic genes. CaMK I and IV directly phosphorylate HDAC5 on 
conserved residues at Ser259 and Ser498. These sites are conserved in HDAC4 as 
Ser246 and Ser467, which creates a docking site for the intracellular chaperone 
protein 14-3-3 (McKinsey et al. 2000a; Vega et al. 2004). In skeletal muscle fibers, 
the signal-dependent regulation of HDAC4, but not HDAC5, seems to be under the 
control of CaMK II (Liu et al. 2005). The specificity among the different class Ila 
HDACs with respect to their responsiveness to upstream kinases is not fully 
determined yet. The binding of 14-3-3 to HDACs disrupts its interaction with 
MEF2, and subsequent export of the 14-3-3: HDACs complex from the nucleus to 
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the cytoplasm through a CRMl-dependent nuclear export process (Grozinger & 
Schreiber, 2000; McKinsey et al. 2000b) (Figure 17). 
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Figure 17. Regulation of class Ila HDACs activity. MEF2 factors bind to their 
target promoters and repressed by a variety of HDACs complexes. Class II 
HDACs, including HDAC4, HDACS, HDAC7 and HDAC9, interact directly 
with the MEF2 DNA-binding domain. Class I HDACs, such as HDACl and 
HDAC2, can also be recruited to MEF2 through the corepressor Cabinl, 
inhibits MEF2 target gene expression in myogenic and neurgenic cells. 
In addition to its chaperone role, 14-3-3 can also associate with MEF2D 
directly and enhance its activity (Grozinger & Schreiber, 2000). Phosphorylation-
dependent association of class Ila HDACs with 14-3-3 has additional effects, such 
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as blocking the interaction between these HDACs and importin a, which prevents 
nuclear import and dissociation of class Ila HDACs from HDAC3, which would 
attenuate deacetylase activity (Grozinger & Schreiber, 2000; Gregoire et al. 2007). 
Most of the previous studies document that only class II HD A Cs are able to bind to 
MEF2 proteins, whereas Class I and III HDACs can not bind to MEF2 due to the 
lack of the 18 conserved amino acids that mediates the interaction. However, one of 
the class I HDAC proteins (HDAC3) can directly interact with MEF2D through the 
MADS-box domain (Gregoire et al. 2007). Moreover, HDAC3 can also bind to the 
acetyltransferases p300/PCAF to attenuate autoacetylation. Consequently, HDAC3 
is able to repress MEF2-dependent transcription and inhibits myogenesis via the 
physical interaction and deacetylase activity. Whereas, the negative effect of 
HDAC3 was reversed by silencing HDAC3 expression with RNA interference 
resulted in enhanced MEF2 transcriptional activity and myogenesis. However, 
forced expression of HDAC3 had little effect on MEF2 activity in skeletal muscle 
cells (Gregoire et al. 2007). In contrast to HDAC4 and 5, HDAC3 efficiently 
deacetylated MEF2D in vitro and in vivo and this effect is specific to HDAC3, 
whereas other class I HD A Cs (HDAC 1, 2, and 8) failed to act in similar manner 
(Gregoire et al. 2007). 
The role of the HD AC-mediated regulation of MEF2 has begun to be explored 
in neurons that linked to regulation of neuronal survival as well as death (Li et al. 
2001; Linseman et al. 2003). A substantial body of evidence indicates that the 
activity of MEF2 transcription factors play a critical role in neuronal survival. 
MEF2 family members, MEF2A and MEF2D are highly expressed and active in 
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cerebellar granule neurons (CGNs) promoting neuronal survival, particularly in 
response to depolarization-induced signals that is important during neuronal 
development (Li et al. 2001). In neurons, class Ila HDACs are identified to contain 
a MEF2 binding site, HDAC5 is the only member interacts with MEF2 in CGNs. 
Previously it was demonstrated that HDAC5 play a critical role in regulation of 
neuronal cell death. Overexpression of HDAC5 induces apoptosis in CGNs, as a 
result of inhibiting pro-survival role of MEF2 (Linseman et al. 2003). Localization 
of both HDAC4 and 5 appears to be calcium signaling dependent in cell culture. In 
CGNs, HDAC4 and 5 are mainly localized in the cytoplasm in the presence of 
depolarizing media (containing high potassium) but translocates to the nucleus 
under neuronal death conditions, such as withdrawal of depolarization media or 
excitotoxic glutamate conditions (Nakanishi & Okazawa 2006). By contrast, 
treatment with the neuronal survival factor BDNF suppresses HDAC4 nuclear 
translocation, whereas blocking CaMKs expression by pro-apoptotic CaMKs 
pharmacological inhibitors (KN-93) stimulates HDAC4 nuclear accumulation, 
mimics the effect which is accompanied by loss of MEF2 activity. These 
experiments suggest that CaMK induces neuronal survival by phosphorylating 
HDAC4, which leads to its ~ytoplasmic localization (Chawla et al. 2003; Bolger & 
Yao, 2005). HDAC5 binds to MEF2 in the nucleus and inhibit the expression of 
MEF2 regulated genes whose activities responsible for neuronal survival (Linseman 
et al. 2003) (Figure 18). 
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Figure 18. Regulation of class Ila HDACs activity in myogenic and neurogenic 
cells. In response to calcium signalling, class II HDACs are phosphorylated by 
activated calcium/calmodulin-dependent protein kinases (CaMKs). This results 
in recruiting the 14-3-3 family of chaperone proteins, which displace HDACs 
from MEF2 and promote HDAC export from the nucleus. After releasing from 
HDACs repressive complex, MEF2 become activated and activate target gene 
expression. 
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However, in hippocampal neurons, these HDACs act differently in response to 
depolarization activity, was shown to be sufficient for nuclear export of HDAC4 but 
not that of HDAC5 (Chawla et al. 2003). HDAC5 nuclear export was demonstrated 
to be induced following stimulation of calcium influx through NMDA receptors or 
L-type calcium channels (Chawla et al. 2003). Isozyme CaMKIIa is a brain-specific 
kinase and well-known for its role in depolarization-mediated survival of CGNs and 
in hippocampal long term potentiation, a cellular model of learning and memory 
(Linseman et al. 2003; Belfield et al. 2006). However, CaMKIIa is also expressed 
in cerebellum, where it has been implicated in CGN neurite outgrowth (Faison et al. 
2002; Yang et al. 2008). These studies have shown that HD A Cs play a substantial 
role in inhibition of MEF2 dependent gene expression leading to neuronal cell 
death. Furthermore, overexpression of CaMKIIa rescued neurons from HDACs 
mediated cell death (Linseman et al. 2003; Bolger & Yao 2005); as a result of 
HDAC and 14-3-3 binding, HDACs are exported out of the nucleus (Bolger et al. 
2007). The functional significance of the interaction between MEF2 family 
members and other class Ila HDACs in the context of neuronal survival is not 
known and needs further study. Previous studies has shown that overexpression of 
HDAC9 in muscle inhibits the upregulation of activity-dependent genes and 
chromatin acetylation in association with MEF2 and class! HDACs (Mejat et al. 
2005). Moreover, HDAC9-null mice were demonstrated to be supersensitive to 
denervation-induced changes in gene expression. The splice variant of HDAC9 has 
been shown to contain a conserved MEF2 binding site functioning in cardiac 
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myocytes but no interaction between HDAC9 and MEF2 has been defined in CGNs 
(Mejat et al. 2005). 
In addition, Protein Kinase C (PKC) signaling and its downstream effector, 
Protein kinase D (PKD) effectively block the nuclear export of HDAC5 in response 
to hypertrophic agonists in primary cardiomyocytes (Vega et al. 2004 ). PKD acts as 
a direct class Ila HDAC kinase. PKD has recently been reported to phosphorylate 
HDAC5 at the same sites which are phosphorylated by CaMK in skeletal muscle 
(Vega et al. 2004 ; Kim et al. 2008). The findings of PKD as HDAC kinase is 
critical to cardiac biology, while studies attempting to link HDAC5 regulation to 
CaMKs signalling in cardiac tissues have been unclear (Vega et al. 2004 ). PKD 
identified as a key regulator of skeletal muscle function and phenotype (Kim et al. 
2008). Strikingly, levels ofHDAC4 and HDAC5 phosphorylation were increased in 
the conditional PKD 1 transgenic mice and correlate with elevated levels of MEF2 
transcriptional activity (Kim et al. 2008). Abolishing the nuclear export of HDAC5 
by inhibitors of PKC/PKD but not CaMK indicates the predominant role of the 
PKC/PKD pathway in regulating HDAC5 localization in heart. Ectopic expression 
of active PKDl in the heart resulted in dilated cardiomyopathy (Vega et al. 2004). 
Furthermore, a novel and selective PKD inhibitor, bipyridyl PKD inhibitor 
(BPKDi), blocked the phosphorylation and nuclear export of class Ila HDACs, 
leading to the suppression of cardiac hypertrophy (Monovich et al. 2010). 
Interestingly, co-immunoprecipitation studies indicate that PKD, and not PKC, 
physically associates with HDAC5 while, PKC isoforms have also been identified 
to phosphorylate MEF2 in vitro and in vivo (Vega et al. 2004 ). PKDs are clearly 
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involved in regulating class Ila HDACs in cardiac tissues. Although, the exact 
mechanism of phosphorylation compared to PKD-induced HDAC export in muscle 
development is still unknown. Furthermore, a link between PKDs and class Ila 
HDACs in neurons has not been established. 
Previous studies suggested that protein kinase A (PKA) also regulates MEF2 
activity through HDAC-mediated mechanisms by promoting HDACs nuclear 
retention, as a result inhibiting of MEF2 activity in neuronal cells (Belfield et al. 
2006). Series of studies in recent years, particularly in the McDermott laboratory, 
have revealed that class Ila HDACs isoforms, such as HDAC4 and HDAC5, act as 
signal-responsive repressors of nuclear MEF2 activity and MEF2-dependent target 
genes in skeletal and smooth muscle, and in hippocampal neurons (Du et al. 2008; 
Gordon et al. 2009; Perry et al. 2009; Salma & McDermott, 2012). The salt-
inducible kinase 1 (SIK 1) was originally identified as a serine/threonine protein 
kinase whose expression was enhanced in the adrenal glands of rats fed a high salt 
diet (Wang et al. 1999; Berdeaux et al. 2007). SIKs are also upregulated in response 
to ACTH signaling, and depolarization and kinase-induced seizures in 
adrenocortical tumor cells and in the nervous system, respectively (Feldman et al. 
2000; Okamoto et al. 2004). In unstimulated adrenal cells, SIKl is localized to both 
cytosolic and nuclear compartments; however, when adrenal cells are stimulated 
with ACTH, SIKl is exported from the nucleus (Takemori et al. 2002). The nuclear 
shuttling of SIKl is regulated by direct phosphorylation by PKA at Ser577; whereas 
mutation of this serine residue to alanine r~sults in a nuclear distribution and 
constitutively active SIKl activity (Takemori et al. 2002). Furthermore, previous 
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studies have revealed that SIKl also phosphorylates class Ila HDACs specifically, 
HDAC4 and HDAC5 at Ser246/Ser467 and Ser259/Ser498 respectively and 
promote nuclear export of these HDACs (Berdeaux et al. 2007). Knockdown of 
SIKl suppresses HDAC5 phosphorylation, whereas overexpression of SIKl 
induced the nuclear export of an HDAC5-GFP fusion protein in C2C 12 myoblasts 
culture (Takemori et al. 2009). In addition, forced expression of SIKl in vivo was 
able to increase the amount of phosphorylated HDAC5 and decrease the necrotic 
foci number in a muscular dystrophy model (Berdeaux et al. 2007). Interestingly, 
SIKl homologue (KIN-29) in C. elegans phosphorylates the class Ila HDAC 
(HDA-4) on one conserved residue in mammalian HDAC5 (van der Linden et al. 
2007). In skeletal muscle, PKA phosphorylates SIKl at Ser577 residue to inhibit its 
catalytic activity and reduce the amount of phosphorylated HDAC5. Another 
evidence suggests that SIKl is an important regulator of HDAC4-mediated c-jun 
repression in vascular smooth muscle cells (VSMC) and forced expression of SIKl 
promoted nuclear export of HDAC4 which leading to induce c-jun expression in 
cultured VSMCs (Gordon et al. 2009; Ginnan et al. 2012). SIKl, that is normally 
phosphorylate by PKA, co-expression of PKA, initiate rapid shuttling of HDAC4 
into the nuclear region as a result increased repression of c-jun expression. However 
mutation of PKA phospho site in SIKl, serine 577 to alanine, increases c-jun 
expression. Therefore, these results indicate that SIKl is an important HDAC 
kinase that regulates MEF2-dependent c-jun expression through PKA signaling in 
VSMCs (Gordon et al. 2009). 
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According to one study ataxin-1 is identified as a neurodegenerative disorder 
protein whose mutant form causes the spinocerebellar ataxia type-1 (SCAl). This 
acts as a repressor of MEF2-dependent transcription in cerebellar granule neurons 
by associating MEF2-HDAC4 transcriptional complex which compromised 
neuronal survival (Bolger et al. 2007). Interestingly, ataxin-1 binds specifically to 
HDAC4 and colocalizes with MEF2-HDAC4 in the nuclear inclusion bodies. 
Additionally, studies have revealed that phosphorylation at S776 is a critical 
modulator for ataxin-1 toxicity (Emamian et al. 2003; Chen et al. 2003) and 
phosphorylation of this site shown to recruit the phospho-binding protein 14-3-3, 
resulting in increased ataxin-1 stabilization, aggregation, and toxicity (Chen et al. 
2003). Remarkably, mutation of serine776 to alanine severely impairs the ability of 
ataxin-1 to obtain a prominent neurodegeneration phenotype (Emamian et al. 2003). 
The findings of this study provide evidence of functional interaction between 
ataxin-1 and MEF2-HDAC complex, suggested repression of MEF2 activity may 
contribute to ataxin-1-induced neurotoxicity in cerebellar granule neurons (CGN). 
Whereas, ectopic expression of MEF2 partially rescues cellular toxicity caused by 
ataxin-1 in CGN. Therefore, restoring MEF2 transcriptional activity, for example, 
by HDAC inhibitors could be beneficial for SCAl patients (Bolger et al. 2007). 
Taken together, these findings suggested that the class Ila HDACs and MEF2 
association play a significant role in the development of muscle and neurons. 
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1.5.3. MEF2 and Protein phosphatase 1 (PP 1) 
There are several co-factors that have been identified to directly or indirectly 
interact with MEF2 proteins and their contribution in regulation of MEF2 
transcriptional properties such as kinases, Class Ila HDACs, discussed in above 
subsection. However, until very recently, the identity of the phosphatases as a 
MEF2 co-factor and effect of phosphatases dephosphorylation on their interacting 
partners remained unknown. Phosphorylation is reversible processes and many 
phosphatases are involved in dephosphorylation kinase activities in range of tissue 
types (Grozinger & Schreiber, 2000). The first evidence was obtained by using 
phosphatases inhibitor ( calyculin A) in skeletal muscle, confirms the involvement 
of a serine/threonine phosphatase in the regulation of class Ila HDACs. Treatment 
with phosphatases inhibitor decreases the amount of HDACs in the nucleus of 
skeletal muscle fibers (Grozinger & Schreiber, 2002; Liu et al. 2005). Previously, it 
was shown that bidirectional synaptic plasticity at cerebellar parallel fiber (PF)-
Purkinje cell (PC) synapses is under control of a kinases/phosphatases switch 
mechanism, which control the postsynaptically expressed long-term depression 
(LTD) or long-term potentiation (L TP) and similar mechanisms also observed at 
hippocampal synapses (Belmeguenai & Hansel, 2005). Protein phosphatases are 
classified into three families on the basis of phospho-amino acid specificity, 
structure and interaction with regulatory subunits (Ceulemans & Bollen, 2004). The 
family of phosphatases, protein phosphatase 1 (PP 1) is one of the most conserved in 
eukaryotes. The family PP 1 is composed of three ubiquitously expressed isoforms 
(a, ~ and y) that regulate a variety of cellular functions (Ceulemans et al. 2002; 
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Cohen, 2002). Substrate specificity and localization of PP 1 phosphatases is 
achieved through interaction with regulatory subunits CR-subunits) which typically 
contain the highly conserved 'RVXF'([K/R]-X-[V/I/L]-X-[F/W]) binding motif. 
PP 1 a phosphatase activity is regulated by direct phosphorylation of a C-terminal 
threonine residue (T320) by cyclin dependent kinase complexes or direct interaction 
with inhibitory R-subunits (Ceulemans et al. 2002). 
Recently from our group, a novel physical interaction has been identified 
between the catalytic subunit of the protein phosphatase la (PPla) and MEF2. 
Binding of PPla to MEF2 occurs within the nucleus and shown to inhibit MEF2-
dependent transcriptional activity, in part, by recruiting HDAC4 to MEF2A (Perry 
et al. 2009). Interestingly, PPla phosphatase activity is not required for MEF2 
repression and was originally thought to dephosphorylate class Ila HDAC4 to 
promote their nuclear import in both phosphatase-dependent and phosphatase-
independent manner (Grozinger & Schreiber, 2000; Perry et al. 2009). Moreover, 
PP 1 a overrides the positive influence of calcineurin signaling on MEF2 regulation 
and MEF2-PP1a interaction leads to control nuclear retention of HDAC4 followed 
by recruitment of HDAC4 to MEF2 transcription complexes in skeletal muscle cells 
(Perry et al. 2009). This study also provided evidence that PP 1 a- interferes with the 
pro-survival effect of MEF2 in primary hippocampal neurons by repressing MEF2 
function. Taken together, these findings reveal the first functional interaction 
between PP 1 a and MEF2 proteins and MEF2-mediated transcriptional repression 
with a phosphatase in skeletal muscle and hippocampal neurons. As such this 
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interaction between PP 1 a and MEF2 exhibit an important and novel aspect of 
MEF2 regulation in both tissue types. 
1.5.4. MEF2: NFAT interactions 
In vertebrates, nuclear factor of ~ctivated I cells (NF AT) family consist of five 
isoforms NFATcl/2/c, NFATc2/1/p, NFATc3/4/x, NFATc4/3 and NFAT5/TonEBP 
(Rao et al. 1997; Graef et al. 2001; Macian 2005). All family members contain the 
DNA binding domain, however only NFATcl-c4 contains the Ca2+ 
sensor/translocation domain (Jain et al. 1995; Graef et al. 2001). The NFAT family 
of transcription factors functions as integrators of multiple signaling pathways by 
binding to chromatin in combination with other transcription factors such as MEF2 
to regulate genes essential for many developmental processes. Evidence from 
previous studies that NF AT plays a role in vertebrate development came from 
NF AT kockout mouse. Targeted disruption of NF A Tc 1 results in embryonic 
lethality with defects in cardiac valve formation (de la Pompa et al. 1998; Ranger et 
al. 1998). Deletion of NF ATc2 causes hyperproliferation of lymphocytes (Hodge et 
al. 1996; Xanthoudakis et al. 1996), and also dysregulation of chondrogenesis 
(Ranger, Gerstenfeld et al. 2000). NF ATc3 null mice have defects in myogenesis 
(Oukka et al. 1998; Kegley et al. 2001). 
In T-1 ymphocyte, NF AT are most important co-activator links calcineurin 
signaling to MEF2, which is critical in the regulation of T-lymphocyte apoptosis 
(Blaeser et al. 2000, Youn et al. 2000). MEF2 factors act as integrators of calcium 
signaling. Variations in intracellular calcium (Ca2+) concentration can alter MEF2's 
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phosphorylation status as well as the interaction with co-regulators in muscle 
(McKinsey et al. 2002). NF AT activation is dependent upon a rise in intracellular 
Ca2+, which activates the serine/threonine phosphatase, PP2B/calcineurin (Clipstone 
& Crabtree 1992; Jain et al. 1993; Hogan et al. 2003). This phosphatase directly 
dephosphorylates several residues in the Ca2+ sensor/translocation domain of 
NF AT, resulting in nuclear import of NF AT. In contrast, the nuclear export of 
NF AT requires the sequential rephosphorylation of this domain by several kinases 
like GSK3~ (Beals et al. 1997; Okamura et al. 2004). Previously, it has been shown 
that calcineurin activate MEF2 by recruiting members of the NF AT family of 
transcription factors and form complex that regulate MEF2 mediated gene 
expression (Molkentin et al. 1998; McKinsey et al. 2002). Upon dephosphorylation 
by calcineurin, NF AT translocates to the nucleus where it directly interacts with 
MEF2 family members, MEF2A and -D (Blaeser et al. 2000). Number of studies 
demonstrated that NF AT is involved in skeletal muscle fiber type acquisition (Chin 
et al. 1998, Wu et al. 2000). The direct interaction between MEF2-NF AT greatly 
stimulates MEF2-dependent genes expression by facilitating recruitment of 
p300/CBP to MEF2 response elements (Youn et al. 2000). However, NF AT also 
known for their co-activation of GATA transcription factors, where they induce cell 
hypertrophy (Wada et al. 2002). In addition, forced expression of calcineurin in vivo 
powerfully activated a MEF2-LacZ reporter gene in skeletal muscle and to a lesser 
degree in the heart (Wu et al. 2000). 
NFAT is an important player in the developing as well as in adult CNS. MEF2 
and calcineurin is highly expressed in the brain, and transgenic mice containing 
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NF AT reporters show that the brain is the organ having the highest levels of NF AT 
transcriptional activity (Plyte et al. 2001; Wilkins et al. 2004). The cooperative 
binding of NF AT with other transcription factors to form NF AT transcriptional 
complexes appropriate for neuronal development appears to be downstream of 
neurotrophin and netrin signaling pathways. Therefore, MEF2-NAFT physical 
association may play a critical role in neuronal development. In neurons, L-type 
calcium channel signaling modulates intracellular calcium levels to regulate the 
nuclear import and transcriptional activity of NF AT by activating the phosphatase 
calcineurin. The rephosphorylation and following nuclear export of NF AT is 
mediated by GSK3 ~' which contribute to the induction of NF AT transcriptional 
activity in neurons (Beals et al. 1997; Neal & Clipstone 2001; Sheridan et al. 2002). 
Modulation of Ca2+ levels through voltage gated Ca2+ channels might also allow 
NF AT transcription complexes to sense and integrate synaptic activity during the 
process of synaptogenesis. The calcineurin/NF AT signaling is important in 
neuronal axon growth and guidance during vertebrate development. Studies with 
triple NF ATc2/c3/c4 mutant mice demonstrated that the organization of sensory 
neurons projection and commissural axons growth are both dependent upon NFAT 
activity (Graef et al. 2003). In addition to calcium signaling, neurotrophin 
(BDNF/NGF) also play an important role in NFAT transcriptional activity mediated 
axon growth in several neuronal populations, including cortical and hippocampal 
neurons (Groth & Mermelstein, 2003; Benedito et al. 2005). However, according to 
another study NFATc4 promoted neuronal survival in the developing cerebellum 
(Benedito et al. 2005). It may be suggested that genes in developing neurons are 
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regulated by integrating transcription factors, such as MEF2-NF AT transcriptional 
complexes, and involve in diverse neuronal pro-differentiation and pro-survival 
functions. 
1.5.5. MEF2 and MRF proteins 
Many promoters and enhancers are particular in their regulation due to specific 
transcription factors binding. It is thought that the specificity of transcriptional 
regulation is controlled by combinations of transcription factors. During skeletal 
muscle differentiation, muscle-specific genes are regulated by two groups of 
transcription factors, the MyoD and MEF2 families, which work together to drive 
the differentiation process. The transcriptional activity of MEF2 is highly sensitive 
to regulation of gene expression by post-translational modifications that modulate 
MEF2 mediated gene expression and interactions with co-factors (Black et al. 1998; 
McKinsey et al. 2002). The most studied interaction of MEF2 proteins is with 
MyoD; myogenic regulatory factors (MRFs). This plays an important role in the 
control of skeletal muscle development by enhancing the muscle-inducing activity 
of myogenic bHLH proteins. The MRFs belong to basic helix-loop-helix (bHLH) 
family of sequence specific DNA binding transcription factors. Members of the 
bHLH family have been shown to control determination and differentiation of a 
variety of cell types, including skeletal muscle, neurons, and hematopoietic cells 
(Black & Olson, 1998). There are four myogenic bHLH proteins, the MRFs, consist 
of Myogenic Differentiation-1 (MyoD), Myogenic Factor-5 (Myf5), Myogenin 
(MyoG), and Myogenic Regulatory Factor-4 (MRF4/Herculin/Mfy6) (Pownall et al. 
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2002). In the skeletal muscle lineage, the four MRFs compose of a regulatory 
pathway that establishes myoblast identity and control terminal differentiation. 
Ectopic expression of any members of MRF family into nonmuscle C3H10Tl/2 
fibroblasts in culture, each of these members can activate the entire program for 
skeletal myogenesis (Davis et al. 1987; Yu et al. 1996; Molkentin & Olson, 1996). 
The MRFs heterodimerize with another class of ubiquitously expressed bHLH 
proteins known as E proteins (such as E12, E47), and binding to a consensus DNA 
sequence (CANNTG) commonly known as an E-box. This is found in the 
regulatory region of most muscle specific genes to induce muscle specific gene 
expression in co-operation with other transcription factors (Murre et al. 1989; 
Brennan & Olson, 1990; Etzioni et al. 2005). This leads to the differentiation of 
muscle progenitor cells to morphologically and biochemically distinctive skeletal 
myocytes (Olson et al. 1991). MEF2 proteins can potently synergize with MyoD-
E 12 heterodimers and capable of converting nonmuscle cells to differentiated 
myotubes, whereas these proteins cannot activate transcription in collaboration with 
E12 homodimers (Molkentin et al. 1995, Naidu et al. 1995, Ornatsky et al. 1997) 
(Figure 19). Mutation or substitution of the MyoD basic domain with the E 12 
basic domain allows interaction to occur but blocks the transmission of activation 
signal (Molkentin et al. 1995). 
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Figure 19. Schematic of MEF2-MRFs interaction. Four potential mechanisms 
for synergistic activation of gene expression. a) MEF2 heterodimerize with 
MRFs (MyoD/E12) bound to DNA. b) Recruitment of MRFs when MEF2 
bound to DNA. c) MRFs and MEF2 heterodimerize by binding to adjacent 
sites on DNA. d) Binding of MRFs and MEF2 heterodimers to non-adjacent 
site on DNA and synergistically activate gene expression by protein-protein 
interaction (Adapted from Black & Olson, 1998). 
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There is accumulating evidence that MEF2 and MyoD associate through direct 
physical interaction to synergistically activate transcription and myogenesis when 
only one factor is bound to DNA (Kaushal et al. 1994; Molkentin et al. 1995; 
Molkentin et al. 1996). The bound factor is then capable of recruiting the other 
factor through protein-protein interactions. This interaction occurs through DNA-
binding and dimerization domains (Molkentin et al. 1995). However, many muscle-
specific promoters and enhancers contain MEF2 sites and E boxes in proximity to 
one another, suggesting that both classes of transcription factors may be bound to 
DNA at the same time while interacting with each other (Cheng et al. 1993; Yee & 
Rigby, 1993; Edmondson et al. 1992; Black et al. 1995; Naidu et al. 1995). 
Moreover, ectopic expression of MEF2 proteins with MRFs into C3H10Tl/2 
fibroblasts increases myogenic conversion whereas this myogenic conversion can 
be subdued by a dominant negative MEF2A protein lacking its transactivation 
domain (Omatsky et al. 1997). Additionally, this dominant negative MEF2A was 
also documented to repress myotube formation in cultured myoblasts, suggesting 
that MEF2 is required for skeletal muscle differentiation (Omatsky et al. 1997). 
MEF2C and myogenin can interact with each other while both are bound to DNA. 
The structure of the MEF2C skeletal muscle promoter/enhancer is remarkably 
similar to that of the myogenin and MRF4 promoters, both of which contain MyoD-
and MEF2-binding sites. Like MEF2C, myogenin and MRF4 are upregulated 
during myocyte differentiation, presumably through direct transactivation by bHLH 
and MEF2 factors. This type of crosstalk provides a powerful mechanism for 
amplification of both types of regulatory genes, thereby reinforcing and stabilizing 
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the transcriptional program for myogenesis. Alternatively, both MEF2 and 
myogenic bHLH factors bound to DNA may stabilize the protein-protein 
interactions between them to more efficiently activate transcription. 
However, in neuronal cells, MEF2 physically interact with neurogenic basic 
helix-loop-helix (bHLH) transcription factor MASH-1, a protein implicated in the 
development of neurons, to regulate gene expression (Black et al. 1996; Skerjanc & 
Wilton, 2000). MEF2-MASH-1 interaction is neuron specific and with broadly 
expressed in brain which provides the adaptability of MEF2 function in CNS. This 
interaction is mediated through the MADS-MEF2 domain of MEF2 and bHLH 
binding region ofMASHl (Black et al. 1996; Mao & Nadal-Ginard, 1996). Further 
this interaction allows MEF2 and MASH 1 to activate gene expression through their 
respective DNA-binding sites in a cooperative and synergistic manner, thereby 
providing functional mode that potentially expand its regulatory targets. 
1.5.6. Interaction between MEF2 and other co-factors 
It is clear that MEF2 function depends on its ability to recruit co-factors for 
appropriate activation of target gene. The HATs cyclic adenosine monophosphate 
(cAMP) response element binding protein (CREB)-binding protein (CBP) and p300 
interact directly with the MEF2 domain. The site overlaps with the HDACs binding 
site (Sartorelli et al. 1997; DeLuca et al. 2003). Displacement of HDACs and 
recruitment of HAT activity following myogenic stimuli have been shown to 
enhance lysine acetylation in chromatin at MEF2 responsive genes, a common 
correlate of transcriptional activation (Zhang et al. 2002). In T-lymphocytes, MEF2 
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is required for apoptosis upon activation of the T-cell receptor (McKinsey et al. 
2002). This process requires dissociation of the calcium-sensing receptor Cabin I, 
which competes with p300 for MEF2 binding, from the MADS-MEF2 domain. 
Disruption of CabinI binding to MEF2 by calcium signaling leads to transcription 
of the pro-apoptotic nur77 gene in a p300 and MEF2-dependent manner (Youn & 
Liu, 2000). In addition to HATs, MEF2 interacts indirectly with the co-activator-
associated arginine methyltransferase-I (CARMI). The enzymatic activity of 
CARMI, which promotes histone arginine methylation, is requires for myoblast 
differentiation (Chen et al. 2002). 
The interaction of MEF2 and CARMI is dependent upon a nuclear receptor 
co-activator, glucocorticoid receptor interacting protein-I (GRIP-1). GRIP-1 is a 
member of the steroid receptor co-activator (SRC)/p I 60 FAMILY of proteins that 
facilitate chromatin remodeling through the recruitment of histone acetyl and 
methyltransferases (Xu & Li, 2003). GRIP-I targets MEF2 upon differentiation and 
enhances MEF2-dependent transcription (Chen et al. 2000). Conversely, stimuli 
that block muscle differentiation, such as transforming growth factor (TGF~) 
activation of SMA- and MAD-homolog 3 (SMAD3) or the activity of cyclin-
dependent kinases, disrupt the association of MEF2 and GRIP I and prevent the 
GRIP I dependent subnuclear targeting of MEF2 (Lazaro et al. 2002; Liu et al. 
2004). Smad2/4 complexes, key mediators of the TGF~ signaling, have been shown 
to cooperate with MEF2 to initiate transcription in cultured C2C 12 muscle cells 
(Quinn et al. 2001). An alternative coactivator of MEF2 dependent transcription is 
the peroxisome proliferators activated receptor y (PPAR y) coactivator I a (PGC-I 
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a). It is a master regulator of mitochondrial biogenesis and energy homeostasis and 
it promotes transcription through its ability to recruit chromatin modifying and 
RNA processing complexes (Puigserver & Spiegelman, 2003). In addition to 
MEF2A cofactor, expression of the PGC-la gene is stimulated by calcium signaling 
and MEF2 dependent transcription. PGC-1 a is not required for muscle formation 
but instead promotes fast-to-slow fiber type switching and enhances the expression 
of genes required for oxidative metabolism (Czubryt et al. 2003). A physical 
association between MEF2 and two SAP domain transcription factor, including 
myocardin (a cardiac-enriched isoform arising from alternative splicing) and 
MASTR, which robustly activates MEF2-dependent gene expression (Creemers et 
al 2006b). Interestingly, MEF2 can also cooperate with the broadly expressed 
transcritption factors SPl to regulate the promoters of the neuronal N-methyl-D-
aspartate (NMDA) receptor subtypel (NRl) and trophic factor NT3, respectively 
(Grayson et al 1998; Krainc et al. 1998; Shalizi et al. 2003). 
2. Function of MEF2 in myogenic & neurogenic cells 
The robust expression of MEF2 transcripts and protein expression in myogenic 
and neurogenic tissues correlates with the strong MEF2 activity in diverse tissue 
types. Several lines of evidence have implicated MEF2 function in muscle 
progenitor cell specification and differentiation (Black & Olson 1998). Drosophila, 
D-mef2 gene demonstrated an essential role of MEF2 in myogenesis and 
morphogenesis (Bour et al. 1995; Prokop et al. 1996). In addition to its functional 
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role in myogenesis, MEF2s are also involved in cardiac hypertrophy 
(Kolodziejczyk et al. 1999). The phenotypes of mef2s null mice showed distinct 
role of MEF2 in skeletal and cardiac muscle (Lin et al. 1997; Black & Olson, 1998; 
Naya et al. 2002; Phan et al. 2005; Kim et al. 2008). 
Since the members of the MEF2 family (MEF2A-D) are critical during muscle 
differentiation and cardiovascular function (Black & Olson, 1998; Molkentin et al. 
1998) but their individual roles within the central nervous system are still largely 
unknown. In addition to muscle, all members of the MEF2 family are highly 
expressed in brain tissues during embryogenesis suggest that these transcription 
factors also play important roles in the developing brain (Leifer et al. 1993, 1994; 
McDermott et al. 1993; Lyons et al. 1995; Lin et al. 1996). MEF2A and MEF2C 
expressions are restricted in cortex and cerebellum region during developing and 
adult neurons (Mao et al. 1999; Marinissen et al. 1999). Cortex contains a high 
level of MEF2C protein (Lin et al. 1996). In the mouse brain, MEF2A, C and D are 
expressed at high levels in multiple regions, including cortex, hippocampus and 
cerebellum (Lyons et al. 1995). MEF2A and MEF2D have been shown to play a 
specific role in cerebellar development and further involve to promote 
differentiation and survival of cerebellar granule neurons (Leifer et al. 1993, 1994; 
McDermott et al. 1993; Lyons et al. 1995; Lin et al. 1996; Mao et al. 1999; 
Marinissen et al. 1999; Salma & McDermott, 2012). Distinct patterns of expression 
during pre- and postnatal development suggest specific and distinct functions for 
each MEF2 protein at different stages of neuronal development. Furthermore, there 
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are indications that MEF2 proteins regulate acquisition of neuronal phenotypes 
(Ikeshima et al. 1995; Okamoto et al, 2000). 
2.1. The role of MEF2 in neuronal cells 
Over the last two decades significant progress has been made towards 
enhancing our understanding of the MEF2 functional role in CNS during 
embryogenesis, postnatal development, and adult tissue maintenance. Several lines 
of evidence suggest that MEF2 proteins are critically important for differentiation in 
post-mitotic neurons (Lyons et al. 1995; Li et al. 2001; Lam & Chawla, 2007; 
Genikhovich & Technau, 2011). In recent years, MEF2 protein has emerged as a 
key regulator in the development of the CNS (Kim et al. 2011; Salma & 
McDermott, 2012; Yin et al. 2012). Inhibition of MEF2 function in primary 
hippocampal and cortical neurons has been shown to induce neuronal cell death, 
suggesting that MEF2-dependent transcriptional regulation is necessary for 
neuronal survival (Mao et al. 1999; Okamoto et al. 2000; Kato et al. 2000; Shalizi et 
al. 2007; Yang et al. 2009; Perry et al. 2009; Lam et al. 2010; Kim et al. 2011; 
Salma & McDermott, 2012). Further the predominance of work on MEF2 function 
in the CNS has focused on the role of this transcriptional factor in controlling 
neuronal survival in response to a variety of extra- and intracellular stimulations 
(Shalizi et al. 2003; Linseman et al. 2003b; Wiedmann et al. 2005; Shalizi et al. 
2006; Bolger et al. 2007; Fiore et al. 2009; Lam et al. 2010). In cerebellar granule 
neuron (CGN) survival depends on activity of MEF2 transcription factors. 
Depolarization-mediated MEF2 activity and CGN survival are compromised by 
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MEF2 inhibition. Both MEF2A and MEF2D undergo phosphorylation and caspase-
mediated degradation during neuronal apoptosis (Li et al. 2001 ). Another study 
documented that ectopic expression of dominant-negative MEF2C cause apoptosis 
in cortical neurons. In dopaminergic neuron, modulation of MEF2 by cdk5 induced 
neuronal death (Smith et al. 2006). Additional evidence showed that MEF2 
regulates activity dependent survival of granule neurons but overexpression of the 
MEF2 repressor histone deacetylase-5 (HDAC5) abolished this effect (Tian et al. 
2010; Lam et al. 2010; Dietrich et al. 2012; Lyon et al. 2012). Knockdown of 
MEF2A using RNA interference (RNAi) markedly decreases the survival of 
granule neurons (Gaudilliere et al. 2002; Flavell et al. 2006). Moreover, 
depolarization-induced MEF2 activation is necessary for the survival of 
differentiating neurons (Gaudilliere et al. 2002) and MEF2 mediates activity-
dependent survival of both cortical and cerebellar neurons (Mao et al. 1999). 
MEF2C is expressed in postmitotic differentiating neurons, but not in proliferating 
precursor cells in the cortex region, suggesting that MEF2 controls maturation of 
newly differentiated neurons (Mao et al. 1999). MEF2C transcription is stimulated 
by membrane depolarization in cerebellar neurons (Mao and Wiedmann, 1999). 
Another study has shown that loss of MEF2C in nestin-expressing neural 
stem/progenitor cells impairs neuronal differentiation in vivo. The neurotrophin 
comprise family of secreted proteins that has numerous functions in the nervous 
system development and plasticity (Poo, 2001 ). Neurotrophins (NGF and BDNF) 
promote the survival of distinct neuronal populations during brain development and 
their potential to promote recovery of neurons after injury in the mammalian adult 
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brain. Recent study found that BDNF activate MEF2C transcription in both neuron-
like PC 12 cells and in primary cultured cortical neurons which involve in neuronal 
plasticity (Lyons et al. 2012). ERK5 signaling contributes to neurotrophin 
stimulation of MEF2C transcription involves in neuronal survival. An intriguing 
feature of this effect is that ERK5 and MEF2D survival pathway is predominantly 
important for the survival of neurons that depend exclusively on neurotrophin 
support applied to distal axons (Liu et al. 2003). These observations suggest that the 
expression of different MEF2 isoforms during neuronal development in response to 
external stimuli can change the fine-tuning of transcription-dependent neuronal 
plasticity and MEF2 transcriptional inducibility of important activity-regulated 
survival genes (Tian et al. 2011 ). Another group demonstrated that neurotrophin-
induced expression of anti-apoptotic gene (bcl-w) and MEF2D promote survival of 
developing sensory neurons (Pazyra-Murphy et al. 2009). However increased 
expression of MEF2D, in response to neurotrophin stimulation, eliminates synapse 
formations, but promotes neuronal survival. This indicates that MEF2 plays a dual 
role in maintaining number of synaptic formations, while simultaneously 
controlling the neuronal survival. Collectively, these findings suggest that MEF2 
function is required for neuronal survival during the early stages of neuronal 
development and maturation. In vitro data strongly suggest important roles for 
specific MEF2 isoforms in neuronal survival, whereas the precise functions of the 
individual MEF2 isoforms in vivo remains to be defined. 
Functions of the CNS rely upon synapses, the sites of communication between 
neurons and functional nodes in neural circuits. Synapses are complex structures, 
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changes in the structure and efficacy of synapses are the biological basis of 
neuronal functions such as learning and memory. Proper organization and activity 
of synapses define normal brain functions (Ruegg, 2001 ). MEF2 family members 
are highly expressed in the neurons where they regulate calcium-dependent 
transcriptional programs that are important for synapse and dendritic development 
(Flavell et al., 2006; Shalizi et al., 2006; Pfeiffer et al. 2010; Akhtar et al. 2012). 
Range of studies indicated that MEF2 protein is required for neurite growth, 
dendrite morphogenesis, and differentiation of post-synaptic structures (Flavell et 
al. 2006; Shalizi et al. 2006; Lam et al. 2007; Fiore et al. 2009; Kawashima et al. 
2009; Tian et al. 2011; Akhtar et al. 2012; Chen et al. 2012). The expression of 
MEF2 proteins in the CNS is regulated temporally and spatially in an isoform-
specific manner, and coincides with neuronal maturation. For example, cerebral 
cortical neuronal development is associated with changes in the expression of 
MEF2C (Leifer 1993 & 1994 ), whereas CGN maturation is coupled to enhanced 
expression of MEF2A and MEF2D (Lin et al. 1996). MEF2A and MEF2D are 
expressed in virtually all striatal neurons, including dorsal striatal and ventral 
striatal (nucleus accumbens) regions. The co-localization of MEF2A and MEF2D 
isoforms bind to DNA as heterodimers in striatal neurons (Pulipparacharuvil et al. 
2008). Expression of MEF2A and MEF2D is found only in neurons but absent in 
astrocytes, indicating that MEF2 is restricted to neurons in the mammalian cortex 
and the cerebellum (lkeshima et al. 1995). The predominantly neuronal expression 
of the MEF2 factors in the mammalian brain is particularly important in neuronal 
survival, synapse formation and maintenance (Flavell et al. 2006; Shalizi et al. 
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2006). MEF2 differential tissue distribution suggests that MEF2 proteins may be 
regulated in an isoform-specific manner and the regionally-specific differences of 
MEF2 involvement in neuronal differentiation and survival. RNA-interference-
mediated knockdown of both MEF2A and D or activation in cultured hippocampal 
neurons results in increased excitatory synapse formation, or loss of synapses and 
dendritic spines, respectively. This suggests that activation of MEF2 restricts 
synapse numbers in hippocampal neurons (Flavell et al. 2006) (Figure 20). These 
alterations depend on the ability of the MEF2 isoforms to stimulate neuronal 
activity-dependent regulation of target genes expression (Flavell et al. 2008). MEF2 
promotes post-synaptic dendritic morphogenesis that control neuronal survival. 
MEF2D expression is identified in both proliferating precursor cells and in 
differentiated neuronal cells that converts into two different population, neurons and 
glial cells but MEF2D expression increases in the nuclear region of neurons while 
decreases in the glial cells. MEF2D regulate neuronal development by controlling 
synapse formation and protecting newly differentiated neuronal cells (Shalizi et al. 
2007). Interestingly, similar knockdown of MEF2A in developing cerebellar 
granule neurons in vitro or in vivo result in decline in the number of dendritic claws 
and synaptic formation (Shalizi et al. 2006; Pulipparacharuvil et al. 2008). Recent 
study documented that MEF2C is the major isoform involved in hippocampal 
synaptic function (Akhtar et al. 2012). Conditional deletion of MEF2C result in a 
marked increase in the number of excitatory synapses, accompanied by synaptic 
potentiation and decreased synaptic transmission, but with significant impairments 
in hippocampal-dependent learning and memory (Barbosa et al. 2008). 
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In hippocampal and cerebellar neurons, MEF2A regulates the formation and 
maintenance of neurite and excitatory synapses by modulating the expression of 
synapse specific genes (Flavell et al. 2006). The MEF2A plays an important role in 
the formation of excitatory synapses in the hippocampus and the cerebellum, where 
it is localized exclusively in the nucleus. MEF2A plays an additional role in the 
lateral septum and bed nucleus of the stria terminalis (LS/BNST), amygdala, and 
paraventricular hypothalamus, where it is localized to axons and dendrites as well 
as nuclei and is primarily associated with inhibitory synapses (Neely et al. 2009). 
Acute transcriptional activation of MEF2 causes a decrease in synapse number 
via induction of MEF2 mediated target genes, Arc and Homerla which actively 
disassemble excitatory synapses formed onto MEF2 expressing neurons. Induction 
of Arc by MEF2 leads to internalization of postsynaptic AMP A receptors de-
represses excitatory transmission. However, induction of Homer la by MEF2 leads 
to the deconstruction of scaffolding proteins complexes at the synapse (Flavell et al. 
2008). Although BDNF (brain derived neurotrophic factor) is also identified as a 
potential MEF2 target gene in neurons that are involve in limits synapses number 
but further studies are needed to exactly define the detailed molecular mechanism 
by which MEF2 activity involve in synapse formations and neuronal survival. 
Originally BDNF has been identified primarily in the context of synapse maturation 
and recent studies have shown that BDNF has diverse functions depending on its 
posttranscriptional modification and cellular localization, as well as the selection of 
receptor (Lyons et al. 2012). It is possible that under certain conditions BDNF and 
possibly some other MEF2 target genes may be selectively deployed to a subset of 
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synapses that will ultimately be retained rather than eliminated. Role of MEF2 in 
Drosophila is well known in muscle development. Recently MEF2 expression, 
recorded in clock neurons, reported as playing a role in circadian behavior. 
(Blanchard et al. 2010). So the knockdown of MEF2 means loss of circadian 
behavioral rhythms. 
3. MEF2 target genes 
MEF2 plays an important role in myogenic program by activation of muscle 
specific target genes which determine the transition of single cell to differentiate 
into multinucleated myotubes. Regardless different level of MEF2 activity, it has 
been demonstrated that MEF2 can independently affect different muscle genes. 
Some genes require higher MEF2 activity levels for their expression than others 
(Chen et al. 2012). In contrast to the wealth of information available on the 
regulatory targets of MEF2 in skeletal muscle, relatively little is known about the 
identities of the MEF2 controlled genes in neuronal cells. Therefore it is important 
to understand MEF2 role in neuronal cells by characterization of MEF2 target 
genes. It is also worthwhile to understand how hundreds of genes are regulated in a 
controlled program by a single transcription factor. MEF2 coordinate the complex 
process of development in diverse tissue types. In this study we have uncovered a 
novel MEF2 target gene in neuronal cells known as Knippel-like factor 6 (KLF6). 
KLF6 gene expression is observed in neuronal and non-neuronal cells which 
dynamically responsive to extracellular stimuli. We found that KLF6 play critical 
role in neuronal survival and it is also involved in skeletal and cardiac muscle 
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development (Dionyssiou et al. 2013). Characterization of KLF6 may steps 
forwards our understanding of the role of MEF2 in the regulation of gene 
expression during skeletal muscle differentiation, cardiac and neuronal cells 
development. An emerging body of evidence implicates an important role for KLF6 
factors in neuronal and cardiovascular development, but the role of KLF6 in muscle 
development is still need to be identified. 
The Kriippel-like factor 6: 
The Knippel-like factor 6 (KLF6), also known as Core Promoter Binding 
Protein (CPBP)/GC-rich sites binding factor (GBF), is a zinc-finger transcription 
factor (Zf9) (Koritschoner et al. 1997). It belongs to the Knippel-like factor (KLFs) 
family of gene regulatory proteins implicate in many biological processes, including 
proliferation, apoptosis, differentiation and development. The Knippel-like factors 
(KLFs) are members of the zinc-finger family of transcription factors named after 
their similarity to the Drosophila body pattern-determining gap gene Kruppel 
(meaning "cripple") (Nusslein-Volhard & Weischaus 1980; Schuh et al. 1986). 
KLFs are closely related to the Sp family of zinc-finger transcription factors (Dang 
et al. 2000) and are critical regulators of phenotypic modulation and physiologic 
function. In 1993 the first mammalian KLF gene, KLF 1 or Erythroid Kriippel-like 
factor (EKLFl), was cloned. To date, 17 members of the KLF family have been 
identified in mammalian cells and are known to be expressed in a broad range of 
tissue types. According to phylogenetic relationships and recent nomenclature are 
referred to as KLFl-KLFl 7. The majority of KLF family members are discovered 
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within the last 5 years (Suske et al. 2005; Pearson et al 2008). The 17 genes 
encoding different KLFs are found all over the human genome and identical to 
mouse genome which are also contain 17 Kif genes. These genes are evolved 
during gene duplications process. The high level of conservation of structure and 
function of KLF proteins in different species is a reflection of their ancient 
evolutionary history. 
Initially, KLFs were named after the tissue in which they were highly 
expressed and detected first time such as erythroid Eklf (KLF 1 ), lung Lklf 
(LKLF2), gut Gklf (KLF4), intestinal Iklf (KLF5) and KLF15 is kidney Kklf 
(Bieker, 1996; Shields et al. 1996; Turner & Crossley, 1999a; Pearson et al 2008). 
KLF9 was identified as a basal transcription element binding (BTEB) protein, with 
KLF5 (BTEB2) and KLF13 (BTEB3) as homologues (Kobayashi et al. 1995). 
KLFlO and KLFl 1 were identified as early genes induced by transforming growth 
factor~ and they are also named as TIEG and TIEG2, respectively (Fautsch et al. 
2008). Other KLFs family members are widely expressed including basic Bklf 
(KLF3) and ubiquitous Uklf (KLF6 and KLF7). During the last decade, the KLF 
family members have been known for investigation in human health and diseases 
(Ratziu et al. 1998; Black et al. 2001; Dong & Chen, 2009). These factors appear to 
exert important regulatory functions on many biological processes, including 
endothelial development (SenBanerjee et al. 2004; Parmar et al. 2006); 
hematopoiesis (Nuez et al. 1995; Turner & Crossley, 1999b; Matsumoto et al. 
2006); cardiac remodeling (Shindo et al. 2002; Fisch et al. 2007); angiogenesis 
(Bhattacharya et al. 2005); neoplasia (Rowland et al. 2005; Wei et al. 2006); 
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gluconeogenesis (Gray et al. 2007); monocyte activation (Feinberg et al. 2005; Das 
et al. 2006) and determination of pluripotent stem cell fate (Takahashi & 
Yamanaka, 2006) (Figure 21). 
KLF1, KLF2 & KLF4 
N c 
KLF3, KLFB & KLF12 
N c 
KLF6&KLF7 
N• c 
KLF9, KLF13, KLF14& KLF16 
N• 
N 
KLF10& KLF11 
Co-activator/repressortransactivation 
domain 
c 
c 
DNA binding domain 
Containing Zinc-finger 
motif 
Figure 21: The schematic family members of Kriippel-Iike factor. KLF 
proteins are grouped according to common structural and functional domains. 
KLFs are highly homologous in their carboxyl-terminal DNA-binding regions, 
which contain three C2H2 zinc finger motifs. 
Structure: There is significant conservation in several aspects among the KLF 
family members, for example, all KLFs are characterized by a highly conserved 
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DNA binding domain at the carboxyl terminus and recognize GC-rich DNA 
sequences that has a CACCC homology in its target gene promoters to mediate 
activation and/or repression of transcription (Miller & Bieker, 1993; Pearson et al. 
2008). The unique feature of the KLF family is the presence of highly conserved 
classical three Cys2/His2 zinc fingers with more than 65 per cent amino acid 
sequence identity among the family members. Zinc fingers 1 and 2 contain 23 
residues, while the third finger has only 21 residues. The Cys2/His2 zinc fingers 
present in the KLFs consist of two short beta strands followed by an alpha helix, 
two conserved cysteines and histidines coordinate a zinc ion in the classical 
Cys2/His2 zinc-finger domain (Philipsen & Suske, 1999) (Figure 22). 
N 
c 
Figure 22: The structure of Kriippel-like factor. Shown are the three C-
terminal C2H2 zinc fingers, each chelating a single zinc ion. The fingers are 
linked by the "TGERP"-like motif, which assists in binding to target DNA. The 
activation/repression domain is found at the N-terminus of the molecule. 
In addition, the seven residue sequence in between the zinc-finger domains 
(TGE(R/K)P(Y/F)X) is highly conserved in KLF family members and this linker 
sequence is located to the extreme C-terminus of the proteins (Dang et al. 2000). 
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KLFs have unique N-terminal regions, which enable them to participate in diverse 
cellular processes including transcriptional regulation, cell proliferation, or 
differentiation (Cook & Urrutia, 2000; Sun et al. 2001; Kaczynski et al. 2003; 
Suske et al. 2005) (Figure 22). 
Expression of Kriippel-like factor 
KLF6 is evolutionary conserved and broadly expressed in numerous tissue 
types and at several developmental stages including the placenta, heart, lung, 
kidney, liver, and brain (in the forebrain and midbrain) (Ratziu et al. 1998; 
Blanchon et al. 2001; Fischer et al. 2001; Laub et al. 2001a; Ito et al. 2004; 
Matsumoto et al. 2006; Miele et al. 2008; Jeong et al. 2009). In the mouse, KLF6 is 
expressed in embryonic tissues at El0.5 and in undifferentiated mesenchyme 
surrounding the neural tube and brain vesicles by El 1.5, with strong expression in 
the nervous system by El2.5 and low levels in the heart, ureteric bud, and lung buds 
(Fischer et al. 2001; Laub et al. 200la). By E14.5, KLF6 is nearly undetectable 
except in the ventral horn at the level of the forelimbs. Subsequently, strong KLF6 
expression is observed between E16.5 and E18.5 in the intestinal mucosa and in the 
fetal liver between E14 and E20 (Laub et al. 2001a; Ratziu et al. 1998). KLF6 is 
detected in the developing cornea of the 7-weeks old fetus. KLF6 mostly localize in 
the cytoplasm of cornea cells but accumulate more in the nucleus after birth 
(Nakamura et al. 2004 & 2007). Phylogenetically, KLF6 is most related to KLF7 
(Laub et al. 2005). KLF6 and KLF7 have been segregated into distinct group based 
on structural and functional features. Thus both genes have comparable exon/intron 
organization in mammalians tissues. In addition to the high homology of the DNA-
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binding domains, KLF6 and KLF7 share 47 residues at the N-terminus region 
providing similar transcriptional activation properties as the stimulation of the p21 
gene promoter. KLF7 is highly expressed ubiquitously during development but at 
low levels in adult tissue. The main difference between KLF6 and KLF7 residue in 
a distinct expression pattern, KLF6 highest expression level is observed in placenta, 
while KLF7 high expression level is restricted to brain tissues, both in the 
peripheral nervous system (PNS) and CNS which reflects essential role of KLF7 in 
neuronal development. But KLF6 and KLF7 are both found to be highly expressed 
throughout the process of brain development (Laub et al. 2001b; Lei et al. 2005; 
Veldman & Bemben, 2007; Moore et al. 2009). Expression of KLF6 is observed in 
various regions in the forebrain, including the cerebral cortex, thalamus, 
hypothalamus and amygdale in the adult brain (Laub et al. 2001a; Jeong et al. 
2009). KLF6 is highly expressed in the neurons of both the pyramidal and granule 
cell layers of the hippocampus. KLF6 signals are detected in the stratum radiatum 
and lacunosum-moleculare of the CAI subfield. The phenotypes of KLF6 
expressing cells in the normal brain are indicative of neurons. The KLF6 expression 
level in the pyramidal cell layer of CA 1 and CA3 regions disappeared after epileptic 
seizures possibly due to neuronal cell death (Jeong et al. 2011). Expression of 
KLF6 in neuronal progenitor cells in the adult forebrain indicates functional role of 
KLF6 (Jeong et al. 2009). In terms of the vascular distribution of KLF6, there are 
several reports showing KLF6 expression in endothelial cells under physiological 
conditions and after vascular injury (Botella et al. 2002; Atkins & Jain, 2007; 
Andreoli et al. 2010; Garrido-Martin et al. 2012). Taken together, widespread 
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neuronal and endothelial distribution of KLF6 protein suggests that KLF6 plays 
specific roles in the physiological functions of the mature brain. 
Researchers have reported that expression of KLF6 increases in various cells 
following the tissue injury. For example number of KLF6 positive cells increases 
upon renal ischemic insults especially in renal epithelial cells (Holian et al. 2008). 
KLF6 is expressed in hepatic stellate cells after liver injury induced by carbon 
tetrachloride, which is a model for hepatic fibrosis (Ratziu et al. 1998). Moreover, 
KLF6 expression is induced in vascular endothelial cells from the aorta and the 
carotid artery after ballooning (Kojima et al. 2000). Therefore, it is highly likely 
that KLF6 expression is directly linked to the mechanism which responds to tissue 
injuries. KLF6 expression is regulated in a number of physiological processes and 
the induced production of KLF6 may mediate some of the subsequent physiological 
responses to extrinsic/intrinsic stimuli. Certain KLFs show a tissue restricted 
expression pattern, but most are widely expressed. The mechanisms regulating 
expression of KLFs are incompletely defined, although it is becoming clear that 
they are often differentially expressed during differentiation. KLF2 is down-
regulated upon activation of T cells. Similarly KLF 4 shows changes in expression 
during B-cell development and KLF5 plays a major role in injury-induced cardiac 
remodelling (Shindo et al. 2002). 
KLF9, a basal transcription element binding (BTEB) protein, is expressed in 
dentate granule neurons of the dentate gyrus (DG ), a region of the mammalian brain 
in which neurogenesis occurs in adulthood. KLF9 is upregulated during the early 
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postnatal period and is expressed in dentate granule neurons during the late stage of 
maturation, when the cells are integrated into the hippocampal network (Scobie et 
al. 2009). Dentate granule neurons from KLF9-/- mice show delayed maturation, 
and adult KLF9-/- mice exhibit impaired differentiation of adult-born neurons. 
Thus, KLF9 is necessary for late-phase maturation of dentate granule neurons both 
in DG development and during adult hippocampal neurogenesis. KLFl 3 is highly 
expressed in adult hearts and is required for normal cardiac development (Lavallee 
et al. 2006). KLFl 5 is also highly expressed in adult hearts and in cardiac 
myocytes. Overexpression of KLF 15 in cardiac myocytes suppresses the 
morphological changes and reduction in gene expression induced by hypertrophic 
stimuli (Fisch et al. 2007; Noack et al. 2012). The expression patterns of the 
individual KLFs vary during development and adulthood. Overlapping patterns of 
expression and function of KLFs suggest distinct functional role of the KLF family 
members, involving cardiac hypertrophy, hematopoiesis, adipogenesis and the 
pluripotency of stem cells. 
Despite the similarities, the majority of KLFs seem to have unique tissue-
specific roles in an in vivo setting. Some of these roles have begun to be elucidated 
primarily by in vivo experiments involving gene knockout. All KLFs knockout mice 
generated to date shows a lethal phenotype. KLF6 knockout mice die by embryonic 
day 12.5 and are characterized by markedly reduced hematopoietic differentiation 
in yolk sacs, placenta and liver. In culture, ES cells are less able to proliferate and 
differentiate in the absence of KLF6 (Matsumoto et al. 2006). KLF7 null mice die 
within 2 days after birth and show severe neurological defects resulting from 
120 
incorrect development of axonal pathways. These defects include disruption of the 
olfactory and visual systems, cerebral cortex and hippocampus. Further analysis of 
the KLF7 null mouse revealed that loss of the protein results in increased apoptosis 
of sensory neurons (Laub et al. 2005). KLF5 -/- mice die before E8.5 due to 
impaired cardiovascular development and adipogenesis (Oishi et al. 2005; Shindo et 
al. 2002). KLF2-/- mice are lethal, cardiac failure at E12.5 to E14.5 (Wani et al. 
1998; Lingrel et al. 2012). KLFlO and KLF15 knockout mice are viable with bone 
defects, impaired skeletal development and aged cardiac defects (Subramaniam et 
al. 2005; Fisch et al. 2007; Wang et al. 2008). Ablations for several KLF gene 
family members indicate an essential role for these factors in the regulation of 
remarkable diverse functions. 
Function of KLF6: 
Many lines of evidence has shown distinct types of human cancers describing 
infrequent genetic alterations of KLF6 gene or even enhanced expression in some 
tumors. Studies has demonstrated that KLF6 function as a tumor suppressor in 
various cancers, such as in prostate and colon cancers, because of its ability to 
reduce cell proliferation through several biochemical mechanisms including 
regulation of cell cycle components, oncogene products and apoptosis. Specifically 
KLF6 appears to be growth suppressive, in part by up-regulating p21, a cyclin-
dependent kinase inhibitor. However, up-regulation of p21 by KLF6 occurs 
independently of p53. Mutation within the KLF6 gene, decreased expression, and/or 
loss-of-heterozygosity is associated with the development of different human 
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malignancies. Thus, loss of KLF6 might lead to removal of cellular proliferation 
controlled mechanism (Narla et al. 2007; DiFeo et al. 2009). Additionally, increased 
evidence suggests that KLF6 is a bonafide target of several signaling cascades, 
which ultimately regulate decisions of cell survival and death. KLF6 interaction 
with c-Jun determines different cell outcomes such as proliferation control or 
apoptosis which depends on the external stimuli received by the cell. 
Most KLFs act primarily as transcriptional repressors and/or activators 
according to specific circumstances. KLF6 is largely transcriptional activator but 
suppresses variety of genes (Jeong et al. 2011; Calderon et al. 2012). As an 
activator of transcription, KLF6 interacts with the core promoter element present in 
both TATA-less or TATA box-containing promoters (Koritschoner et al. 1997; 
Gehrau et al. 2005). In addition to interactions with other proteins, post-
translational modifications (e.g. phosphorylation or acetylation) regulate the 
transactivating activities of different KLFs (Li et al. 2005a). KLF family members 
regulate fundamental cellular responses such as growth, apoptosis, angiogenesis and 
proliferation for example; overexpression of KLF5 is associated with cell 
proliferation, whereas KLF2, KLF4 and KLF6 are more consistently implicated in 
cell cycle arrest (Ghaleb et al. 2005). In diverse tissues, induction of KLF6 
expression occurs rapidly during satellite cell activation. KLF6 has been shown to 
transcriptionally activate structural and cytokine genes including those encoding 
pregnancy-specific glycoprotein 5 (PSG5) (Racca et al. 2011), platelet-derived 
growth factor (PDGF) receptor (Kimmelman et al. 2004), collagen al (Botella et al. 
2002), leukotriene C4 synthase (LTC4S) (Zhao et al. 2000), urokinase plasminogen 
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activator (uPA) (Kojima et al. 2000), transforming growth factor (TGF)-pl, and 
types I and II TGF-P receptors (Mgbemena et al. 2011). Urokinase plasminogen 
activator is a key enzyme implicated in tissue remodeling, tumor metastasis, and 
apoptosis. In addition, KLF6 physically interacts with KLF4 and together they 
activate the human keratin 4 promoters (Okano et al. 2000). 
In addition, an association between KLF6 and transforming growth factor 
(TGF beta) has been reported in different tissues including liver, kidney and 
vascular cells (Kojima et al., 2000). In response to vascular injury, KLF6 interacts 
with Sp 1 and cooperatively binds and transactivates the endoglin promoter 
(Garrido-Martin et al. 2012). Endoglin is an endothelial membrane glycoprotein 
involved in vascular remodeling and cardiovascular development that is up 
regulated in response to arterial injury. KLF6 has been demonstrated to play a role 
in endothelial cell motility (Das et al. 2006). Upregulation of matrix 
metalloproteinase-9 induces endothelial cell migration, a fundamental step in the 
process of vascular remodeling and repair (Garrido-Martin et al. 2012). Receptor 
activation leads to the disruption of Sp2/KLF6 repression complex on the matrix 
metalloproteinase-9 promoter via SHP (small heterodimeric partner). Taken 
together, these results strongly implicate KLF6 as playing a key role in vascular 
development, remodeling and response to injury. KLF6 gene products have also 
been identified in lower vertebrate and invertebrate organisms such as Luna, the 
Drosophila progenitor of the mammalian KLF6/KLF7 group, in which they appear 
to control cell differentiation during embryonic development (Slavin et al. 1999; 
Laub et al. 2001; De Graeve et al. 2003; Zhao et al. 2010). KLF6 also involve in 
123 
pre-adipocyte development by promoting adipocyte differentiation while inhibiting 
delta-like 1 (Li et al. 2005b ). KLF6 was initially shown to be rapidly induced in 
activated hepatic cells, the key fibrogenic cell type during liver injury and repair, 
implicating this factor as playing a role in tissue injury (Ratziu et al. 1998). In 
addition, number of genes directly involve in the liver injury are transactivated by 
KLF6 in hepatic cells, including TGF~ 1, type I and II TGF~ receptors, and collagen 
al (Botella et al. 2002; Mgbemena et al. 2011). Induction of KLF6 occurs in distinct 
models of liver injury in vivo and in vitro, suggesting that the upregulation of KLF6 
is important feature of liver cell development. The expression of KLF6 target genes 
play critical role in the process of hepatic fibrogenesis. 
Despite significant progress in the understanding of KLF6 as a tumor 
suppressor factor and in cancer biology over the last two decades, the expression 
and function of KLF6 in the brain is only beginning to be elucidated. To date, there 
are only few reports published describing the expression and localization of KLF6 
in the brain, however, it remains unclear how the expression of KLF6 changes after 
brain insults, such as epilepsy and ischemia. KLF7, which has 84% homology to 
KLF6 according to the phylogenetic classification, is found in neuronal precursors 
in the brain (Laub et al. 2001 b ). KLF7 knockout mice have deficits in neurite 
growth and axonal projections in the cerebral cortex and the hippocampus, 
suggesting the possible role of KLF6 and KLF7 in the differentiation or maturation 
of neurons and necessary for CNS development (Veldman et al. 201 O; Caiazzo et al. 
2011; Blackmore et al. 2012). In addition, KLF6 and KLF7 have been identified for 
their effects on axon growth in zebrafish retinal explants, where KLF7 was detected 
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together with KLF6, to be necessary for axonal outgrowth in retina (Veldman et al. 
2007; Moore et al. 2011). However, ectopic expression of KLF6 and KLF7 in 
cortical neurons was not synergistic, suggested redundant role in their function 
(Moore et al. 2009). KLF6 and KLF7 that act as positive and negative regulators of 
axon outgrowth are coordinated to control the regenerative capacity of CNS 
neurons. Expression of KLF6 is detected in neuronal progenitor cells by positive 
PSA-NCAM signal in the specialized areas such as the rostro-migratory stream 
(RMS) and the subventricular zone (SVZ), where neuronal progenitors move 
toward the olfactory bulb by chain migration (Jeong et al. 2009). KLF6 has been 
reported to be localized in endothelial cells and neurons where KLF6 transactivates 
TGFP 1 and TGFP receptors, as a result KLF6 may increases transcriptional activity 
of TGFP 1 in endothelial cells and TGFP receptors in neurons. TGFP signaling is 
known to associate with proinflammatory responses and neuronal hyperexcitability 
in the brain (Sanyal et al. 2004; Ivens et al. 2007; Levin & Godukhin, 2011). 
Various brain insults, including cerebral ischemia, subarachnoid hemorrhage and 
excitotoxicity, have been shown to markedly enhance the expression of HSP47 (a 
collagen-specific molecular chaperone) (Bui et al. 2009; Turturici et al. 2011; 
Bornstein & Poon, 2012). It has been known that HSP4 7 whose expression is 
activated by KLF6 in brain tissue, suggested that up-regulation of KLF6 after 
seizure could be associated with tissue remodeling following brain insult (Yasuda et 
al. 2002; Ho & Piquette-Miller, 2007; Dityatev, 2010; Jeong et al. 2011). 
Furthermore in astrocytes, HSP47 has been reported to be induced by TGFp, which 
is also regulated by KLF6 and known KLF6 target gene (Yu et al. 2009). These 
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observations indicated that KLF6 may play critical role in brain inflammation and 
epileptogenesis through activation of HSP4 7 and TGF~ signaling. Taken together, it 
is suggested that KLF6 may involve in regulation of neuronal homeostasis such as 
regulation of neurotransmitter release or synaptic plasticity, by regulating type I and 
type II TGF~ receptors in the adult brain (Vivien et al. 1998; Sanyal et al. 2004; 
Levin & Godukhin, 2011 ). Furthermore, KLF6 may acts as a "molecular switch" 
regulating different function in health and disease (Kimmelman et al. 2004; 
McConnell & Yang, 201 O; Moore et al. 2011 ). 
The MEK5/ERK5/MEF2 pathway has been implicated as playing roles in the 
muscle cell fusion mediated by induction of KLF2 and KLF4. Studies indicate that 
KLF4, KLF2 and KLF6 may have overlapping functions in different tissues (Ruiz-
Gomez et al. 1997; Kumar et al. 2005; Sako et al. 2009; Sunadome et al. 2011). In 
the future, it will be of critical importance to further develop and study animal 
models, such as transgenic and conditional knockout mice, to confirm the in vitro 
results in an in vivo system. The KLFs are emerging as important regulators of 
muscle biology with great interest to cardiovascular biology. The role of KLFs in 
skeletal muscle is significantly less developed than in cardiac or smooth muscle 
(Shindo et al. 2002; Cullingford et al. 2008; Himeda et al. 2010; Li et al. 2010; Sun 
et al. 2011 ). The initial observation was made in Drosophila kruppel protein as a 
critical determinant of myogenic fate (Ruiz-Gomez et al. 1997). KLF family 
members have been identified in developing or mature skeletal muscle cells 
including KLF6 but their regulation and exact role has not been identified yet (Sako 
et al. 2009; Himeda et al. 201 O; Sunadome et al. 2011 ). Recently our group has 
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demonstrated that KLF6 is expressed in skeletal muscle where it involves in 
myoblast proliferation and survival in response to TGF~ signaling (Dionyssiou et 
al. 2013 ). Indeed, future studies are required to better define the spatiotemporal 
expression of the entire family of KLFs across skeletal and cardiac muscle both 
early and postnatal muscle development for our understanding the expression, 
regulation and functional significance of KLFs in muscle tissues. Therefore, a 
deeper understanding of the precise molecular mechanisms by which these factors 
are involved in muscle development will be of fundamental importance for a global 
understanding of gene expression and a variety of muscle pathologies. 
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Chapter II: Statement of purpose 
Myocyte Enhancer Eactor (MEF2) is a key regulator of muscle differentiation. 
In recent years apart from acting as key regulator of muscle differentiation, the 
MEF2 proteins have also emerged as key molecules in the development of the CNS 
and in a variety of neuronal functions. For example MEF2s have been implicated in 
neuronal survival and differentiation. The regulation of MEF2 function is quite 
complex and coordinated at multiple levels including phosphorylation and protein-
protein interaction. However, very little is known regarding regulatory mechanisms 
of MEF2, and functional role of MEF2 mediated target genes in the CNS. In fact, 
until recently there were no MEF2 target genes identified in neurons. There/ ore, 
the main purpose of this study was to characterize signaling pathways 
and novel interacting partners that are involved in the regulation of 
MEF2 transcriptional activity and target-gene expression both in 
myogenic and neurogenic cells. As such the present studies have 
characterized a MEF2 target gene (KLF6) and a novel interacting partner 
(Strawberry notch!). Overall these studies will contribute to our understanding of 
functional role of MEF2 in muscle development and neuronal survival. 
The following objectives will be examined to address the overall goal of this 
study. 
Objective 1: To distinguish the possible role of MEF2 in neuronal survival and 
characterization of PKA signalling in hippocampal neurons (chapter 
III). 
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Objective 2: To identify novel MEF2 interacting partners (chapter IV). 
Objective 3: To investigate the possible role of KLF6 in myogenic cells (chapter 
V). 
These objectives are the main focus of these studies and will be discussed in 
detail in upcoming chapters. 
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Chapter III 
Suppression of a MEF2-KLF6 survival pathway by 
PKA signaling promotes apoptosis in embryonic 
hippocampal neurons 
Published in "The Journal of Neuroscience" 
(2012), 32 (8):2790-2803. 
Experimental design and drafting manuscript by 
Jahan Salma and Dr. John C McDermott. 
Experiments conducted by Jahan Salma 
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Rationale: 
Previous work from our group documented that PKA represses skeletal muscle 
differentiation by directly phosphorylating MEF2D both in vitro and in vivo 
conditions. These observations characterize a potent inhibitory effect of PKA on the 
transactivation properties of MEF2D during myogenic differentiation program. 
MEF2D is abundantly expressed in hippocampal neurons and acts as a pro-survival 
factor but it is unclear how MEF2D is regulated by the PKA signaling in these 
neurons and how exactly the MEF2s promote neuronal survival. Since most studies 
have documented MEF2 survival role activity dependent manner in cortical and 
cerebellar granule neurons. But no evidence were found regarding MEF2 mediated 
target gene (KLF6) in neurons, involved in neuronal survival, regulated by PKA 
signaling. Therefore, we focused two major aspects in present studies: first, 
examining the molecular mechanisms of MEF2D regulation and second, 
characterization of MEF2 mediated target gene, KLF6, in hippocampal neurons 
involved in neuronal survival. 
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Abstract 
In the mammalian nervous system, regulation of transcription factor activity is 
a crucial determinant of neuronal cell survival, differentiation and death. The 
myocyte enhancer factor 2 (MEF2) transcription factors have been implicated in 
cellular processes underlying neuronal survival and differentiation. A core 
component of the MEF2 complex is the MEF2D subunit. Recently, we reported that 
cAMP-dependent protein kinase (cAMP/PKA) signaling negatively regulates 
MEF2D function in myogenic cells. Here, we assessed whether cAMP signaling 
converges on the pro-survival role of MEF2D in Sprague-Dawley rat embryonic 
(E18) hippocampal neurons. Initially, we observed that experimental induction of 
cAMP /PKA signaling promotes apoptosis in primary hippocampal neurons as 
indicated by TUNEL and F ACS analysis. Luciferase reporter gene assays revealed 
that PKA potently represses MEF2D trans-activation properties in neurons. This 
effect was largely reversed by engineered neutralizing mutations of PKA phospho-
acceptor sites on MEF2D (S121/190A). Krilppel-like factor 6 (KLF6) was 
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identified as a key transcriptional target of MEF2 in hippocampal neurons and 
siRNA mediated knockdown of KLF6 expression promotes neuronal cell death and 
also antagonizes the pro-survival role of MEF2D. These observations have 
important implications for understanding the pathways controlling cell survival and 
death in the mammalian nervous system. 
Introduction 
During development of the central nervous system (CNS), a critical balance 
exists between the molecular pathways that control neuronal cell death and survival 
(Contestabile, 2002). Neuronal apoptosis fulfills a crucial role for normal 
organization of the brain through the elimination of excess neurons and synaptic 
connections (Contestabile, 2002; Kano & Hashimoto, 2009; Eroglu & Barres, 
2010). Conversely, abnormal apoptosis contributes to progression of 
neurodegenerative diseases such as Alzheimer's, and Parkinson's (Pfeiffer et al. 
201 O; Legradi et al. 2011; Chu et al. 2011 ). Thus, there is considerable interest in 
the functional characterization of pro-survival molecules in the CNS. 
The transcription factor Myocyte Enhancer Eactor 2 (MEF2) has been 
implicated as playing a pivotal role in neuronal survival as well as in the 
development, differentiation, and plasticity of the mammalian CNS (Leifer et al. 
1994; Schulz et al. 1996; Heidenreich & Linseman, 2004; Pulipparacharuvil et al. 
2008). The MEF2 transcription factor activity was originally identified in myogenic 
cells but has since been shown to function in multiple cell types including cardiac, 
skeletal and smooth muscle, T-cells and neurons (Ornatsky & McDermott, 1996; 
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Black & Olson, 1998; Zhu et al. 2005; Potthoff & Olson, 2007). MEF2 functions as 
a transcriptional regulatory complex that integrates inputs from various signaling 
pathways (Yang et al. 1998; Naya & Olson, 1999; Cox et al. 2000; Mckinsey et al. 
2002). Expression of MEF2 in the brain is consistent with a role in neuronal 
differentiation and survival (Leifer et al. 1993; McDermott et al. 1993; Lyons et al. 
1995; Lin et al. 1996). Disruption of molecular processes that control MEF2 
transcriptional activity can indeed promote neuronal apoptosis (Li et al. 2001; 
Linseman et al. 2003; Butts et al. 2003; Bolger et al. 2007). The MEF2 family 
members (MEF2A, C and D) are expressed throughout the developing and adult 
cerebellum and hippocampus (Ikeshima et al. 1995; Lin et al. 1996). Thus, 
signaling pathways that control MEF2 activity may exert control over neuronal cell 
survival pathways in the CNS. Recently, the MEF2 complex has also emerged as a 
key regulator of synapse development in the CNS (Shalizi et al. 2006; Flavell et al. 
2006 & 2008). RNA interference (RN Ai) of MEF2A markedly decreases formation 
of synaptic structures in cerebellar granular neurons (Gaudilliere et al. 2002; Flavell 
et al. 2006). 
The cAMP-dependent protein kinase A (PKA), an anciently conserved 
signaling molecule, regulates multiple biological processes (Belfield et al. 2006; 
Sands & Palmer, 2008). We reported an inhibitory effect of PKA on the trans-
activation properties of MEF2D during myogenesis (Du et al. 2008). A role for 
PKA as a pro-survival kinase has been demonstrated in some cell types, although it 
has also been implicated in hippocampal neuronal apoptosis (Zhao et al. 2008). 
Thus, we explored a connection between MEF2 and PKA in neuronal cells. Here, 
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we report that repression of MEF2D by PKA signaling promotes neuronal apoptosis 
in hippocampal neurons. Also, we identify Knippel-like factor 6 (KLF6) as a key 
downstream effector of the hippocampal MEF2 survival pathway. 
Materials and Methods 
Reagents and antibodies 
Primary polyclonal antibodies were purchased from Santa Cruz 
Biotechnology; a-Actin (1-19) and a-KLF6 (R-173) sc7158 and a-P-t~bulin III (Tuj 
1) Sigma T3952, a-HDAC4 (ML-19), H9411 Sigma. Primary monoclonal 
antibodies a-P-tubulin III (T8660, Sigma) and a-MEF2D (610775, BD 
Biosciences). GFP(B-2) (Sc-9996 Santa Cruz Biotechnology). Rabbit a- P-tubulin 
III (Tuj 1) T3952 from Sigma. Normal mouse (sc-2025), rabbit (sc-2027), and goat 
(sc-2028) IgGs were purchased from Santa Cruz Biotechnology. FITC and TRITC-
conjugated a-rabbit and a-mouse secondary antibodies were obtained from Sigma. 
Forskolin (F-3917), dbcAMP (D0260), H89-dihydrochloride hydrate (B1427), 
Trichostatin A (Tl 952), DAPI (D9542) and H202 (H0904) were purchased from 
Sigma for use in cell culture. All other reagents were obtained as indicated herein. 
Plasmids 
Expression plasmids for full-length pcDNA3-MEF2D, pMT2 MEF2A, pMT2 
MEF2C pCMV P-galactosidase, and MEF2 reporter gene constructs have been 
described in previous publications (Du et al. 2008; Perry et al. 2009). The firefly 
luciferase reporter gene plasmid pGL3-4xMEF2-Luc was made with 4 copies of the 
MEF2 sites inserted. The expression vector of the catalytic subunit of PKA (pFC-
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PKA) and expression vector for FLAG-tagged HDAC4 were previously described 
(Du et al. 2008; Gordon et al. 2009; Perry et al. 2009). The HDAC4-eGFP and 
HDAC4 Ll 75A plasmids were a kind gift from Dr. X.-J Yang (McGill University). 
Expression plasmids for pcDNA3-Flag-Zf9 and pCineo-KLF6 were a kind gift 
from Prof. Scott Friedman (Mount Sinai School of Medicine, New York, USA). 
The Krilppel-like factor 6 (KLF6) reporter constructs pROM6, pROM5, pROM4 
and pROM3-Luc were generously provided by Dr. Nicolas. P. Koritschoner, 
Facultad de Bioquimica y Ciencias Biologicas, Universidad Nacional del Litoral, 
Santa Fe-Argentina. 
Embryonic hippocampal neuronal cell culture and transfection 
Primary hippocampal neurons were isolated from timed-pregnant (E 18) 
Sprague-Dawley rat embryos (either sex) as described previously (Perry et al. 2009) 
in accordance with the Institutional Animal Care and Use Committee of York 
University, Toronto, Canada. The hippocampi were collected in dissociation 
medium and digested with trypsin, followed by trituration. Neurons were plated on 
pre-coated poly-D-lysine (Sigma), six-well tissue culture plates. Neurons were 
maintained in Neurobasal Medium (Invitrogen) supplemented with B27 (2ml/l 00 
ml, Invitrogen) and L-glutamine (lml/100 ml; Invitrogen), and penicillin (50 
U/mL)/streptomycin (50 µg/ml) in a 37°C humidified incubator with a 5% C02 in 
air. After 24hours one-third of the culture medium was replaced with fresh medium 
and maintained for 7 days in vitro (7DIV) prior to transient transfection. In general 
primary hippocampal neurons were transfected by using calcium phosphate-
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mediated transfection with indicated plasmids on day 6 or 7 in culture and assays 
were conducted 36 h post-transfection. Cells were replenished with fresh growth 
medium 24 h prior to transfection. The transfection efficiency was monitored by 
addition of a constitutively expressed GFP expression vector, typically yielding at 
least 50-60% transfected neuronal cells in each culture. 
Cos7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, 
Gibco) with 10% fetal bovine serum (FBS, HyClone ), 1 % penicillin-streptomycin, 
sodium pyruvate, and L-glutamine in a humidified incubator at 3 7 °C and 5% C02 
in air. Cells were seeded 1 day prior to transfection and transient transfections were 
performed using the standard calcium phosphate precipitation method. Cells were 
washed 16 hours post-transfection with phosphate-buffered saline (PBS) and 
harvested 48 hours after transfection followed by preparation of lysate for reporter 
gene assays (see below). 
TUNEL assay 
TUNEL (terminal deoxynucleotidyl transferase UTP-biotin nick end labelling) 
staining was performed using Jn Situ Cell Death Detection Kit (Roche) according to 
the manufacturer's instructions. Primary hippocampal neurons were harvested and 
washed twice with PBS. Cells were trypsinized (0.2%) and then fixed with 4% PFA 
in PBS for 1 hat RT. Cells were washed twice and permeabilized with 0.1 % Triton 
X-100 for 4 min on ice followed by incubation with TUNEL assay reagent and PI 
for 1 h at 3 7°C. Cells were washed with PBS twice and TUNEL-positive cells were 
quantified by fluorescence microscopy. 
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Reporter gene assays 
Primary hippocampal neurons (7DIV) and COS7 cells were transiently 
transfected using the calcium phosphate precipitation method. Reporter gene 
plasmids (1 µg) and expression plasmids (1.5 µg) were transfected as indicated in 
figures. pCMV -~-galactosidase (1 µg) was transfected as an internal control for 
monitoring transfection efficiency. The total amount of DNA for each experiment 
was kept constant by using empty vectors. Primary neuronal cells were seeded in 6-
well plates for reporter gene assays. Neuronal cells were incubated with transfection 
reagent for 8 h. Cells were harvested after 36 hrs post-transfection. 
Cos7 cells were plated in 6-well plates 1 day before transfection. Transient 
transfection was performed using standard methods and cells were washed twice 
with PBS after 16 h transfection and then harvested at 48 h post-transfection. Both 
~-galactosidase and luciferase activities were measured. Luciferase activity was 
assayed according to manufacturer's instructions (Promega), using a Berthold 9501 
luminometer and Luciferase values were normalized to ~-galactosidase values. All 
measurements were made in triplicate for at least three independent experiments 
with data presented as means ± standard error of the mean. 
Western blot analysis 
Protein extracts were prepared in NP-40 lysis buffer (0.5% NP-40, 50 mM 
Tris-HCI [pH 8.0], 150 mM NaCl, 1 mM EDTA [pH 8.0], 100 mM sodium 
fluoride, 10 mM sodium pyrophosphate) containing 0.2 mM PMSF and 0.5 mM 
sodium orthovanadate and protease inhibitor cocktail. Protein concentrations were 
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determined by Bradford assay (BioRad) with bovine serum albumin (BSA) as a 
standard. Equivalent amounts of total protein (15-20 µg) were diluted in sample 
buffer (sodium dodecyle sulphate-polyacrylamide)containing ~-mercaptoethanol, 
boiled for 4-5min, and electrophoretically resolved by 10% SDS-PAGE gels, then 
electrophoretic transfer to an Immobilon-P membrane (Millipore Inc). Non specific 
binding sites were blocked with 5% milk in PBS for one hour at RT. 
Immunoblotting was carried out using appropriate primary antibodies in 5% milk 
(PBS), a-MEF2D (1:1000), a-KLF6 (1:1000), a-HDAC4 (1:1000) and a-Actin 
(1: 1000). The blots were then incubated with the appropriate secondary horseradish 
peroxidase (HRP) antibody (BioRad) at 1 :2000 with 5% milk in PBS for 1 hour at 
RT followed by Chemiluminescence detection of immunoreactive proteins as per 
the manufacturer's instructions (Amersham Biosciences). 
Co-immunoprecipitation assays 
Protein extracts were prepared from primary hippocampal neurons as 
described above. lmmunoprecipitation was performed using the ExactaCruz kit 
(Santa Cruz), as per manufacturer's instructions. Precipitated proteins were 
separated by SDS page and immunoblotting of precipitated proteins was carried out 
as described above. 
Flow Cytometry Analysis 
Flow cytometry analyses were performed as previously described (Perry et al. 
2009) using the Annexin V-FITC apoptosis detection kit (Sigma) following the 
manufacturer's instructions. Cell viability and apoptosis were measured by a 
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combination of Annexin V-FITC and propidium iodide (PI) staining. Primary 
hippocampal neurons were washed and briefly trypsinized, and then washed twice 
with cold lxPBS. Cells were pelleted by centrifugation and re-suspended in lx 
binding buffer followed by incubation with staining solution (Annexin V-FITC and 
PI) for 15 min in the dark at 4°C. The cells were re-suspended in lx binding buffer. 
Samples were kept on ice during the entire procedure and analyzed immediately by 
flow cytometry. Ten thousand cells from each sample were scanned and analyzed 
by F ACS Cali bur flowcytometry (Becton Dickinson) using the standard 
configuration and parameters. Data acquisition and analysis was performed using 
the CellQuest software (BD). Necrosis and apoptosis were determined by PI (FL2) 
and Annexin V -FITC (FL 1) fluorescence respectively. 
Site-directed mutagenesis 
PCR-based mutagenesis of the MEF2 cis-element contained within the KLF6 
promoter (pROM6) was performed by insertion of double-stranded oligonucleotides 
containing the mutated sequences using the QuikChange site-Directed Mutagenesis 
kit (Stratagene, cat # 200518) according to the manufacturer's instructions. Mutated 
constructs were verified by DNA sequencing (York University Core Facility). 
Immunocytochemistry 
Hippocampal neuronal cells were seeded on pre-coated poly-n-lysine glass 
cover slips at a density of 0.5x105 cells/coverslip. After 7-9 days in vitro, cells were 
fixed in 4% paraformaldehyde in PBS for 10 min at RT and then permeabilized 
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with 0.3% Triton X-100 in PBS for 5 min. Cells were blocked with 10% goat serum 
in PBS for 30 min at 37°C and incubated overnight at 4°C with primary antibodies 
a-MEF2D, a-KLF6, a-HDAC4, and a-~-tubulin III (1: 100) diluted in 1.5% goat 
serum (PBS). Cells were washed 3x with PBS for 10 min and then incubated with 
the appropriate TRITC/FITC-conjugated secondary antibodies (1 :500) in 1.5% goat 
serum (PBS) for 2 hours at RT following DAPI (4',6-diamidino-2-phenylindole) 
staining for 15 min at RT. Cells were washed 3x with PBS and cover slips were 
mounted with DAKO mounting media (Dako) on glass slides. The fluorescence 
images were captured using a Fluoview 300 (Olympus). 
siRNA gene silencing 
Small interfering RNAs (siRNA's) targeting KLF6, HDAC4 and a nonspecific 
scrambled RNA were purchased from (Sigma). Primary hippocampal neurons were 
seeded for F ACS analysis and Immunoblotting analysis. Cells were replenished 
with antibiotic-free Opti-MEM I (cat# 31985, Invitrogen) media 2-3 h prior to 
transfection. Cells were transfected with siRNA and scrambled RNA using 
Lipofectamine RNAiMAX reagent (cat# 13778, Invitrogen) according to the 
·manufacturer's instructions. Cells were harvested after 48hrs post-transfection for 
western immunoblotting analysis to determine the efficacy of protein knock down 
or F ACS analysis. 
RT-PCR and Real-time quantitative PCR 
Total RNA was isolated from primary hippocampal neurons (7/9DIV) using 
the RNeasy™ kit (Qiagen) followed by DNAse treatment (Qiagen) according to the 
143 
manufacturer's protocol. All RNA samples were assessed for quality by agarose gel 
electrophoresis gels. Reverse transcription (RT) was performed from equal amounts 
of total RNA using Superscript III reverse transcriptase (Invitrogen) and used for 
semiquantitative RT-PCR analysis for primer specificity. All Quantitative RT-PCR 
reactions were performed on cDNA using Power SYBR Green Mastermix (Applied 
Biosystem) and detected using a 7500 Fast real time PCR system, Applied 
Biosytems according to the manufacturer's protocol. All values were normalized to 
GAPDH (internal control) mRNA levels. Each experiment was done in triplicate 
and independently validated 3 times. 
Results 
cAMP signaling increase neuronal apoptosis 
Previous studies have shown that activation of cAMP/PKA signaling in 
neuronal and non-neuronal cells can provoke apoptosis (Lomo et al. 1995; 
Myklebust et al. 1999; Zhao et al. 2008; Zhang et al. 2008). MEF2D acts as pro-
survival factor and we showed previously that it is expressed in the hippocampal 
neurons (Perry et al. 2009). In skeletal muscle, cAMP/PKA signaling has been 
shown to inhibit MEF2D function and myogenic differentiation (Du et al. 2008). 
We therefore undertook the current studies to determine if the PKA-MEF2 pathway 
impinges on neuronal survival. Initially, we performed a survival assay to examine 
the effect of cAMP-PKA signaling in primary hippocampal neurons (7DIV) using 
the TUNEL method (Terminal deoxynucleotidyl transferase dUTP nick end 
labelling). A cell permeable cAMP analog was used to manipulate PKA activation 
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( dbcAMP). Treatment of primary hippocampal neurons (9DIV) with dbcAMP 
indicated a prominent increase of TUNEL positive cells when compared to 
untreated controls (Fig. 23A bottom panels). Total cell numbers for each treatment 
are indicated by DAPI staining, a nuclear marker (Fig 23A top panels). Quantitative 
analysis shows that cAMP induced an approximately five to six fold increase in 
neuronal apoptosis compared to the control condition (Fig. 23B). Hydrogen 
peroxide (H202) treatment was used in these assays as a positive control. Next, we 
assessed dbcAMP mediated apoptosis in hippocampal neurons by F ACS analysis. 
Estimation of necrosis and apoptosis were determined by a combination of 
propidium iodide (PI) and annexin V-FITC fluorescence, respectively (Fig. 23C). 
Cells appearing in the lower right quadrant of the density plots (high level of 
annexin V -FITC and low level of PI), indicate an increase in the percentage of 
apoptotic cells in the cAMP treated cells (25.7%) compared to controls (11.4%) 
(Fig. 23C). Forskolin treatment, which enhances cAMP levels, also promotes 
apoptosis and a PKA inhibitor (H89) blocks this effect (Fig. 23D). 
PKA signaling represses MEF2 transcriptional activity in hippocampal 
neurons 
To obtain insight into whether the mechanism leading to apoptosis was 
through PKA inhibition of the pro-survival of MEF2D, we utilized a well known 
pharmacological inhibitor of PKA, H89, for one hour before treatment with FSK. 
We found that H89 blocked FSK effects and to some extent rescued neurons from 
apoptosis (Fig. 23D) and parallel reporter gene analysis demonstrated a reduction of 
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MEF2 activity in FSK and dbcAMP treated cells which was reversed by H89 
treatment (Fig. 23E, F and G). As an indicator of promoter specificity we monitored 
the activity of a generic CMV enhancer/promoter reporter gene under the same 
experimental conditions (Fig. 23 H, I and J). 
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Figure 23. Activation of cAMP signaling induces apoptosis in hippocampal 
neurons. (A) Primary hippocampal neurons (9DIV) were treated with a cAMP 
analog (100 µM db-cAMPS, Sigma) for 6 hrs or 200 µM H20 2 (hydrogen peroxide) 
for 2 hrs as a positive control. Neuronal apoptosis was observed by using TUNEL 
assay. DNA fragmentation in apoptotic cells was visualized by terminal 
deoxyribonucleotidyl transferase-mediated dUTP-biotin nick end labelling. 
Representative images were taken from ten randomly selected fields using 
fluorescence microscopy, both Total (DAPI positive, a nuclear marker) and TUNEL 
positive cells were counted. (B) Quantitation of these data represents the percentage 
of apoptotic cells in each condition. Data are expressed as mean +/- SEM from three 
separate treatments. (C) Primary hippocampal neurons were stimulated with 100 
µM db-cAMP for 6 hrs. Percentage of apoptotic cells was determined by 
propidium iodide (Pl) and annexin V-FITC fluorescence staining using flow 
cytometry analysis (FACS analyzer). (D) Primary hippocampal neurons were 
treated with 10 µM FSK alone and in combination with 1 OµM H89 for 6 hrs. 
Percentage of apoptotic cells were determined by propodium iodide (PI) and 
annexin V-FITC fluorescence staining using FACS analyzer. (E) Primary E18 
hippocampal neuronal cells were transiently transfected with pGL3-4XMEF2-Luc 
reporter gene and pCMV-P-Galactosidase after 7 days in culture using the calcium 
phosphate precipitation method. 36 hrs after transfection, cells were treated with 
100 µM db-cAMP or solvent (Control) for 6 hrs. MEF2 mediated transcriptional 
activity was determined by Luciferase and p-galactosidase assay as described in 
Materials and Methods. Luciferase values were normalized by p-galactosidase 
activity. Experiments were conducted at least three times, yielding comparable 
results. (F) Primary hippocampal neuronal cells were transfected with pGL3-
4XMEF2-Luc reporter gene and pCMV-P-Galactosidase. Cells were treated with 10 
µM FSK alone and in combination with lOµM H89 for 6 hrs (as indicated) (F and 
G). Data indicating the activity of a generic enhancer/promoter are indicated in H, I 
and J). Primary hippocampal neuronal cells were co-transfected with pGL3-
4XMEF2-Luc reporter gene and wtMEF2D expression vector. MEF2 mediated 
transcriptional activition was determined by luciferase and p-gal assays. 
These data illustrate no demonstrable effect of PKA on this promoter construct 
indicating that there is some specificity to the effects seen on the MEF2 dependent 
reporter gene. This specificity is also evident in the data shown later in Fig. 24A in 
which the message levels for a number of MEF2 target genes are unaffected by 
activation of PKA signaling whereas some, such as KLF6, clearly are affected. 
Together, these data indicate that the effect of PKA activation is not a generalized 
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down regulation of all transcribed genes. To further investigate the link between 
MEF2 transcriptional activity and PKA activation, primary hippocampal neurons 
(7DIV) were transiently transfected with a MEF2 reporter gene (MEF2-Luc) and 
increasing amounts of an expression plasmid encoding the catalytic subunit of PKA 
which results in constitutive cellular PKA activity (pFC-PKA). It was observed that 
PKA potently suppressed MEF2 dependent reporter gene activation in a dose 
dependent manner (Fig. 24A). Also, exogenous expression of wild type (wt) 
MEF2D increased MEF2 reporter gene activation and PKA repressed this activation 
(Fig. 24B). To further investigate whether PKA plays a direct role in neuronal 
survival/apoptosis, neurons were transiently transfected with empty vector or pFC-
PKA followed by F ACS analysis. Substantial increases in apoptotic cells were 
observed with PKA (15.42%) (Fig. 24C, right panel) when compared to control 
(0.83%) (Fig. 24C). In congruence with the results seen with dbcAMP and activated 
PKA, similar results were also seen with forskolin (FSK) treatment, which activates 
adenylate cyclase (data not shown). Taken together, these results demonstrate that 
cAMP/PKA signaling regulates MEF2 activity and also potentiates apoptosis in 
hippocampal neurons. 
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Figure 24. Exogenous expression of activated PKA suppresses MEF2's pro-
survival role in hippocampal neurons. (A) Primary E18 hippocampal neuronal 
cells (7DIV) were transiently transfected with pGL3-4XMEF2-Luc reporter gene, 
pCMV -P-Galactosidase to normalize transfection efficiencies and increasing 
amounts of the catalytic subunit of PKA (pFC-PKA 250 ng-1 µg). (B) Primary 
hippocampal neuronal cells were co-transfected either with empty vector or 
pcDNA3-MEF2D, in combination with or without pFC-PKA (as indicated). MEF2 
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mediated transcriptional activity was determined by pGL3-4XMEF2-Luc reporter 
gene and pCMV-~-Galactosidase assays. (C) Primary hippocampal neuronal cells 
were co-transfected either with empty vector or pFC-PKA (as indicated). 36 hours 
after transfection, primary hippocampal neuronal cells were stained with annexin V -
FITC and propidium iodide (PI) (Annexin V-FITC apoptosis detection kit, Sigma). 
Necrosis and apoptosis were determined by flow cytometry analysis. (The 
percentage of apoptotic cells labelled with annexin V-FITC appeared in the lower 
right quadrant of the density plot, are shown in the bottom right comer of each 
panel). 
MEF2's role in hippocampal neuronal survival 
Our observations at this point suggested that PKA signaling might target 
MEF2's pro-survival role. Previously, we have documented that PKA directly 
phosphorylates S121 and S190 on MEF2D using mass spectrometry (Fig. 25A) and 
these sites were sufficient to confer repressive effects on the skeletal muscle 
differentiation program in response to cAMP signaling (Du et al. 2008). Moreover, 
neutralization of these phospho-acceptor sites by mutation to Alanine (A) rendered 
MEF2D resistant to PKA signaling and thus allowed rescue of differentiation when 
the PKA resistant MEF2D was transfected into cells even in the presence of cAMP 
signaling (Du et al. 2008). We therefore reasoned that this PKA resistant form of 
MEF2D might be capable of rescuing hippocampal neuronal cells from cAMP 
mediated apoptosis if the primary target of cAMP-PKA signaling is indeed 
MEF2D. Primary hippocampal neurons were transfected with empty vector or 
mutated forms of MEF2D S 121/190A (neutralizing) and S l 21/190D (phospho-
mimetic) with or without PKA at 7DIV (see Fig. 25A for schematic of where these 
phospho-acceptor sites are in relation to other domains). 
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Figure 25. MEF2D-S121/190A confers resistance to PKA in hippocampal 
neurons. (A) Schematic of mouse MEF2D indicating PK.A phospho-acceptor sites 
(B) Primary hippocampal neuronal cells (7DIV) were transiently transfected with 
empty vector or mutated forms of MEF2D S 121/190A (neutralizing) and 
Sl21/190D (phospho-mimetic) with or without PK.A. 36 hrs after transfection, cells 
were stained with annexin V-FITC and propiduim iodide (PI) (Annexin V-FITC 
apoptosis detection kit, Sigma). Neuronal apoptosis was determined by 
flowcytometry analysis (F ACS analyzer). (C) Primary hippocampal neurons were 
transiently co-transfected at 7DIV with pGL3-4XMEF2-Luc reporter gene and 
pCMV-~-Galactosidase to normalize transfection efficiencies and with empty 
vector or double mutated forms of MEF2D S121/190A and S121/190D, in 
combination with or without pFC-PKA (as indicated). MEF2 mediated 
transcriptional activity was determined by Luciferase and pCMV-~-Gal assays. (D) 
Primary hippocampal neuronal cells were transiently co-transfected with 5XGAL4-
Luciferase reporter vector, GAL-DBD or GAL4-MEF2D (87-507), with and 
without pFC-PKA and ~-Galactosidase to normalize transfection efficiencies. (Data 
are the mean +/- S.E.M.; n=3). (E) Primary hippocampal neuronal cells (7DIV) 
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were transiently transfected with empty vector or mutated forms of MEF2D 
Sl21/190A (neutralizing) and Sl21/190D with or without PKA. Cells were 
harvested and lysates were prepared 36hrs later. Equal amounts of total protein 
were separated by 10%SDS-PAGE followed by immunoblot analysis using MEF2D 
monoclonal antibody (1: 1000) to detect the expression levels of transfected 
constructs. Acitn (polyclonal, 1 :2000) was used as a loading control. 
Subsequently, F ACS analysis was carried out using Annexin-V /PI to assess cell 
death. Interestingly, a decrease in apoptotic cells was observed when Sl21/190A 
was co-expressed with PKA compared to PKA alone in hippocampal neurons (Fig. 
25B). Conversely, phospho-mimetic forms of MEF2D, Sl21/190D failed to alter 
PKA mediated cell death and, if anything, showed an increase in the percentage of 
apoptotic cells even in the absence of PKA when compared with the control 
condition (Fig. 25B). These data support the idea that a PKA resistant MEF2D 
(Sl21/190A) protects neurons from PKA mediated cell death. This effect is 
corroborated by reporter gene analysis in which a Gal4-MEF2D fusion protein is 
repressed by PKA and also that MEF2D Sl21/190A neutralizing mutation is much 
more resistant to the effects of PKA than wild type MEF2 (Fig. 25C and D). 
Expression levels of the various mutated and wild type MEF2D protein are shown 
in Fig. 25E. 
Characterization of MEF2 target genes in Hippocampal neuronal cells 
We next assessed the pro-survival effect of MEF2D and its inhibition by 
cAMP/PKA signaling by analyzing downstream MEF2 target genes identified in a 
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study in which a high throughput chromatin immunoprecipitation method coupled 
to massively parallel sequencing (ChIP-seq) was employed (Flavell et al. 2008). To 
directly examine whether the expression of KLF6 is targeted under conditions when 
MEF2 activity is repressed by PKA signaling, primary hippocampal neurons 
(7DIV) were treated with FSK or solvent for 6 hours to induce PKA signaling. 
After stimulation, total RNA was isolated using RNeasy™ kit (Qiagen) followed by 
quantitative real-time reverse transcription PCR (qRT-PCR) using Power SYBR 
Green Master mix. We carried out qPCR analysis of a number of these identified 
MEF2 target genes to identify which ones might be affected by PKA activation 
(Fig. 26A and B) and, from this analysis, a prominent responder was Kriippel-like 
factor 6 (KLF6). Other reported MEF2 target genes showed variable responses to 
FSK treatment suggesting that MEF2 might play a different role at these genes (Fig. 
26A and B). Primary hippocampal neurons (7DIV) were also transfected with 
empty vector or the catalytic subunit of PKA (pFC-PKA) followed by qRT-PCR 
analysis. Again this showed that KLF6 mRNA level was suppressed by activated 
PKA (Fig. 26C). These results suggested that the decrease in KLF6 gene expression 
by PKA signaling might be through MEF2 inhibition. 
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Figure 26. Kriippel-like factor 6 (KLF6) gene expression in hippocampal 
neurons. (A and B) Nine previously reported hippocampal MEF2 target genes were 
selected for qRT-PCR analysis. Primary hippocampal neurons (7DIV) were 
stimulated with lOµM FSK or solvent for 6 hours to induce PKA signaling. After 
stimulation, total RNA was isolated using RNeasy™ kit (Qiagen) followed by 
quantitative real-time reverse transcription PCR (qRT-PCR) using Power SYBR 
Green Master mix. Gene expression was analyzed using 7500 Fast real time PCR 
detection system as described in Material and methods. GAPDH housekeeping gene 
primers were used to normalize expression of target genes. (C) Primary 
hippocampal neurons (7DIV) were transiently transfected with empty vector or the 
catalytic subunit of PKA (pFC-PKA) followed by qRT-PCR analysis of KLF6 
expression. (D) KLF6 protein is expressed in hippocampal neuronal cells. Cell 
lysates of primary hippocampal neurons and COS7 were prepared for 
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immunobloting analysis as indicated. Equal amounts of total protein were separated 
by 10% SDS-PAGE followed by immunoblot. KLF6 polyclonal antibody (1: 1000) 
was used to detect the endogenous KLF6 protein. Actin (polyclonal, 1 :2000) was 
used as a loading control. 
KLF6 is highly expressed in various regions of the brain including the 
hippocampus (Fischer et al. 2001; Jeong et al. 2009). We therefore sought to define 
whether KLF6 might constitute an important downstream effector of the MEF2 pro-
survival role in hippocampal neurons 
A DAPI MEF2D MEF20/ p-tubulln Ill 
B DAPI KLF6 KLF6 / P·tubulin Ill 
c MEF2D KLF6 MEF2D/KLFO 
Figure 27. Cellular localization of MEF2D and Kriippel-like factor 6 (KLF6) in 
hippocampal neurons. (A) Primary hippocampal neuronal cells were fixed with 
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4% paraformaldehyde. Double immunofluorescence analysis was performed using 
primary antibodies to MEF2D (Green) and a neuronal marker beta tubulin III (Red). 
DAPI ( 4' ,6-diamidino-2-phenylindole) was used to identify nuclei (blue). The 
merged picture demonstrates localization of MEF2D (nuclear) and B-tubulin III 
positive cells (Red). (B) Primary hippocampal neurons express KLF6. Hippocampal 
neuronal cells were fixed and double immunofluorescence analysis was performed 
with primary antibodies to KLF6 shown in red and B-tubulin III shown in green. 
The merged picture demonstrates localization of KLF6 (nuclear) and B-tubulin III 
positive cells (green), counterstained with DAPI (Blue). (C) Double 
immunofluorescence labelling demonstrating KLF6 (red) and MEF2D (green) in 
primary hippocampal neurons. The merged picture indicates MEF2D positive cells 
are mostly positive for KLF6 and both proteins are predominantly nuclear. 
Endogenous expression of KLF6 is detected in E 18 hippocampal neuronal 
cells (Fig. 26D) and immunofluorescence labelling to observe the cellular 
localization of KLF6 and MEF2D in primary hippocampal neurons was also carried 
out. Primary hippocampal neurons, confirmed by B-tubulin III expression (red), 
were positive for nuclear MEF2D (green) (Fig. 27 A). Neuronal cells also show 
strong nuclear localization of KLF6 (red) in B-tubulin III positive cells (green) (Fig. 
27B). Nuclear co-localization of MEF2D and KLF6 in primary hippocampal 
neurons is evident (Fig. 27C). Interestingly, the co-localization of MEF2D and 
KLF6 that we have observed in primary cultured neurons is also reflected in data 
from the Allen Brain Atlas Resources in which in situ hybridization of KLF6 and 
MEF2D show strikingly similar patterns of expression in the hippocampal region 
(http://www.brain-map.org). 
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MEF2D regulates KLF6 promoter activity in Hippocampal Neurons 
To further define the potential role of MEF2D in KLF6 gene regulation, we 
examined the previously characterized upstream KLF6 promoter (Gehrau et al. 
2005) which contains a MEF2 cis-element, between -320 and -310 bp (Fig. 28A). 
This site is highly conserved in different species as depicted in Fig. 6B. The 
conservation of this cis-element suggests that MEF2 may play an evolutionary 
conserved role in KLF6 gene expression. To investigate MEF2D dependent 
regulation of the KLF6 promoter in hippocampal neurons, we utilized a number of 
KLF6 reporter gene constructs containing different fragments of the KLF6 
promoter, pROM6 (-507 bp to +l bp), pROM5 (-407 bp to +l bp), and pROM4 (-
344 bp to + 1 bp ), which contain the MEF2 cis-element, and pROM3 (-307 bp to + 1 
bp) which does not (schematic illustrations of KLF6 reporter deletion constructs are 
shown in Fig. 28C). All KLF6 fragments were cloned into the pGL3-basic reporter 
vector (pGL3-KLF6-Luc). Reporter gene assays were undertaken to assess MEF2D 
transactivation of the KLF6 promoter. Primary hippocampal neurons were 
transiently transfected with the KLF6 promoter constructs (pROM6 to pROM3) 
with and without wtMEF2D and pGL3-basic empty vector was used as a control. 
As shown in Fig. 28D, ectopically expressed MEF2D strongly induced pROM6 and 
pROM5 reporter transcriptional activity. MEF2D did not potentiate KLF6-pROM3 
reporter activity which lacks the MEF2 binding site (Fig. 28 & E). 
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Figure 28. Functional analysis of KLF6 promoter in hippocampal neurons. (A) 
Schematic illustration of upstream KLF6 promoter construct depicts location of 
MEF2 cis-element between -320 and -310 hp. (B) Sequence of MEF2 cis-element is 
highly conserved in the KLF6 promoter from human to mouse. (C) Schematic 
illustrations of KLF6 reporter deletion constructs used in reporter assays. All KLF6 
promoter constructs were cloned into the pGL3-basic reporter vector (pGL3-KLF6-
Luc) and were utilized in examining KLF6 promoter activity. (D) Primary 
hippocampal neuronal cells were transiently co-transfected with various constructs 
of the KLF6 promoter (pROM6 to pROM3), pCMV-~-Galactosidase was utilized to 
normalize transfection efficiencies. Cell extracts were prepared and analysed for 
luciferase and ~-gal assays. (E) Cos7 cells were transiently co-transfected with 
various KLF6 promoter constructs (pROM6 to pROM3), pCMV-~-Galactosidase 
(to normalize transfection efficiencies) with and without wtMEF2D by using 
calcium phosphate method. pGL3-basic empty vector was use as a control. Cell 
extracts were prepared for luciferase and ~-gal assays as described in Material and 
Methods. (Data are the mean+/- S.E.M n=3). 
We wanted to precisely dissect the absolute requirement for the MEF2 cis-
element in the KLF6 promoter and we therefore carried out site-specific mutation of 
the pROM6 MEF2 site. Primary hippocampal neurons were co-transfected with 
MEF2D and the pROM6 reporter construct containing the intact or mutated MEF2 
binding site as shown in Figure 29A. MEF2D did not induce KLF6 reporter activity 
when the MEF2 binding site was mutated to a sequence that no longer fits the 
consensus binding site (Fig. 29B). Furthermore, increasing amounts of MEF2D 
induced a dose dependent increase in pROM6 reporter activity compared to the 
mut.pROM6-luc which was not activated by MEF2D (Fig. 29B). To further 
determine if other MEF2 isoforms (MEF2A and C) can alter KLF6 promoter 
activity, we performed reporter gene assays as described above using pROM6 
reporter gene constructs containing the intact or mutated MEF2 binding site specific 
mutation. Increasing amounts of MEF2A induce pROM6 reporter gene activity 
compared to the mut.pROM6-luc reporter in which the MEF2 site is inactivated by 
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mutation (Fig. 29C). Conversely, although MEF2C is a reasonably strong trans-
activator on synthetic and other natural promoters it had essentially no effect on 
pROM6 (Fig. 29D). 
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Figure 29. PKA represses KL6 promoter activity in primary hippocampal 
neurons. (A) Schematic illustrations of KLF6 promoter construct (pROM6) with 
intact MEF2 binding site or with MEF2 site mutated. (B-D) Primary hippocampal 
neurons were co-transfected with pROM6 reporter constructs and increasing 
amounts (250 ng to 1.5 µg) of wtMEF2D, MEF2A, and MEF2C plasmid 
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respectively. pCMV-P-Galactosidase was used to normalize transfection 
efficiencies. (E) Primary hippocampal neurons were transiently transfected with 
pGL3-KLF6-Luc reporter construct, pCMV-P-Galactosidase and wtMEF2D with or 
without pFC-PKA (as indicated). MEF2 mediated transcriptional activity was 
determined by luciferase and P-gal assays as described in Material and Methods 
(Data are the mean+/- S.E.M n=3). 
There are differences between MEF2A, C and D in their ability to 
heterodimerize with each other, warranting further analysis of these observations. 
We next assessed whether PKA signaling targets the KLF6 promoter through the 
MEF2 cis- element. To investigate this, hippocampal neuronal cells were co-
transfected with wtMEF2D and pROM6 (-507 bp to + 1 bp) in the presence and 
absence of pFC-PKA. The activity of these reporter genes was markedly reduced by 
PKA. The wild type MEF2D was not able to reverse the inhibitory affect of PKA 
when ectopically expressed which is consistent with our previous studies showing 
that PKA repression trans-dominantly represses exogenously expressed MEF2D 
(Fig. 29E). Together, these data indicate that MEF2D, possibly in combination with 
MEF2A, is a potent transcriptional regulator of the KLF6 promoter and this 
promoter can be repressed by PKA signaling through its MEF2 cis-element. 
Interestingly, we observed that exogenous overexpression of KLF6 can reduce 
the amount of cell death provoked by PKA suggesting it might play an important 
survival role downstream of MEF2 in hippocampal neurons (Fig. 30A and B). 
To further investigate MEF2 mediated regulation of KLF6 by PKA we performed 
reporter gene assays utilizing pGL3-KLF6-Luc (pROM6) and double mutations of 
MEF2D (S121.190A or S121.190D). 
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Figure 30. Exogenous KLF6 expression promotes hippocampal neuronal 
survival. (A) Primary hippocampal neurons were transfected with expression 
vectors encoding wtMEF2D, wtKLF6 or empty vector with or without the catalytic 
subunit of PKA (pFC-PKA). 36 hrs after transfection, neurons were stained by 
annexin V-FITC and propidium iodide (PI) using Annexin V -FITC apoptosis 
detection kit, Sigma. Neuronal apoptosis was determined by flow cytometry 
analysis (F ACS analyzer). (B) Detection of KLF6 protein expression. Primary 
hippocampal neurons were transiently transfected with empty vector or wtKLF6 
expression vector. Cell extracts were prepared for immunoblotting analysis as 
indicated. KLF6 polyclonal antibody (1: 1000) was used to detect the KLF6 protein 
level. Actin (polyclonal, 1: 1000) was used as a loading control. (C) Cos7 cells were 
co-transfected with pGL3-KLF6-Luc reporter gene, wtMEF2D and MEF2D double 
mutants (Sl21/190A or S121/190D) with or without pFC-PKA. pCMV-P-
Galactosidase was used to normalize transfection efficiencies. MEF2 mediated 
transcriptional activity was determined by luciferase and P-gal assays as described 
in Material and Methods (Data are the mean+/- S.E.M n=3). 
Cos7 cells were co-transfected with wtMEF2D and MEF2D double mutants 
(S121.190A or S121.190D) with or without pFC-PKA. Consistent with our 
previous observations, the MEF2D double mutation S 121.190A is partially resistant 
to PKA (Fig. 30C). However, as observed before (Du et al. 2008), phospho-mimetic 
mutations are still partially responsive to PKA suggesting an indirect mechanisms 
may be involved in MEF2 mediated KLF6 gene regulation. 
PKA mediated MEF2 repression by HDAC recruitment 
Previously, we have documented that HDACs ( 4 & 5) bind MEF2 with high 
affinity and, importantly, the mechanism by which PKA inhibits MEF2 
transcriptional activity is due to two effects. One being a direct conformational 
change in the MEF2D protein caused by phosphorylation at Ser 121/190. The other 
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being an indirect mechanism by enhancing the nuclear content of HDACs which 
results in an increase in abundance of MEF2/HDAC repressor complexes (Du et al. 
2008). The contribution of the latter mechanism varies depending on the opposing 
signals for nuclear HDAC content. In differentiating skeletal muscle there is a 
strong stimulus for HDAC nuclear extrusion which counteracts the nuclear 
retention effects of PK.A whereas in other cell types we reasoned that PK.A 
mediated nuclear retention of HDACs might account for more of the repressive 
effects on MEF2 activity (Du et al. 2008). A recent study has also documented that 
this mechanism occurs in cardiac myocytes (Backs et al. 2011 ). Interestingly, it has 
been documented previously that PK.A signaling enhances HDAC localization to 
the nucleus in hippocampal neuronal cells (Belfield et al. 2006). We therefore 
assessed the contribution of HDAC nuclear retention to the inhibition of MEF2 
activity and KLF6 transcription. To begin to elucidate the possible functional role 
of HDAC4, the endogenous protein level of HDAC4 was documented in primary 
hippocampal neurons (Fig. 3 lA). Next, we examined whether PK.A signaling 
mediated any modulation of the cellular localization of endogenous HDAC4 
protein. Primary hippocampal neuronal cells were treated with FSK followed by 
immunofluorescence labelling using polyclonal HDAC4 antibody. As shown in Fig. 
31 B, HDAC4 accumulated in the nucleus in response to FSK compared to that in 
the solvent treated cells. We further confirmed that PK.A signaling promotes the 
nuclear localization ofHDAC4 in hippocampal neurons by utilizing a GFP-HDAC4 
fusion protein or GFP alone which was co-transfected with or without activated 
PK.A (Fig. 31 C). The GFP-HDAC4 localization data indicates that PK.A increases 
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the nuclear levels of GFP-HDAC4 (Fig. 31 C bottom panels) while having no effect 
on GFP alone (Fig. 31 C top panels). These results are consistent with previous 
observations, suggesting that PKA signaling promotes the formation of 
HDAC4/MEF2 repressor complexes by increasing the levels of HDAC4 in the 
nuclear compartment leading to downstream repression of key MEF2 target genes 
involved in survival such as KLF6. 
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Figure 31. Increased nuclear localization of HDAC4 by PKA signaling in 
hippocampal neurons. (A) Cell lysates of primary hippocampal neuronal and Cos7 
cells were prepared and equal amounts of total protein were separated by 10% SDS-
PAGE followed by immunoblot analysis. HDAC4 polyclonal antibody (1: 1000) 
was used to detect the endogenous HDAC4 protein. Acitn (polyclonal, 1 :2000) was 
used as a loading control. (B) Primary hippocampal neuronal cells were treated with 
10 µM FSK or solvent for 6 hrs followed by immunofluorescence labelling using 
polyclonal HDAC4 antibody. (C) Primary hippocampal neurons were co-
transfected with GFP alone and GFP-HDAC4 fusion protein, with or without pFC-
PKA. Hippocampal neurons expressing GFP alone showed a non specific 
distribution throughout the neuronal cell body including axon, dendrites and 
dendritic spines and this was unaffected by PKA. The shuttling of GFP-HDAC4 
from cytoplasm to nucleus in response to PKA was visualized by fluorescence 
microscopy. (D) MEF2 reporter activity is repressed by PKA signaling and rescued 
by HDACs inhibitor trichostatin A (TSA). Primary hippocampal neurons were 
transiently transfected with pGL3-4XMEF2-Luc reporter gene and cells were 
treated with 10 µM FSK alone and in combination with lµM TSA (as indicated). 36 
hrs after transfection, cell extracts were prepared for luciferase and P-gal assays. (E) 
Primary hippocampal neurons were stimulated with lOµM FSK alone and in 
combination with 1 µM TSA for 6 hrs. Percentage of apoptotic cells was determined 
by annexin V-FITC apoptosis detection kit, using FACS analyzer. Bar graph 
represents the changes in number of apoptotic cells. (F) Primary hippocampal 
neurons were transiently transfected with pGL3-KLF6-Luc reporter construct and 
wtMEF2D expression vector alone or combination with HDAC4 and HDAC4-
Ll 75A vectors (as indicated). MEF2 mediated transcriptional activity was 
determined by luciferase and p-gal assays as described in Material and Methods. 
To further assess the extent of the HDAC4 contribution to PKA mediated 
MEF2 repression, we performed transcriptional reporter gene assays in conjunction 
with HDAC inhibition using trichostatin A (TSA). Primary hippocampal neurons 
were transfected with a MEF2 reporter gene and cells were treated with FSK alone 
and in combination with TSA. HDAC inhibition with TSA reduced the FSK effect 
and partially superactivates MEF2 transcriptional activity (Fig. 3 lD). Subsequent 
F ACS analysis indicated that treatment with TSA also rescues neuronal cells from 
apoptosis (Fig. 31 E). HDAC4 strongly represses MEF2 dependent transcriptional 
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activation of the KLF6 promoter and a mutation of HDAC4 (Ll 75A) that has 
previously been shown not to interact with MEF2, has no effect (Fig. 31 F). The lack 
of interaction between HDAC4-Ll 75A and MEF2D was confirmed in co-
precipitation assays (Fig. 32A). Also, the enhanced amount of HDAC4 co-
precipitating with MEF2D when active PKA is co-transfected confirms our 
previous observations. To gain further insight into the role of HDAC4 in neuronal 
survival, we utilized siRNA to down regulate HDAC4 expression. First we tested 
the efficacy of HDAC4 silencing by western blot analysis. Primary hippocampal 
neurons (7DIV) were transfected with three independent HDAC4 siRNAs and a 
control scrambled siRNA (scRNA). As shown in Fig. 32B the reduction of HDAC4 
protein level was observed in cells expressing siHDAC4 in contrast to cells 
expressing the scRNA. In order to examine whether HDAC4 silencing can induce 
hippocampal neuronal survival, primary hippocampal neurons were transfected with 
HDAC4-siRNA or scRNA. Neuronal apoptosis was quantified by flow cytometry. 
Depletion of HDAC4 protects neurons from apoptosis when neurons are treated 
with forskolin (Fig. 32C). These data indicate that the HDAC4-MEF2 interaction is 
an important component of PKA mediated MEF2 repression in hippocampal 
neurons. 
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Figure 32. PKA induces physical association of HDAC4 with MEF2D in 
hippocampal neurons. (A) Primary hippocampal neurons were transiently 
transfected with indicated expression plasmids. Cell extracts were 
immunoprecipitated with anti-MEF2D followed by immunobloting with anti-
HDAC4. Whole cell lysates were immunoblots with indicated antibodies. HDAC4 
interacts with MEF2D in the presence of PKA and this association is lost with 
HDAC4 Ll 75A with or without PKA. (B) For HDAC4 gene silencing in primary 
hippocampal neurons, three independent siRNAS were transfected along with a 
control scrambled RNA (scRNA). Cells were harvested and lysates were prepared 
48 hrs later. Protein level of HDAC4 was analysed by immunoblot using HDAC4 
polyclonal antibody (1: 1000). Acitn (polyclonal, 1 :2000) was used as a loading 
control. (C) Primary hippocampal neurons were transfected with two independent 
siRNAs and a control scrambled siRNA (scRNA). 48 hrs after transfection, cells 
were stained with annexin V-FITC and propodium iodide (PI) using Annexin V-
FITC apoptosis detection kit, as described in Material and Methods. Neuronal 
apoptosis was measured using flow cytometry (F ACS analyzer). 
KLF6 protects hippocampal neurons from apoptosis 
There is growing evidence that the KLF factors are involved in cell survival 
and we postulated that the activation of KLF6 could be an important downstream 
component of the MEF2D dependent pro-survival pathway. As shown earlier, 
KLF6 over expressing cells showed a substantially reduced percentage of apoptotic 
cells in the presence of PKA compared to PKA alone. To further address the role of 
KLF6 expression in hippocampal neuronal survival, we employed a loss of function 
assay using siRNA to down regulate KLF6 expression. First we assessed the 
efficacy of KLF6 silencing by western blot analysis. Primary hippocampal neurons 
(7DIV) were transfected with three independent KLF6 siRNAs and a control 
scrambled siRNA (scRNA). As shown in Fig. 33A. The reduction of KLF6 protein 
level was observed in cells expressing siKLF6 in contrast to cells expressing the 
scrambled siRNA. In order to further examine whether KLF6 silencing can induce 
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hippocampal neuronal apoptosis, primary hippocampal neurons were transfected 
with KLF6-siRNA or scrambled siRNA. Neuronal apoptosis was quantified by flow 
cytometry as described previously. Depletion of KLF6 enhanced neuronal apoptosis 
relative to the scRNA (Fig. 33B), suggesting that KLF6 functions as a pro-survival 
molecule in neuronal cells although this effect was not as penetrant as MEF2 
inhibition. Taken together, the pro survival effect of exogenous overexpression 
KLF6 shown earlier and the modest but evident effects of KLF6 knock down on 
survival reveal that KLF6 may be an intrinsic component of the neuronal survival 
pathway mediated by MEF2. 
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Figure 33. Silencing of KLF6 expression enhances apoptosis in primary 
hippocampal neurons. (A) For KLF6 gene silencing in primary hippocampal 
neurons, 3 independent siRNAS were transfected along with a control scrambled 
RNA (scRNA). Cells were harvested and lysates were prepared 48 hrs later. Equal 
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amounts of total protein were separated by 10%SDS-PAGE followed by 
immunoblot analysis using KLF6 polyclonal antibody (1: 1000) to detect the KLF6 
protein level. Acitn (polyclonal, 1 :2000) was used as a loading control. (B) Primary 
hippocampal neurons were transfected with three independent KLF6 siRNAs and a 
control scrambled siRNA (scRNA). 48 hrs after transfection, cells were stained with 
annexin V -FITC and propodium iodide (PI) using Annexin V -FITC apoptosis 
detection kit, as described in Material and Methods. Neuronal apoptosis was 
measured using flow cytometry. 
Discussion 
Apoptosis has been implicated in the pathogenesis of various 
neurodegenerative diseases including Alzheimer's and Parkinson's disease 
(Bredesen et al. 1995; Gupta et al. 2006; Zhao et al. 2008). The cAMP-protein 
kinase A (PKA) signaling pathway regulates a variety of cellular functions and 
numerous important biological processes. More specifically, PKA signaling has 
been reported to be associated with the progression of Alzheimer's disease in the 
hippocampus (Martinez et al. 1999; Lim et al. 2005; Zhao et al. 2008). Modulation 
of gene expression networks underlying these pivotal cellular events ultimately 
leading to neurodegeneration is still in its infancy (Crews & Masliah, 2010). 
Furthermore, neurodegenerative diseases often exhibit alterations in many cellular 
processes such as increased oxidative and toxic stress, mitochondrial dysfunction, 
failure of synaptic activities and aberrant phosphorylation (Zhang et al. 2008). In 
this report, we demonstrate that a variety of perturbations of protein kinase A 
signaling induce apoptosis of primary hippocampal neurons through inactivation of 
the pro-survival role of the MEF2D transcription factor. Also, identification of 
171 
KLF6 as a key downstream component of the MEF2D survival pathway that is 
down-regulated by PKA signaling provides further insight into the physiology and 
pathophysiology of the nervous system. 
Interestingly, a recent report has implicated KLF6 induction in the response to 
pilocarpine-induced seizures in the hippocampus (Jeong et al. 2011). In view of our 
data implicating MEF2D as a critical regulator of KLF6 expression, it will be of 
considerable interest to determine whether MEF2 activity is indeed induced in this 
pilocarpine-induced seizure model which mimics features of temporal lobe epilepsy 
(TLE) in humans. Since MEF2 had been implicated as a pro-survival molecule in 
the CNS, it is tempting to speculate that its induction may well occur in the 
physiologic response to the pronounced neuronal damage that results from 
excitotoxic stress. Also, in a model of zebra fish neural regeneration after optic 
nerve injury, KLF6 knockdown ablates regeneration due to the attenuated 
expression of KLF6 target gene, Tuba 1 a (Veldman et al. 2010). KLF6 expression 
has been documented in multiple other adult brain regions apart from the 
hippocampus including the olfactory bulb, cerebral cortex, amygdale, thalamus, and 
hypothalamus (Jeong et al. 2009). Moreover, loss of heterozygosity on.chromosome 
1 Op in glioblastoma (Camacho-Vanegas et al. 2007) has implicated KLF6 as a 
potential tumor suppressor in this region and KLF6 expression has also been 
reported to be suppressed by transcriptional silencing in esophageal squamous cell 
carcinoma (Yamashita et al. 2002). The requirement for MEF2 for appropriate 
expression of KLF6 in all of these brain regions and potentially also in cancer 
models remains to be fully elucidated. In conjunction with the studies reported here, 
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a variety of experimental systems suggest a potential role of the MEF2-KLF6 
pathway in neuronal survival and regeneration, future studies to further test this are 
therefore warranted. 
As alluded to above, MEF2 activity has been implicated in a variety of 
contexts when neuronal survival is challenged and, based on available evidence, it 
is reasonable to assume that MEF2 plays a role in the orchestration of survival. 
Conversely, it is perhaps worthwhile to consider what happens to MEF2 activity 
when an insult is sufficiently severe as to overwhelm the survival response to cause 
cell death. One study has indeed reported that 4-phenyl-1, 2, 3, 6-tetrahydropyridine 
(MPTP) induction of neuronal cell death is correlated with cdk5 mediated 
phosphorylation of MEF2D (Smith et al. 2006) and a further study has documented 
that 6-hydroxydopamine (6-0HDA) mediated apoptosis in PC12 cells resulted in a 
marked reduction of MEF2D levels, an effect which was antagonized by treatment 
with roscovitine, a cdk5 inhibitor (Kim et al. 2011 ). As well as these studies, our 
studies presented here show that cAMP mediated PKA activation can lead to a 
potent repression of MEF2 activity which also results in enhanced neuronal 
apoptosis. Our previous studies (Du et al. 2008), along with these reported here, 
document a bipartite mechanism of MEF2D regulation by PKA through direct 
phosphorylation of 81211190 and enhanced assembly of a MEF2D/HDAC4 
repressor complex. Strikingly, in view of these other studies that show a 
mechanistic link between MEF2D and neuronal survival, a recent study has 
documented a down regulation of MEF2D in nigral neurons in Parkinson's disease 
patients when compared to those of age-matched controls (Chu et al. 2011). The 
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implication of pro-survival MEF2 activity in a variety of neuronal damage models 
does suggest the possibility that MEF2 protects against a variety of cellular stresses 
and toxic insults. We have observed that overexpression of MEF2D does protect 
hippocampal neurons somewhat from H202 mediated cell death supporting this 
idea further (data not shown). Further delineation of the complex signaling 
pathways converging on MEF2 will be important in potentially identifying other 
cellular signaling pathways that modulate neuronal survival. 
There are some studies clearly implicating cAMP in neuronal protection as 
well as in cell death and further clarification of this issue is warranted. It is possible 
that the duration and intensity of the signaling could be a factor in determining the 
cellular outcome. The effects of PKA/cAMP signaling on cell survival also likely 
depend on cell type, for example cAMP has been implicated in a neuroprotective 
role in cerebellar granule neurons (Wang et al. 2005). Conversely, our studies using 
a variety of perturbations of cAMP signaling (F orskolin, dbcAMP, exogenous 
expression of the active catalytic subunit of PK.A) all indicate the same effect of 
promoting cell death in cultured primary hippocampal neurons. However, survival 
of neurons depends on a complex series of cellular and intracellular communication 
networks mediated by cross-talk between signal transduction cascades. Therefore it 
is entirely possible that modulation of the type of signaling ( eg. short term versus 
chronic, high intensity versus low) may shift the balance resulting in a different 
cellular outcome. 
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In addition to the well defined survival role of MEF2 in neurons, MEF2 has 
also been implicated in activity dependent synapse elimination which fulfills a 
crucial role in the refinement of neuronal circuitry by altering synapse calibre and 
number (Flavell et al. 2006; Wierenga et al. 2006; Chandrasekaran et al. 2007; 
Turrigiano, 2008; Barbosa et al. 2008). Moreover, a recent study has reported that 
this MEF2 dependent excitatory synapse elimination is lost in hippocampal neurons 
from mice that are nullyzygous for an RNA binding protein (FMRP) whose 
function is lost in Fragile X syndrome, the most prevalent form of human autism 
and mental retardation (Pfeiffer et al. 2010). Lastly, and of relevance for our study, 
it was reported that cocaine administration inhibits striatal MEF2 activity through a 
cAMP dependent mechanism (Pulipparacharuvil et al. 2008) and cocaine mediated 
increases in dendritic spine density were dependent on MEF2 suppression. 
Consistent with this idea that MEF2 regulates dendritic morphogenesis, Shalizi et 
al. (2007) reported that PIASx, which functions as a MEF2 SUMO E3 ligase, 
represses MEF2 activity in neurons to orchestrate morphogenesis of postsynaptic 
dendrites. Thus, the regulation of MEF2 activity by PKA may also impinge on 
MEF2 dependent synapse modulation. 
Clearly, the regulation of MEF2 activity and its downstream targets in the 
CNS by cAMP-PKA signaling requires consideration in terms of understanding the 
capability to dynamically alter synaptic connectivity and neural circuitry as well as 
neuronal survival during development, physiology and pathology of the mammalian 
CNS. 
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Chapter IV 
An interaction with Strawberry notchl (Sbnol) connects MEF2 to 
Notch signaling during myogenesis 
Experimental design and writing of manuscript 
Jahan Salma and Dr. John C McDermott 
Experiments conducted by 
J ahan Salma (all figures except figure 3 7B; Fig 41 C & D) 
Dionyssiou, M.G (Figure 37B; Fig 41C & D) 
Eric Yang (Performed Mass spectrometry analysis) 
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Rationale: 
The initial objective of this study was to identify MEF2 co-factors by using 
TAP (tandem affinity purification) tag protein purification system and modem mass 
spectrometry technology. Numerous studies have demonstrated the prominent role 
of MEF2 family members in orchestrating myogenic differentiation. The process of 
myogenesis is critical and tightly controlled by various myogenic factors. Previous 
studies have documented that activation of notch signaling inhibits myogenesis by 
induction of notch target genes. Notch signaling regulates the balance between 
maintenance of progenitor cells by inhibition of differentiation and facilitation of 
commitment to the muscle lineage. Notch signaling is known to block the 
expression and activity of the myogenic factors such as MEF2s but no exact 
mechanism of myogenic inhibition has been identified as yet. Interestingly, we 
identified a novel MEF2 interacting partner, strawberry notch l(Sbnol), which has 
been characterized as a downstream effecter of Notch signaling pathway 
component. We, therefore, initiated studies to identify the mechanism of myogenic 
inhibition by notch signaling and characterize the detailed role of Sbno 1 during 
skeletal muscle differentiation. 
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Abstract 
Skeletal muscle development requires the coordinated expression of numerous 
transcription factors to control the muscle differentiation process by committed 
myoblasts into functional, contractile muscle. Myocyte enhancer factor 2 (MEF2) is 
essential for muscle differentiation. MEF2 interacts with various transcriptional 
cofactors/interacting partners and previous studies have shown that MEF2 proteins 
function combinatorially with cofactors to regulate transcription and muscle 
differentiation. In this study, we have identified a novel MEF2 interacting partner, 
Strawberry notch 1(Sbno1 ), which is known to be a downstream effector of Notch 
signaling. Notch signaling is an evolutionary conserved pathway that plays a critical 
role in cell fate decisions in proliferative cells including myogenic and neurogenic 
cells during development, but it is also involved in repair and maintenance in the 
adult after injury. In skeletal muscle, regulation of Notch signaling is involved in 
proliferation and cell fate determination of muscle stems cells during somite and 
muscle development. We, therefore, focused on characterization of the mechanism 
of skeletal muscle differentiation by Notch. First we investigated the role of Sbno 1 
in skeletal muscle proliferation and differentiation. We found that Sbno 1 represses 
MEF2 trans-activation properties and plays a critical role in inhibition of skeletal 
muscle differentiation. Moreover, immunocytochemistry analysis revealed that 
Sbno 1 may be involved in maintaining the "reserve" population of C2C 12 cell 
differentiation. Thus, our data provide the evidence that a protein-protein 
interaction between Sbno 1 and MEF2D results in interference with the myogenic 
program. 
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Introduction 
The transcription factor myocyte ~nhancer factor 2 (MEF2) was originally 
identified in muscle tissues but has been shown to be expressed in a variety of tissue 
types although activity seems to be largely restricted to cardiac, skeletal, smooth 
muscles, T-cells and neurons (Omatsky & McDermott, 1996; Zhu et al. 2005; 
Potthoff & Olson, 2007, Salma & McDermott, 2012). MEF2 has been implicated as 
playing a pivotal role in controlling cell proliferation, differentiation, and survival. 
Vertebrate MEF2 proteins are encoded by four genes MEF2 A, -B, -C, and -D (Yu 
et al. 1992; McDermott et al. 1993; and Breitbart et al. 1993), and a single MEF2 
gene in Drosophila (Lilly et al. 1994; Nguyen et al. 1994). The organization of the 
MEF2 genes is identical within conserved regions, from Drosophila to Homo 
sapiens. This indicates that they evolved from a common ancestral MEF2 gene 
present in invertebrates (Breitbart et al. 1993). In Drosophila, genetic analyses have 
demonstrated the key role of MEF2 in terminal muscle differentiation (Bour et al. 
1995). During embryogenesis, the MEF2 genes are expressed throughout 
developing cardiac and skeletal muscle lineages (Edmondson et al. 1994; Naya et 
al. 1999) and brain development (Leifer et al. 1994; Lyons et al. 1995) indicating 
MEF2's diverse role in cellular processes during development (Dodou et al. 1995). 
In adult tissues, members of the MEF2 family are critical regulators of skeletal 
muscle, cardiac hypertrophy, and activity-dependent remodeling of neuronal 
synapses (Omatsky & McDermott, 1996; Flavell et al. 2008; Akhtar et al. 2012). 
Inhibition of MEF2 activity in cultured hippocampal neurons has been shown to 
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cause neuronal cell death, suggesting that MEF2-dependent transcriptional 
regulation is critical for neuronal survival (Salma & McDermott, 2012). 
MEF2 belongs to the MADS-box (MCMl, Agamous, Deficiens, .S.erum 
response factor) super family of transcription factors (Black & Olson, 1998). The 
N-terminus of all MEF2 proteins is highly conserved, consisting of a MADS 
domain followed by an adjacent MEF2 domain which is required for high affinity 
DNA binding (T/C)TA(A/T)4TA(G/A), homo- and hetero-dimerization, and co-
factor interaction. The region C-terminal to the MADS/MEF2 domain is less 
conserved and contains domains required for trans-activation (TAD) and nuclear 
localization (NLS). The C terminus of MEF2 proteins are subjected to extensive 
alternative splicing and post-translational modifications (Black & Olson, 1998; 
Omatsky et al. 1999; Gregoire et al. 2006). Thus, MEF2 allows the receipt of 
multiple inputs from various signaling pathways including calcium-dependent 
(Ghosh & Greenberg,1995; Mckinsey et al. 2002), MAPK-dependent (Yang et al. 
1998, Naya & Olson, 1999; Zhao et al. 1999; Cox et al. 2000), ERK (Kato et al. 
1997; Cavanaugh et al. 2001), and cyclic-AMP dependent signaling pathways that 
regulate MEF2 activity in wide range of cell types (Li et al. 1992; Du et al. 2008; 
Salma & McDermott, 2012). 
The activity of MEF2 proteins is modulated by signal-dependent protein-
protein interactions with a variety of other proteins in order to regulate diverse 
programs of gene expression. These proteins include transcriptional co-activators 
such as NFAT (Chin et al. 1998), Smads (Quinn et al. 2001), p300 (Sartorelli et al. 
1997; Youn et al. 2000; Ma et al. 2005) and myocardin (Pipes et al. 2006) which 
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function in a cooperative manner with MEF2 factors. MRFs and MEF2 factors 
physically interact and synergistically potentiate MRFs mediated myogenic 
activities (Molkentin et al. 1995; Black & Olson 1998). The MEF2-HDACs 
association has been well characterized in skeletal and cardiac muscle and neuronal 
cells as a transcriptional co-repressor (Lu et al. 2000b; McKinsey et al. 2002; Perry 
et al. 2009; Salma & McDermott, 2012). Other MEF2 interactions have been 
reported with Sp 1, PCAF, GRIP 1, and MITR which enhances/represses MEF2 
transcriptional activity (Morin et al. 2000; Park et al. 2002; McKinsey et al. 2001 a; 
Ma et al. 2005; Creemers et al. 2006b). It is clear that MEF2 function depends on its 
ability to recruit such factors for appropriate target gene expression in variety of 
tissue types, underlying the MEF2 diverse roles in development and physiology of 
multiple organisms. Interactions between MEF2 factors and their interacting 
partners are critical determinants of cell growth, differentiation, and survival. 
The notch signaling pathway is an evolutionary conserved mechanism in 
which cell-cell interactions influence distinct cellular fates in variety of tissues such 
as skeletal and smooth muscle, heart, and brain (Conboy & Rando, 2002; Rios et al. 
2011; Pierfelice et al. 2011; MacGrogan et al. 2011; Gude & Sussman, 2012; 
Boucher et al. 2012). In mammals, there are four Notch receptors (Notchl-4) that 
interact with Notch ligands (DLLl, 3, 4 and Jaggedl, 2) that are expressed on the 
surfaces of neighboring cells. The ligand-receptor interaction is followed by the 
sequential cleavage of Notch extracellular and intracellular domains by an ADAM 
protease and by y-secretase, resulting in the release of the intracellular domain of 
Notch (ICND). The NICD (Notch intracellular domain) translocates to the nucleus 
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where it interacts with CSL transcription factor (CBFl {C promoter-binding factor 
1} in human, ~u(H) {Suppressor of Hairless} in Drosophila, LAG-I {Longevity-
assurance gene-1} in C.elegans, RBP-J in mouse) cooperates with coactivator 
Mastermind-Like l(MAML) to form a complex that induces transcription of 
multiple target genes including the well-characterized bHLH gene family, Hes and 
Hey (Kopan & Ilagan, 2009). Notch signaling pathway emerged as a critical 
regulator of myogenesis and muscle stem cell proliferation (Nye et al. 1994; Luo et 
al. 2005; Vasyutina et al. 2007; Buas et al. 2009; Wen et al. 2012). Notch signaling 
regulates the balance between maintenance of progenitor cells by inhibition of 
differentiation and facilitation of commitment to the muscle lineage (Kopan et al. 
1994; Conboy & Rando, 2002). Notch signaling is essential for satellite cell 
activation in injured muscle (Luo et al. 2005). Deregulation of notch signaling 
contributes to severe pathological defects (Wilson & Radtke, 2006). Previous 
studies have documented that activation of notch signaling inhibits myogenesis by 
induction of notch target genes including Hes and Hey. These genes block the 
expression and activity of the myogenic determination and differentiation factors 
such as MRFs and MEF2s (Kopan et al. 1994; Shawber et al. 1996; Kuroda et al. 
1999). Activation of Notch signaling in muscle cells by overexpression of Deltal 
prevents MyoD expression during chick limb development resulting in inhibition of 
myogenesis in vivo (Delfini et al. 2000; Hirsinger et al. 2001 ). Ectopic expression 
of a constitutively active form of Notch 1 in myogenic cell cult~e or co-culture 
with notch ligand expressing cells inhibits myogenic differentiation (Kopan et al. 
1994; Shawber et al. 1996; Kuroda et al. 1999; Lehar et al. 2005). Pharmacological 
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manipulations such as y-secretase inhibitor or overexpressing Numb (a negative 
regulator of Notch), inhibit Notch signaling and subsequently promote cell 
differentiation by blocking the proteolytic cleavage of notch receptor (Conboy & 
Rando, 2002; Kitzmann et al. 2006; Moellering et al. 2009). Furthermore, 
overexpression of Notch target genes markedly inhibits of MyoD and MEF2 
activity and suppresses myogenic differentiation (Kopan et al. 1994; Wilson-Rawls 
et al. 1999; Kuroda et al. 1999; Buas et al. 2010). 
MEF2D is highly expressed in skeletal muscle and neuronal cells where it is 
required for skeletal muscle differentiation and neuronal survival respectively 
(Black & Olson, 1998; Du et al. 2008; Salma & McDermott, 2012). To further 
understand the diverse role of MEF2D in myogenesis and neurogenesis, we sought 
to identify new interacting partners of MEF2 using tandem affinity purification 
(TAP) coupled with mass spectrometric techniques. During the course of the 
present studies in mammalian cells, we detected and identified a novel interaction 
between MEF2D and strawberry notch 1 (Sbnol). Sbnol is known as a downstream 
effector of notch signaling pathway which plays a critical role during embryo 
development of zebra fish and wing development of Drosophila (Coyle-Thompson 
& Banerjee, 1993; Majumdar et al. 1997; Nagel et al. 2001; Takino et al. 2010). 
Sbno 1 was observed to be strongly expressed in the olfactory bulb, hippocampus, 
and cerebellum of the adult brain (Li et al. 2007; Takano et al. 2011). But to date, 
no evidence was found that Sbno 1 regulates MEF2 activity through notch signaling 
in skeletal muscle or brain. However, it was documented previously that notch 
signaling involves modulation of MEF2 activity in myogenic cells (Wilson-Rawls 
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et al. 1999; Shen et al. 2006). A recent study in Drosophila identified a synergy 
between MEF2 and Notch which affects cell proliferation and metastasis (Pallavi et 
al. 2012). This led us to hypothesize that the Sbnol-Notch signaling pathway may 
play a role in cellular development such as myogenesis and neurogenesis through 
direct association with MEF2. We therefore examined the role of Sbnol-MEF2 
interaction on muscle differentiation. 
Materials and Methods 
Antibodies and reagents 
The following Primary antibodies were used: a-MEF2D from BD Biosciences. 
a-MEF2A rabbit polyclonal antibody was prepared in the lab as describe previously 
(Perry et.al. 2009).a-Actin (1-19), a-GFP (B-2), a-MyoD (C-20), a-Myf-5 (C-20), 
a-MCK, and a-SBNOl (H-240) antibodies were purchased from Santa Cruz 
Biotechnology. Monoclonal antibodies a-MyHC (MF20) and a-myogenin (F5D) 
were purchased from Developmental Studies Hybridoma Bank. Normal mouse (sc-
2025), rabbit (sc-2027), goat (sc-2028) IgGs and ImmunoCruz™ IP/WB Optima 
reagents were purchased from Santa Cruz Biotechnology. FITC and TRITC-
conjugated a-rabbit and a-mouse secondary antibodies and DAPI (D9542) were 
obtained from Sigma. Antibodies used to detect Notch ligand (a-delta 1, H-20), 
Notch receptor (a-Notch 1, M-20), and Notch target gene (a-Hesl, H-140) were 
obtained from Santa Cruz Biotechnology. Gamma secretase inhibitor was 
purchased from TOCRIS. Expression plasmids for full-length pcDNA3-MEF2D, 
pMT2 MEF2A, pCMV ~-galactosidase, MEF2 and Knippel-like factor 6 (KLF6) 
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reporter gene constructs have been described in previous publications (Du et al. 
2008; Perry et al. 2009; Salma & McDermott, 2012). pcDNA4/TO/TAP empty 
vector and pcDNA4/TO/TAP-MEF2D, pcDNA4/TO/TAP-MEF2A were previously 
described in detail (Du et al. 2008). 
Cell culture and differentiation assay 
C2C 12 myoblasts and Cos7 cells were obtained from the American Type 
Culture Collection and cultured as described previously (Perry et al. 2009; Salma & 
McDermott, 2012). Cells were maintained in high-glucose Dulbecco's modified 
Eagle medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum 
(FBS, HyClone ), sodium pyruvate, L-glutamine, and 1 % penicillin-streptomycin 
(GM: growth medium). Cells were incubated at 37° C in 5% C02 humidified 
incubator. Transient transfections were performed using the standard calcium 
phosphate precipitation method. Cells were harvested and lysed 48hours after 
transfection according to experiments or twenty four hours after transfection, cells 
were transferred to DM. 
Proliferating C2C 12 cells were grown to 80-90% confluence, and induced for 
differentiation by switching from GM (serum withdrawal) to differentiation 
medium (DM: DMEM containing 5% horse serum supplemented with 1 % 
penicillin-streptomycin) for 48, 72, 96, and 120 hours. Cells were kept in DM, 
replaced every 2 days and monitored for appropriate morphology (multinucleated 
myotube formation). C2C 12 cells normally started differentiating 48-72 h after the 
serum withdrawal. 
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Co-culture of C2C12 and Delta 1 expressing cells 
Parental OP9 stromal cells and cells expressing Deltal (Dlll-Notch ligands) 
were a kind gift from J. C. Zuniga-Pflucker (University of Toronto, Ontario, 
Canada). C2C12 cultures were carried out as described previously (Du et al. 2008; 
Perry et al. 2009). OP9 monolayers were prepared one day in advance in 1 Ocm/6 
well culture plates, and C2C 12 myoblasts cells were plated in 1 Ocm/6well plates on 
monolayers of OP9 stromal cells that had been plated on the previous day. One day 
later, when cells were ,...,,80-90% confluent, C2C12 differentiation was induced by 
replacing the culture medium with differentiation media, DMEM 5% horse serum 
(DM). The y-secretase inhibitor (final concentration: 1 µM) or dimethyl sulfoxide 
(DMSO) carrier was added to selected cultures, and the DM was replaced every 2 to 
4 days. C2C12 cells _were incubated for 48, 72, 96, and 120 hours in DM. To 
monitor differentiation (multinucleated myotubes), MF20 staining was performed 
and viewed with a fluorescence microscope. 
Reporter gene assays 
C2C 12 cells were transiently transfected using calcium phosphate precipitation 
method. Cells were seeded at a density of 12.5 x 103 cells/well in 6-well plates 1 
day prior to transfection. Transcription reporter assay plasmids (1 µg) and 
expression plasmids ( 1.5 µg) were transfected as indicated in figures. pCMV-~­
galactosidase ( 1 µg) was transfected as an internal control for transfection 
efficiency. The total amount of DNA for each experiment was kept constant by 
using empty vectors. Cells were washed 16 hours post-transfection with phosphate-
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buffered saline (PBS) and harvested 36-48 hours after transfection followed by P-
galactosidase and luciferase assays according to manufacturer's instructions 
(Promega), using a Berthold 9501 luminometer. All measurements were made in 
triplicate for at least three independent experiments with data presented as means ± 
standard errors of the means. 
Western blot analysis 
Protein extracts were prepared in NP-40 lysis buffer (0.5% NP-40, 50 mM 
Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA [pH 8.0], 100 mM sodium 
fluoride, 10 mM sodium pyrophosphate) containing 0.2 mM PMSF and 0.5 mM 
sodium orthovanadate and protease inhibitor cocktail. Protein concentrations were 
determined by Bradford assay (BioRad) with bovine serum albumin (BSA) as a 
standard. Equivalent amounts of total protein (15-20 µg) were diluted in sample 
buffer (sodium dodecyle sulphate-polyacrylamide) containing P-mercaptoethanol, 
boiled for 4-5min, and electrophoretically resolved by 10% SDS-PAGE gels, then 
electrophoretic transfer to an Immobilon-P membrane (Millipore Inc.). Non specific 
binding sites were blocked with 5% milk in PBS for one hour at RT. 
Immunoblotting was carried out using appropriate primary antibodies in 5% milk 
(PBS), a-MEF2A (1:1000), a-MEF2D (1:1000), a-MyoD (1:1000), a-Myf5 
(1:1000), a-Sbnol (1:1000), a-MCK (1:1000), a-MyHC (1:5), a-Myogenin (1:5), a-
GFP (1:1000), and a-Actin (1:1000). The blots were then incubated with the 
appropriate secondary horseradish peroxidase (HRP) antibody (BioRad) at 1 :2000 
with 5% milk in PBS for 1 hour at RT followed by Chemiluminescence detection of 
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immunoreactive proteins as per the manufacturer's instructions (Amersham 
Biosciences). 
Co-immunoprecipitation assays 
Protein extracts were prepared from COS7 and C2C12 cells as described 
earlier. Immunoprecipitation was performed using the ExactaCruz kit (Santa Cruz), 
as per manufacturer's instructions. Protein complexes were immunoprecipitated 
with 3 µg of IP antibody or normal rabbit/mouse IgG, 40 µl of suspended IP matrix 
(50% slurry) (Santa Cruz) and 500 µl of PBS by incubation at 4 °C overnight on a 
nutating platform. The beads were washed 3Xwith NETN wash buffer (0.1 % NP-
40, 150 mM NaCl, 1 mM EDTA, and 50 mM Tris-HCl pH 8.0). Equal amounts of 
total protein (500 µg) were diluted with NP-40 lysis buffer containing protease 
inhibitor to a final concentration of 1 µg/µl, incubated with IP matrix at 4 °C 
overnight on a nutating platform. The beads were washed 3X NETN wash buffer 
and boiled in sample buffer for 4-5min. Precipitated proteins were separated by 
SDS page and immunoblotting was carried out as described above. 
Immuno-fluorescence Analysis 
C2C 12 myoblasts were seeded at a density of 1x105 cells when they reached a 
confluence of 80-90% differentiation was induced the next day. The cells were 
fixed at MB, 48, 96 and 120 hours after start of differentiation, and processed for 
immunofluorescent detection as described previously (Salma & McDermott, 2012). 
Cells were incubated overnight at 4°C with primary antibodies a-MEF2D, a-Sbnol, 
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and a-MyHC (1: 100) and then incubated with the appropriate TRITC/FITC-
conjugated secondary antibodies (1:500) for 2 hours at RT following DAPI (4',6-
diamidino-2-phenylindole) staining for 15 min at RT. Cells were washed and cover 
slips were mounted with DAKO mounting media (Dalm ). All images were captured 
using a fluorescent microscope. 
MF-20 Staining 
MF-20 staining was performed to detect myosin heavy chain (MHC) 
expression, C2C12 cells cultured in DM for various time points were washed 3x 
with PBS (pH7.4and fixed with 95% methanol at -20 °C for 10 min. Following a 30 
min blocking using 5% milk in PBS at 3 7 °C, cells were incubated at room 
temperature (RT) with MF-20 (primary antibody) diluted in blocking buffer (5% 
milk PBS) for 1 hour. After incubation, the cells were washed 3x with .PBS and 
incubated for 60 min at RT with Horseradish peroxidase (HRP)-conjugated a-
mouse secondary antibody. The cells were washed 3x with PBS and incubated in 
DAB staining solution (0.6 mg/ml DAB, 0.1 % H202 in PBS) to detect MyHC. The 
nuclei were counter-stained with haematoxylin. Images were obtained with a Carl 
Zeiss microscope. 
Tandem Affinity purification (TAP) 
C2C 12 cells ( 1x105) were transiently transfected with (25 µg of DNA per 100 
mm dish) either pCDNA4/TO/TAP-MEF2A and TAP-MEF2D or empty vector. 
The purification scheme and tandem affinity purification (TAP) vector system was 
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described previously (Du et al. 2008). Cells were lysed by quick-freeze-thaw in 
IPP 150 lysis buffer with protease inhibitors. The cell lysate was incubated with 
rabbit immunoglobulin G (lgG) resin (Sigma) overnight on a rotator. After washing 
the resin with IPP150 buffer, Tagged proteins were eluted by cleaving with AcTEV 
protease (Invitrogen), then incubated with calmodulin resin (Stratagene) in IPP150 
calmodulin binding buffer supplementing with Ca++ for 1 h at 4 °C. Proteins were 
eluted using either 2 mM EGT A following liquid chromatography tandem MS 
(MS/MS) analysis or SDS sample buffer and boiled for 4 min at 95°C then 
separated by 10% SDS-PAGE. Proteins were visualised using Gelcode Blue 
(Pierce). 
Results 
Identification of novel interacting partners of MEF2 
The function of MEF2 proteins is highly regulated by their multiple interacting 
partners (acting as co-activator/co-repressor) to regulate target gene expression in a 
variety of tissue types. This suggests that gene expression requires not only DNA 
binding of MEF2 but also interaction between two or more proteins as critical 
determinants of cell growth, survival, and differentiation. Previously our lab 
identified endogenous MEF2 interacting partner HDAC4 (a co-repressor) from 
cultured Hela cells by using a tandem affinity purification (TAP) technique (Puig et 
al. 2001; Cox et al. 2002). This technique is based on generic two step affinity 
purification under physiological/native conditions which has proven successful in 
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the identification of multi protein complexes for subsequent analysis by mass 
spectrometry (Rigaut et al. 1999). 
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Figure 34. Strategy for Affinity purification and protein-protein interaction 
identification. 
(A) Typical workflow for sample preparation, in-solution digestion, and mass 
spectrometry based identification of a protein. (B) Schematic representation of 
TAP-tagged fusion protein. TAP complex purified from C2C 12 separated by 
denaturing protein gels and stained with coomassie blue. TAP-tag approach allows 
more stringent washing preventing the loss of protein complexes. (C) C2C12 cells 
were transiently transfected either with empty vector or TAP-MEF2D/TAP-MEF2A 
vectors. Cells extract were prepared for immunobloting analysis as indicated. Equal 
amount of total proteins were separated by 10%SDS-PAGE. MEF2D monoclonal 
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antibody (1:1000) and MEF2A polyclonal antibody (1:1000) was used to detect the 
protein levels. Acitn (polyclonal, 1: 1000) was used as an equal loading control. 
The combination of two purification steps provides gentle binding and 
washing conditions to preserve the protein-protein interaction as well as to remove 
the majority of non-specific protein contaminants (See material & Methods). This 
level of purification also provides high selectivity and unambiguous identification 
of interacting proteins (Figure 34A). 
The primary interest of this study was to identify novel co-
regulators/interacting partners of MEF2 for better understanding of MEF2 diverse 
role in variety of cellular programs. Therefore, we employed TAP technique to 
purify protein complexes from mammalian cells (C2C12) in combination with 
state-of-the-art Liquid chromatography mass spectrometry (LC-MS/MS). C2C12 
myoblasts (MB) were transiently transfected either with pcDNA4/TO/TAP-MEF2D 
or empty vector by using calcium phosphate precipitation method followed by TAP 
purification, in-solution trypsin digestion and subjected to LC-MS/MS analysis 
(Figure 34A). Expression level of tagged proteins was examined by coomassie 
staining and immunoblotting to confirm the tagged protein and its associated 
partners that can be detected from the crude cell extracts (Figure 34B & C). As a 
positive control TAP-MEF2A was used to confirm TAG protein expression, 
identified previously by Cox et al. 2002 (Figure 34C). From MS/MS analysis, 
numerous interacting partners of MEF2 were identified along with MEF2D when 
sample purified with TAP-MEF2D was compared with control sample. One of the 
prominent interacting partner was Strawberry Notch homologl (Sbnol) detected in 
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vivo complex with MEF2D. Previously Sbnol has been reported as a downstream 
component of the Notch signaling pathway (Coyle-Thompson & Banerjee, 1983; 
Majumdar et al. 1997). Notch signaling pathway is crucial for the proper 
development of diverse cell types and tissues and is shown to inhibit muscle 
differentiation (Nye et al. 1994; Giebel, 1999; Wilson-Rawls et al. 1999; Yoon, 
2005; Takano et al. 2010 & 2011; Pierfelice et al. 2011; Rios et al. 2011; Boucher et 
al. 2012). Therefore, we decided to characterize the interaction between Sbno 1 and 
MEF2D. There may be possibility that notch signaling plays an important role in 
muscle differentiation through the activation of Sbno 1 which may involve in 
regulation of myogenic factors (MEF2D) during similarity. 
Sbnol physically interacts with MEF2D 
To begin to elucidate the possible functional role of Sbno 1 in mammalian 
cells, we first validated the physical interaction between Sbno 1 and MEF2D by 
performing immunoprecipitation assays. COS7 cells were transiently transfected 
with expression plasmids of Sbnol and MEF2D alone and both plasmids together. 
Cell extracts were subsequently immunoprecipitated with anti-Sbnol antibody and 
immunobloted with anti-MEF2D monoclonal antibody. A prominent MEF2D 
detection was observed when Sbno 1 is ectopically co-expressed with MEF2D, 
confirmed a specific interaction between Sbnol and MEF2D (Figure. 35A, Co-IP 
panel, compare lane 4). MEF2D and Sbnol was not detectable in pcDNA3 
transfected lysates (Figure 2A, upper panels, lane 1) but their expression were seen 
only in input-lysates when transfected alone or together (Figure 35A, upper panels, 
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lanes 2, 3 & 4). GFP was used as a marker for transfection efficiency and actin as a 
loading control of total protein (Figure 35A, Actin & GFP blots). Detection of faint 
bands of MEF2D from lysates not over-expressing was due to low levels of 
endogenous MEF2D expression in cos7 cells (Figure 35A, MEF2D blot lanes 1 and 
2). Endogenous Sbno 1 protein level was not observed when pcDNA3 ectopically 
expressed in COS7 cells and whole cell lysate (Figure 35B, lanes 1 and 3) compare 
to ectopically expressed Sbnol in cos-7 shown in Figure 35B, lane 2, further 
confirming that there is no endogenous Sbno 1 in these cells which might interact 
withMEF2D. 
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Figure 35. Physical Interaction between Sbnol & MEF2D. 
(A & B) COS7 cells were transiently transfected with empty vector and 
combinations of Sbno 1 and MEF2D expression vectors (as indicated). Cells extract 
were prepared for coimmunoprecipitation and western blot analysis. (A) For 
coimmunoprecipitation 500 µg of total protein extracts was used for analysis, and 
for immunoblotting, 20 µg of total cell extract was diluted with NP-40 lysis buffer 
to a final concentration of 1 µg/µl. Protein complexes were immunoprecipitated 
with 2 µg Sbnol polyclonal antibody or 2 µg normal rabbit lgG, and 20 µl matrix 
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beads (50% slurry) ImmunoCruz (Santa Cruz) by incubation at 4 °C overnight on a 
rotating platform. The beads were washed with three changes of wash buffer. Beads 
were boiled in sample buffer, and protein complexes were resolved by SDS-PAGE 
and immunoblotted as indicated in figure 2A, bottom panel. Western blot of 
MEF2D monoclonal (1:1000) and Sbnol polyclonal antibody (1:1000) as indicated 
in figure 2A, upper panels. Acitn (polyclonal, 1: 1000) and GFP (1: 1000) were used 
for loading control and transfection efficiency respectively. (B) Cos7 cells were 
transiently transfected either with empty vector or Sbno 1 expression vector (as 
indicated). Cells extract were prepared for western blot analysis. Sbno 1 did not 
detected from cos7 cells when whole cell lysate (WCL) was used in western blot 
analysis of Sbnol. 
In order to further verify the direct interaction between Sbnol and MEF2D, we 
initiated experiments to test evidence-whether both proteins localize together in 
myogenic cells by using immunofluorescence assay. Figure 36A shows that Sbnol 
(in red) and MEF2D (in green) specifically and strongly localized in the nuclear 
regions (Figure 36A, top panels) and co-localization of both proteins is visible when 
their respective images were merged together (Figure 36A, bottom panel). Cell 
nuclei were counter-stained with DAPI (in blue). These observations revealed that 
Sbno 1 and MEF2D co-localized together within the nucleus of proliferating 
myoblasts. This co-localization may possibly, by targeting MEF2, have a functional 
role in skeletal muscle differentiation. 
We additionally wanted to confirm, whether Sbno 1 and MEF2D physically 
interact in myogenic context. More direct evidence of the physical interaction 
between these two proteins was obtained by co-immunoprecipitation analysis in 
C2C12 cells (proliferating myoblasts) as shown in figure 36, panels B & C. 
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Figure 36. Cellular localization of Sbnol in myogenic cells. 
(A) Immunofluorescence analysis of C2C 12 cells were performed at proliferative 
myoblast stage. Cells were fixed in 4% paraformaldehyde followed by double 
immunofluorescence analysis. Primary antibodies to anti-Sbno 1 (rabbit) shown in 
red were merged with anti-MEF2D (mouse) labeled with green, revealed co-
localization of both proteins in nuclei (yellow) in the myoblasts. Nuclear DAPI 
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staining is shown in Blue. All images were acquired from same field using a 
confocal laser scanning microscope. (B & C) C2C12 cells were either transfected 
with empty vector or expression vectors of Sbno 1/MEF2D and GFP. Cell extracts 
were prepared for co-immunoprecipitation (Co-IP) analysis as indicated in bottom 
panel of B & C. Westemblots show the expression levels of MEF2D and Sbno 1. 
Actin was used as a loading control and GFP as a marker for transfection efficiency. 
C2C 12 cells were transiently transfected with either Sbno 1/MEF2D alone or 
empty vector. GFP was co-transfected as a transfection marker. Detection of 
endogenous MEF2D was observed when cell extracts were immunoprecipitated 
with anti-Sbnol and immunobloted with anti-MEF2D antibody revealed 
endogenous interaction between Sbnol and MEF2D which occurred in a native 
cellular environment (Figure 36, Co-IP panels B & C, lane 2). Collectively, these 
results further confirm a novel protein-protein interaction between Sbnol and 
MEF2D identified by LC-MS/MS analysis in current studies. 
Sbnol inhibit MEF2 dependent transcription 
Next we precisely examined the direct functional role of Sbno 1 on MEF2 
regulation, C2C 12 cells were transiently transfected with MEF2-dependent 
luciferase reporter gene (MEF2-Luc) and an increasing amounts of an expression 
plasmid of Sbno 1. This experiment clearly demonstrated that Sbno 1 inhibited 
MEF2-mediated transcriptional activity of a MEF2-dependent reporter in a dose 
dependent manner when co-transfected with MEF2D, providing evidence for the 
involvement of Sbno 1 in the regulation of MEF2 activity (Figure 3 7 A). 
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Figure 37. Effect of exogenous Sbnol expression in C2C12 cells. 
(A) Sbno 1 suppresses MEF2 transcriptional activity in mammalian cells. C2C 12 
cells were transiently transfected with pGL3-4XMEF2-Luc reporter gene, pCMV-~­
Galactosidase to normalize transfection efficiencies and increasing amount of 
Sbnol by using calcium phosphate method. (B) Sbnol suppresses KLF6 
transcriptional activity through MEF2. Schematic illustrations of KLF6 promoter 
construct (pROM6) with intact MEF2 binding site or with MEF2 site mutated. 
C2C 12 cells were co-transfected either with empty vector or Sbno 1. MEF2 
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mediated transcriptional activity was determined by pGL3-pROM6-Luc or pGL3-
~pROM6-Luc (KLF6 reporter gene) and pCMV-~-Galactosidase (to normalize 
transfection efficiencies). pGL3-basic empty vector was used as a control. Cell 
extracts were prepared for luciferase and ~-gal assays as described in Material and 
Methods. (Data are the mean+/- S.E.M n=3). 
Given that Sbno 1 was identified as a potential co-repressor of MEF2, we then 
investigated whether Sbnol can alter a known MEF2 downstream target gene 
Kriippel-like factor 6 (KLF6) through targeting MEF2. KLF6, a newly identified 
MEF2 target gene, is involved in neuronal survival (Salma & McDermott, 2012) 
and in muscle differentiation (unpublished data). To investigate the possible role of 
Sbno 1 in the regulation of MEF2 target genes, C2C 12 cells were transfected with 
the pROM6 (KLF6) reporter construct containing the intact or mutated MEF2 
binding site in the presence and absence of Sbno 1. Figure 3 7B demonstrated that 
the pROM6 reporter gene activity driven by MEF2 site was markedly reduced by 
Sbnol (Figure 37B, 2°d bar) compared to control. Similar results were seen with or 
without Sbno 1 when cells were transfected with pROM6 reporter construct which 
lacks the MEF2 binding site (Figure 37B, 3rd and 4th bar). Together, these results 
provide evidence for an important role of Sbno 1 in the regulation of MEF2 activity. 
This association of Sbno 1 with MEF2D suggests that Sbno 1 may be acting as a co-
repressor, inhibiting MEF2 activity in myogenic cells. 
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Exogenous expression of Sbnol inhibits differentiation of C2C12 cells 
Considering our finding that Sbno 1 associates with MEF2D in myogenic cells 
and regulates MEF2 dependent gene expression. We proceeded to examine the 
effect of exogenous expression of Sbno 1 on C2C 12 skeletal muscle cell 
differentiation. The MEF2 factors have been shown to be essential for muscle 
differentiation (Black & Olson, 1998). MEF2 also cooperate with the basic helix-
loop-helix transcription factors (bHLH) in the activation of the muscle specific gene 
expression and function within a regulatory network. Together, they regulate the 
differentiation of myoblasts into multinucleated myotubes by activating muscle-
specific contractile genes (Molkentin et al. 1995). Therefore, we investigated the 
ability of Sbnol in the regulation of muscle-specific transcription factors. C2C12 
cells (myoblasts=MB) were transiently transfected with either Sbno 1 or empty 
vector by using calcium phosphate precipitation method. Cells remain proliferative 
in the presence of growth medium (GM) containing 10% FBS until they were 80-
90% confluent, but start to differentiate upon withdrawal of GM (high serum 
content) and induced to differentiate by culturing them in a differentiation medium 
(DM) containing 5% horse serum (as described in Materials and Methods) and were 
incubated additional 4 days. We used Western blot analysis to examine early 
differentiation markers MEF2 and myogenin and late differentiation marker skeletal 
myosin heavy chain (MyHC) protein expression in the presence of Sbnol. Total 
cellular extracts were isolated from MB in GM and 48hrs, 72hrs, and 120 hrs after 
induction in DM. Western blots indicate that ectopically expressed Sbno 1 
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completely abolished expression of early and late differentiation markers myogenin, 
MyHC, and MCK respectfully. 
c 
Sbno1 + + + + 
pcDNA3 
- - -
I 
., 
------
'MyHC 
MCK 
MEF2D 
....._ ____________ __,, MyoD 
MEF2A 
~ .... ._. ~---1._. 
~-••-.•--• 
Sbno1 
..__'_]·_-_ .. _ ---_--_----~---_·:-_·_~._._ .. _. _._·_~I Actin 
MBlnGM 48 72 
Hours in DM 
Figure 37. Effect of exogenous Sbnol expression in C2C12 cells. 
(C) Overexpression of Sbnol inhibits myoblasts differentiation. C2C12 myoblasts 
were co-transfected either with empty vector and Sbno 1. Transfected cells were 
allowed to recov~r and grow to 80% confluence in growth media (GM) (MB, 0 h) 
and then switched to differentiation media( DM) for a period of 48, 72, 96 hrs. 
Samples were harvested at the indicated time points and analyzed for early and late 
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differentiation markers (MyoD, Myogenin, MyHC, MCK) expression by Western 
blot analysis. MEF2 expression was gradually decreased in the presence of Sbnol 
when cells grown in DM and monitor equal loading expression with Actin 
(polyclonal, 1 :2000). 
The expression of MEF2 factors, and MyoD were markedly decreased with Sbno 1 
relative to the pcDNA3 expressed cells. Interestingly, Sbnol increased the Myf5 
expression in the differentiating cells relative to the pcDNA3 expressed cells 
(Figure. 37C). Together these results show that overexpression of Sbnol is involved 
in impaired expression of myogenic factors resulting in inhibition of myoblast 
differentiation and initiation of multi-nucleated myotubes formation by repressing 
MEF2 and muscle specific gene expression such as MyoD and myogenin. This 
might be occurred through MEF2 dependent regulation due to absolute requirement 
of MEF2 factors for myoblast differentiation and terminal myotubes formation. 
Immunostaining analysis of Sbnol-MEF2D during C2C12 differentiation 
Since we observed the potential role of Sbno 1 in the regulation of MEF2 
activity and in muscle differentiation, we initiated to further explore localization of 
Sbno 1 and MEF2D during the process of skeletal muscle cell differentiation by 
examining double immunofluorescence analysis. In order to performed time course 
immunostaining, C2C12 cells were fixed at MB (GM), 48hrs, 96hrs and 120 hrs 
after induced to differentiate by culturing them in a DM. We found strong nuclear 
localization of Sbnol (red) and MEF2D (green) in proliferating myoblasts and 
merged images clearly depict co-localization of Sbnol and MEF2D in nuclear 
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region of proliferating myoblasts. Cell nuclei were counter-stained with DAPI (in 
blue) (Figure. 38, left panel 1 ). 
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Figure 38. Cellular localization of Sbnol & MEF2D during C2C12 
differentiation. C2C 12 proliferating myoblasts were grown to confluence in GM 
(Oh, panel A) and then switched to DM for a period of 48, 96 and 120 hrs (panels B-
D). Immunofluorescence analysis of C2C 12 cells were performed at the indicated 
I 
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time points. Cells were fixed in 4% paraformaldehyde (panels A-D) followed by 
double immunofluorescence analysis (as described in Materials and Methods). Cells 
were stained with primary antibodies to anti-Sbnol (rabbit) shown in red were 
merged with anti-MEF2D (mouse) labeled with green. Co-localization of both 
proteins in nuclei (yellow) was revealed in the myoblasts (panel A). Nuclei were 
counterstained with DAPI (blue). All images were acquired from same field using 
a confocal laser scanning microscope. 
The detailed analysis of immunostaining of Sbno 1 during the progression of 
differentiation revealed a dramatic change in the localization of Sbno 1 from 
mononucleated myoblasts, when cells remain proliferative in the presence of 
growth medium (GM), to formation of terminally differentiated myotubes 
(multinucleated). Interestingly we observed translocation of Sbno 1 from nucleus to 
cytoplasm at 48hrs in C2C 12 cells in DM. This localization was clearly seen when 
DAPI and Sbno 1 images were merged (Figure. 38, left bottom panel 2). Both 96 
and 120 hrs images demonstrated that Sbno 1 was localized in cytoplasm of un-
differentiated cells (reserve/satellite cells) whereas MEF2D showed strong nuclear 
localization in majority of cells in the early differentiating myoblasts ( 48hr) and in 
the late differentiated myotubes (96 & 120hrs) (Figure. 38, right panel 3 & 4). 
Taken together these observations indicate that Sbno 1 highly localizes in nucleus of 
undifferentiated cells but gradually declines in differentiating cells suggesting that 
heterogenous cell types exists during myogenic differentiation. Sbno 1 negative cells 
(myotubes) are surrounded by Sbnol positive cells which maintain reserve cells 
population. Collectively, these results suggest that Sbnol might be a crucial 
regulator to balance differentiated and undifferentiated cells. 
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Localization of Sbnol during Myoblasts differentiation 
The transition of cellular differentiation is associated with up/down-regulation 
of variety of regulators and co-regulators with direct association of myogenic 
factors such as MEF2 which requires for terminal process of differentiation. 
Normally MEF2 expression is induced upon activation of muscle differentiation 
signal which contributes to enhancement of muscle genes expression. Therefore, we 
intended to examine when Sbno 1 and MEF2D interact to form physical complex in 
myogenic cells during the process of differentiation. C2C 12 cell lysates, both from 
myoblasts and myotubes were immunoprecipitated with anti-Sbno 1 antibody and 
immunobloted with anti-MEF2D monoclonal antibody. Detection of endogenous 
MEF2D was observed only when cell extracts from undifferentiated C2C12 
myoblasts (cultured in GM) was immunoprecipitated with anti-Sbno 1 antibody and 
immunobloted with anti-MEF2D antibody but not in differentiating myotubes in 
DM (data not shown). This revealed endogenous interaction between Sbno 1 and 
MEF2D which occurred in a native cellular environment (Figure 39A, Co-IP). 
Present results demonstrated that these two proteins associate together in myoblasts 
and, not in myotubes. 
In addition we performed immunocytochemistry on differentiated cell culture 
to observe the heterogenic cellular localization of Sbno 1 and skeletal myosin heavy 
chain (MyHC) after 120hrs induction of muscle differentiation. Differentiated 
mature myotubes were positively identified by immunostaining with a monoclonal 
antibody directed against the MyHC, a terminal myogenic differentiation marker (in 
green) (Figure 39B). 
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Figure 39. Physical Interaction between endogenous Sbnol and MEF2. 
(A) Endogenous co-immunoprecipitation analysis was performed using C2C12 
cells at proliferative myoblast and differentiated myotubes stages (myoblasts were 
grown to confluence then switched to DM for a period of 120hrs ). 500 µg total 
protein extracts was used for coimmunoprecipitations diluted with NP-40 lysis 
buffer. Protein complexes were immunoprecipitated (IP) with 2 µg anti-Sbnol 
polyclonal antibody or 2 µg normal rabbit IgG (control), and 20 µl matrix beads 
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(50% slurry) ImmunoCruz (Santa Cruz) (as described in Materials and Methods). 
Protein complexes were resolved by SDS-PAGE and immunoblotted (IB) with 
MEF2D monoclonal (1:1000). (B) C2C12 cells were grown to confluence in GM 
and then switched to DM for a period of 120 hrs. Cells were fixed in 4% 
paraformaldehyde after 120 hrs in DM followed by double immunofluorescence 
analysis (as described in Materials and Methods). Localization of Sbno 1 were 
observed in majority of mononucleated reserve cells stained with primary antibody 
anti-Sbno 1 (rabbit) shown in red. Mature multinucleated myotubes were analyzed 
staining with anti-MyHC (mouse) shown in green as indicated. Nuclei were 
counterstained with DAPI (blue). All images were acquired from same field using a 
confocal laser scanning microscope. 
Interestingly Sbno 1 localization was mainly observed in the cytoplasm of 
undifferentiated cells (reserve cells) (in red) and absent in the nuclear compartment. 
Cells were immunostained for Sbnol and MyHC, counterstained with DAPI 
allowing us to identify the nucleus of both differentiated and undifferentiated cells 
(Figure 39B). Together, these results suggesting that this Sbnol may act to maintain 
the myogenic cells (reserve cells) in an undifferentiated proliferating state. 
Collectively present results further confirm that physical interaction between 
Sbnol-MEF2D occurs only in proliferating myoblast, not in differentiated 
myotubes. It is possible that Sbno 1 inhibits progression of myoblasts differentiation 
to myotubes by inhibition of myogenic factors. As we know MEF2D is required for 
an efficient activation of muscle specific genes during myogenic differentiation but 
consequently inhibition of MEF2D by Sbno 1 prevent myogenic events. 
Deltal expressing cells inhibits differentiation of C2C12 cells 
Activation of Notch signaling inhibits muscle differentiation in vitro and in 
vivo (Wilson-Rawls et al. 1999; Conboy & Rando, 2002; Buas et al. 2009) and 
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previous studies suggested that Sbno 1 is a downstream component of the Notch 
signaling (Coyle-Thompson & Banerjee, 1993; Majumdar et al. 1997) so it is 
possible that Sbno 1 may be involved in muscle differentiation through regulation of 
MEF2. Therefore, we sought to address two questions: (1) whether Sbnol constitute 
as an important downstream effector of Notch signaling in skeletal muscle, (2) the 
role of Notch-Sbno 1 in regulation of myoblast differentiation. Activation of Notch 
signaling is initiated by cell-cell contact, the Notch receptors and their ligands are 
both cell surface molecules and Notch ligands can modulate cell fate through 
activation of a Notch receptor. Therefore to address these questions, we utilized a 
well-characterized co-culture method to examine the effect of Notch signals 
delivered by OP9-Delta cells, a stable cell line expressing notch ligands (Deltal) 
(Lehar et al 2005), on C2C12 myoblasts cells (expressing endogenous Notch 
receptors) (Luo et al. 2005). This method allowed us to monitor C2C 12 
differentiation either by the appearance of multinucleated myotubes or by the 
expression of muscle-specific genes such as myogenin/MyHC. In order to analyze 
the intracellular events induced by Notch activation, we first examined the ability of 
OP9-Deltal to transmit Notch signals to C2C12 and determine whether Notch 
activation prevents myogenic differentiation, C2C 12 cells were co-cultured with the 
control OP9 cells and OP9-Deltal cells initially in GM and induce to differentiate 
for up to 120 h in DM (see material and method). 
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Figure 40. Deltal-expressing cells inhibit myoblasts differentiation. 
Co-culture of C2C12 myoblast cells with notch ligand expressing (OP9-Deltal) 
cells blocks myotubes foramtion. C2C 12 cells were co-cultured with the control 
OP9 cells and OP9-Deltal cells initially in GM and induce to differentiate for up to 
48, 72, 96, and 120 hrs in DM (as described in Materials and Methods). (A) Live 
cells images were obtained at the indicated time points using bright field phase-
contrasts microscopy. C2C12 cells in the absence of notch ligand expressing (OP9-
Deltal) cells differentiated normally and fused to form multinucleated mature 
myotubes. However in the presence of notch ligand expressing (OP9-Deltal) cells 
prevented myoblasts to differentiate into multinucleated myotubes. 
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When proliferating myoblast cells are induced to differentiate in DM they 
undergo myogenic conversion to form mature myotubes formation. Usually few 
myotubes started to appear 48 hours after the induction in DM but more were 
clearly seen at 72 to 120 hours indicating that myoblast cells progressed into 
differentiation normally and fused into multinucleated myotubes in the absence of 
delta-Notch signaling (Figure 40A left panel). As shown in Figure 40A right panel, 
C2C12 cells co-cultured with OP9-Deltal cells prevent the myoblasts to 
differentiate into multinucleated myotubes, in contrast when C2C 12 cells were 
cultured in the presence OP9 control cells. Together these results suggest that 
Deltal transmit Notch signals to C2C12 myoblasts and play a role in inhibition of 
myoblast differentiation to become mature myotubes. 
To further determine the molecular mechanism of inhibition of myoblast 
differentiation when C2C12 cells were co-cultured with OP9-Deltal cells, we 
proceeded to examine expression of early differentiation markers MEF2 and 
myogenin and late differentiation marker skeletal myosin heavy chain (MyHC). 
Total cellular extracts were isolated from MB in GM and 48, 72, 96, and 120 hrs 
after induction in DM. Co-culture of C2C12 cells with Notch-ligand expressing 
cells completely blocked myoblast differentiation by inhibiting muscle 
differentiation markers. As shown in Figure 40B, expression of muscle specific 
differentiation markers such as myogenin, MyHC, and MCK was markedly 
decreased when C2C12 cells co-cultured with OP9-Deltalcells but not with control 
OP9 cells. The expression of Sbno 1, both in C2C 12 cells co-cultured with control 
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OP9 cells and with OP9-Deltal cells, were considerably increased after 48 hrs of 
differentiation induction. 
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Figure 40. Deltal-expressing cells inhibit myoblasts differentiation. 
(B) Total cellular extracts were isolated from MB in GM and after induction in DM 
at the indicated time points mentioned above. Equal amount of cell extracts were 
subject to Western blot analysis for detection of early and late differentiation 
markers. Actin was used as a control to monitor an equal loading. 
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Furthermore, stimulation of Notch signaling increases the expression of Myf5 
before and 48 hrs after differentiation induction, consistent with previous reports, 
Myf5 progressively active in muscle progenitor cells/reserve cells (Figure 40B). 
Collectively, these results indicate that Notch signaling is activated by deltal in 
C2C12 cells when co-cultured with OP9-Deltal expressing cells. Deltal acts as a 
functional ligand for Notch receptor in C2C12 cells and ligand-receptor association 
involves in inhibition of muscle specific genes and myogenic differentiation of 
C2C 12 cells through activation of notch signaling and downstream effector Sbno 1. 
Pharmacological targeting of Notch rescue differentiation of C2C12 cells 
Because Notch signaling plays an important role in muscle development, it is 
possible that targeting notch signaling may have opposite effects on muscle 
differentiation. During the cell-cell contact ligand and receptor undergoes 
sequential proteolytic cleavage by secretases. One of the approaches for 
pharmacologic targeting of the Notch signaling is y-secretase inhibitor, which 
blocks the proteolytic cleavage and subsequent activation of the Notch receptor and 
release of intracellular domain of Notch (NICD)/active notch. Therefore, to explore 
whether OP9-Deltalexpressing cells transmit the signal to the neighboring cells 
which directly involve in muscle specific differentiation genes suppression, we used 
y-secretase inhibitor in co-culture experiment to monitor phenotypic effects of y-
secretase inhibitor and rescue of myotubes formations by immunostaining 
experiments that detect expression of myosin heavy-chain (MyHC), a terminal 
myogenic differentiation marker (Figure 41A). 
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Figure 41. Inhibition of notch signaling triggers myoblasts differentiation. 
(A) Inhibition of notch activity by treatment of y-secretase inhibitor, enhanced 
myoblasts differentiation by preventing proteolytic cleavage of notch receptor and 
release of intracellular notch domain. C2C 12 were co-cultured with notch ligand 
expressing cells (OP9-Deltal) either in the presence or absence of y-secretase 
inhibitor. Cells were grown initially in GM and allowed to differentiate in DM for 
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up to 48, 72, 96, and 120 hrs. (A) Cells were fixed at the indicated time points 
followed by immunocytostaining using the anti-MyHC antibody (MF20) (see 
Materials and Methods for details). MyHC expressing myotubes (shown in brown 
staining) can be detected in co-cultures treated with y-secretase inhibitor. 
C2C12 cells were initially co-cultured with the control OP9 cells and OP9-
Deltal cells in GM and induce to differentiate for up to 120 h in DM (see material 
and method). We found that y-secretase inhibitor blocked notch signaling and 
rescued myoblast differentiation that was observed by considerably increased 
multinucleated myotubes formation and accumulation of MyHC expression from 48 
hrs to 120 hrs (Figure 41A, right panel) in contrast without y-secretase inhibitor 
(Figure 41A, left panel). We next determined whether y-secretase inhibitor could 
able to rescue endogenous expression of muscle specific differentiation markers, 
C2C 12 myoblasts were induced to undergo myogenic differentiation in the presence 
and absence of y-secretase inhibitor. Total cellular extracts were isolated from MB 
and 48hrs, 72hrs, 96hrs and 120 hrs after differentiation induction and subsequently 
analyzed by Western blotting. Expression of muscle specific differentiation markers 
was highly increased with y-secretase inhibitor treatment (Figure 41B) in contrast 
without inhibitor. Whereas expression of Sbnol decreases in the presence of y-
secretase inhibitor throughout myogenic differentiation suggesting that Sbno 1 may 
act as downstream effector or Notch target gene in myogenic cells. 
To obtain insight into whether the mechanism leading to myogenic inhibition 
was through Sbnol-Notch singling, transcriptional reporter gene assays were 
performed using a luciferase reporter driven by the MCK promoter (MCK-Luc) 
(Figure 41 ). 
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Figure 41. Inhibition of notch signaling triggers myoblasts differentiation. 
(B) Western blot analysis of early and late differentiation markers from co-culture 
treated with or without y-secretase inhibitor. Cells extract were prepared for the 
indicated time points under differentiation inducing conditions (see Materials and 
Methods for details). Equal amount of total protein were separated by 10%SDS-
p AGE followed by detection of early and late differentiation markers as indicated 
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in figure 8B. Acitn was used as a loading control. (C & D) y-secretase inhibitor 
rescued MCK promoter activity in myogenic cells. C2C12 cells were transiently co-
transfected with pMCK-Luc reporter gene, pCMV-~-Galactosidase to normalize 
transfection efficiencies and with Sbno 1/Dll 1 or empty vector in combination with 
or without ( 1 µM) y-secretase inhibitor (as indicated). Luciferase and pCMV-~­
galactosidase activities were measured 48 h after cells induce to differentiate in DM 
as described in Material and Methods (Data are the mean+/- S.E.M n=3). 
C2C12 cells were co-transfected with Sbnol and MCK-Luc reporter. 
Transfected cells were cultured with or without pharmacological inhibitor of Notch, 
y-secretase inhibitor in differentiation medium for 48 h before harvesting and 
measuring luciferase activities. Reporter gene analysis demonstrated a reduction of 
MCK reporter activity in Sbnol transfected cells which was reversed by y-secretase 
inhibitor (Figure 41 C). Similar transcriptional assay was performed co-transfected 
with Delta-1 (Dlll) using the MCK promoter luciferase reporter (MCK-luc). We 
found that y-secretase inhibitor blocked Dlll effects and rescued MCK reporter 
gene activity in C2C12 cells (Figure 41D). Taken together these results indicate that 
modulation of Notch signaling can alter myogenic program through activation of 
ligand-receptor and their association induces downstream effector, Sbnol. 
Inhibition of MEF2 through Sbno 1 causes reduction in muscle gene activation, 
providing evidence that Sbno l -MEF2 association play a crucial role in muscle 
development. Together these results strongly suggest a potential role of Sbnol as a 
negative regulator of myogenic differentiation. 
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Figure 42. Proposed model for the Notch-Sbnol signaling pathway. 
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Discussion 
The Myocyte enhancer factor 2 (MEF2) family of transcription factor is 
potential target of multiple signaling pathways and number of cofactors that 
regulates specific gene expression in diverse developmental programs. MEF2 is 
emerged as a key factor in controlling the differentiation, proliferation, and survival 
in various cell types including muscle, and neurons (Perry et al. 2009; Salma & 
McDermott, 2012). In the present study, we revealed a novel interacting partner of 
MEF2 known as Strawberry notch 1 (Sbno 1 ). We have provided evidence that 
Sbno 1 acts as a negative regulator of MEF2 in myogenic cells. Ectopic expression 
of Sbno 1 represses MEF2 mediated transcriptional activity and inhibits myogenic 
differentiation. Interestingly, a recent report found a synergism between MEF2 and 
Notch in Drosophila (Pallavi et al. 2012). Sbnol was originally identified in 
Drosophila, encodes a conserved nuclear protein that functions downstream of 
Notch signaling and involve in wing development (Coyle-Thompson & Banerjee, 
1993; Majumdar et al. 1997; Nagel et al. 2001). Currently, there is no evidence 
that Sbnol is regulated by activation of notch signaling. However, previous studies 
reported that Notch signaling pathway is critical for satellite cell activation and 
myogenic precursor cell expansion in postnatal myogenesis (Conboy & Rando, 
2002). The control of skeletal muscle differentiation is regulated by the muscle 
specific factors MEF2 and cofactors during transcription and the activation of the 
myogenic program. Previously, it was shown that notch signaling and notch 
mediated target genes inhibit myogenesis by targeting myogenic factors such as 
MEF2 and MyoD (Kopan et al. 1994; Wilson-Rawls et al. 1999). Here, our study 
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strongly suggests that terminal skeletal muscle differentiation is linked to MEF2-
Sbno 1 interaction which leads to inhibition of MEF2-dependent myogenic gene 
expression. 
Differentiation of C2C 12 myoblasts is a multistep process that requires a 
coordinated sequence of molecular events, involving an initial withdrawal of cells 
from the cell cycle, followed by expression of terminal differentiation genes and 
subsequent fusion of cells into multinuclear myotubes. It was shown previously that 
activation of Notch signaling inhibits myogenesis of cultured C2C12 cells and 
blocked terminal differentiation events (Kopan et al. 1994; Lindsell et al. 1995; 
Shawber et al.1996; Nofziger et al. 1999; Kuroda et al. 1999). Notch signaling is 
also able to block activation of postnatal myogenic differentiation in muscle 
specific stem cells (Luo et al. 2005). Ectopic expression of notch ligand Dill in the 
limb bud of chick embryos inhibited muscle precursor cells differentiation (Delfini 
et al. 2000). These studies suggested that there may _be multiple molecular 
mechanisms involve in regulation of muscle differentiation process. A previous 
study demonstrated that high levels of notch ligand Dll 1 suppress MyoD in cultured 
C2C 12 myoblasts and NICD can directly bind the muscle differentiation factor 
MEF2C (Kuroda et al. 1999). Activation of Notch signaling blocks its 
DNA-binding site that lead to impaired transcriptional activity of MEF2C which 
might cause inhibition of myogenic process (Kopan et al. 1994; Shawber et al. 
1999; Wilson-Rawls et al. 1999; Gagan et al. 2012). Notch-induced trans-activation 
of DNA-binding protein RBP-J directly regulates the transcription of Hes], Notch 
target gene, which in turn blocked the expression of the muscle determining gene 
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MyoD (Kuroda et al. 1999). However, experiments with mutant Notch receptors 
lacking RBP-J binding site demonstrated that Notch signals are able to inhibit 
myogenic differentiation in the absence of activated RBP-J (Tamura et al. 1995; 
Delfini et al. 2000). 
The process of myogenesis is essential not only for muscle development, but 
also for the regeneration of injured and aged muscle fibers characterized by the 
expression of muscle-specific genes (Karalaki et al. 2009; Taoa et al. 2010). Here, 
we reveal physical association between MEF2D and Sbno l in mammalian cells. 
Sbno 1 is highly localized in proliferating myoblasts, and diminished in mature 
myotubes during differentiation. Furthermore, overexpression of Sbno 1 in C2C 12 
myoblasts inhibits muscle differentiation. MEF2 and myogenic regulatory factors 
(MRFs) including MyoD, Myf5, myogenin, and MRF cooperate together during the 
regulation of myogenic expression program (Black and Olson 1998; Berkes & 
Tapscott, 2005). Together, MEF2 and MRFs proteins regulate the differentiation of 
myoblasts into multinucleated myotubes by activating muscle-specific genes. Our 
study suggests that MEF2-Sbnol interactions with respect to MEF2-MRFs 
cooperation inhibited by Sbno 1 during myogenic differentiation. The role of Sbno 1 
may be linked with the notch signaling directly/indirectly in muscle differentiation 
inhibition (Buas et al. 2009 & 2010). 
Skeletal muscle development and regeneration in vertebrates requires a 
balance between myogenic differentiation and the maintenance of progenitor cells 
(Conboy & Rando, 2002). The role of Notch signaling is to sustain the balance 
between differentiation and the maintenance of undifferentiated cells or reserve 
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cells (Conboy et al. 2003; Morgan & Partridge, 2003). Current studies also confirm 
above findings by establishing that there might be a connection between Sbno 1 and 
notch signaling in sustaining the balance between myogenic differentiation and the 
maintenance of undifferentiated cell (reserve cells) population in vitro. A 
population of reserve cells is usually maintained aside and later these cells are the 
primary source of stem cells of post-natal skeletal muscle (Mourikis et al. 2012). 
These cells are essential for the growth and regeneration of muscles (Conboy & 
Rando, 2002; Rios et al. 2011; Gude & Sussman, 2012). Some mechanisms by 
which the Notch signalling pathway maintains activated reserve cells in an 
undifferentiated state have been documented previously. The NICD interacts with 
MyoD and Myf5 in the nucleus as an active repressor (Kopan et al. 1994 ). In the 
limb development, Delta- I and Serrate-2 activate the Notch pathway and inhibit 
muscle differentiation through Pax3, Myf5, and MyoD (Delfini et al. 2000). Ectopic 
expression of NICD promoted proliferation of satellite cells and attenuated the 
myogenic differentiation, i.e., upregulated Pax3 and downregulated MyoD and 
desmin (Conboy & Rando, 2002). Conversely overexpression of Numb, suppressor 
of Notch signaling upregulated the expression of muscle differentiation genes and 
reduced proliferation of satellite cells ex vivo. Here we provide the evidence that 
Dlll, a Notch ligand, play a critical role in modulation of Notch signaling that leads 
to control myogenic events by maintenance of the reserve cells and differentiation. 
The induction of Sbno 1 was observed in cell-cell contact due to ligand/receptor 
connection, when C2C12 cells were co-cultured with ligand expressing cells (OP9-
Delta 1) then inhibition of myogenesis was observed. Pharmacologic targeting of 
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Notch pathway by blocking proteolytic cleavage of notch using y-secretase inhibitor 
relieved repressive effects of Sbnol. In this study, we also showed that the ligand-
induced Notch signaling activates the Sbnol, a notch downstream effector, leading 
to inhibition of MEF2 mediated myogenic differentiation by an increased 
expression of Sbno 1. We also provided evidence that overexpression of Sbno 1 in 
C2C 12 myoblasts results in impaired expression of muscle specific genes such as 
myogenin, MyoD, and MyHC. 
Our studies also suggest that Notch-Sbnol signaling may play a dual role in 
maintaining muscle progenitors during skeletal muscle development by suppressing 
myogenic differentiation. The mechanistic links between Notch signaling and the 
proliferation and differentiation of skeletal muscle cells are apparently governed by 
more than one mechanism. Finally present data illustrated that Sbno 1-Notch 
signaling may maintain the reserve cells population by promoting their self-renewal 
and inhibit their differentiation. The decreased proliferation and increased 
differentiation ofC2C12 cells, upon treatment of gamma secretase inhibitor, may be 
due to downregulation of Sbnol, the Notch downstream effector. Therefore, it may 
be suggested that Sbnol-Notch signaling play a critical role in the proliferation and 
differentiation of C2Cl2. Over-expression of activated Sbnol in myoblasts results 
in inhibition of differentiation into fusion-competent myoblasts. In addition, 
activation of the Notch-Sbno 1 signaling inhibits the myogenic factors such as 
MEF2D, MyoD and myogenin. Furthermore, Sbno 1 directly inhibits the 
transcriptional activity of MEF2. 
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Future work is still in progress to investigate the functional role of Sbno 1 in 
cardiac and neurogenic cells. Beyond doubt this study may help to understand the 
role of Sbno 1 in cardiac and neurogenic cells and also provide novel insight of 
Notch signaling pathway. Most importantly, a better understanding of MEF2 
interacting partner that, possibly, involve in the development of mammalian tissues 
through MEF2 regulation. 
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Chapter V 
Kriippel-like factor 6 (KLF6) promotes cell proliferation in skeletal 
myoblasts in response to TGFp!Smad3 signaling 
Published in "Skeletal Muscle" 
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Rationale: 
Our previous study documented KLF6, as a novel MEF2D target gene, 
involved in hippocampal neuronal survival. MEF2D is a key transcriptional 
regulator of muscle differentiation. Furthermore, TGF~ is a potent inhibitor of 
myogenic differentiation by maintaining myoblasts in a proliferative state 
(undifferentiated myoblasts). Previous reports indicated that TGF~ and KLF6 
regulate each other's expression in other cell types, we therefore sought to 
investigate the possible role of KLF6 in a myogenic context and assessed whether 
TGF~ activation regulated KLF6 protein expression and function in C2C12 
myoblasts. 
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Abstract 
Kriippel-like factor 6 (KLF6) is a key MEF2D target gene involved in neuronal 
cell survival. Since MEF2D also fulfills a crucial role in skeletal myogenesis, we 
wanted to identify whether KLF6 also functions in a myogenic context. MEF2D 
and KLF6 are co-localized in the nucleus of myogenic cells suggesting that KLF6 is 
a MEF2 target gene in these cells which was confirmed in reporter gene assays 
using the KLF6 promoter. In non-myogenic cells TGFP and KLF6 have been shown 
to regulate each other's expression and, in view of TGFP' s potent effect on survival 
and proliferation of myoblasts, we assessed whether TGFP activation regulated 
KLF6 protein expression and function in C2C 12 myoblasts. Indeed, TGFP potently 
enhanced KLF6 protein levels and this effect was repressed by pharmacological 
inhibition of Smad3. Mutation analysis revealed that activation of the KLF6 
promoter by TGFP was dependent on a MEF2 cis element. Interestingly, 
pharmacological inhibition of MEK/ERK(l/2) signaling resulted in re-activation of 
the differentiation program in myoblasts treated with TGFp, which is ordinarily 
repressed by TGFP treatment. Conversely, MEK/ERK (1/2) inhibition had no 
effect on TGFP induced KLF6 expression whereas Smad3 inhibition negated this 
effect, together supporting the existence of two separable "arms" of TGFP signaling 
in myogenic cells. Loss of function analysis using siRNA mediated KLF6 depletion 
resulted in enhanced myogenic differentiation whereas TGFP induced myoblast 
proliferation was reduced in KLF6 depleted cells. Collectively these data implicate 
KLF6 in myoblast proliferation and survival in response to TGFP with 
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consequences for our understanding of muscle development and a variety of muscle 
pathologies. 
Background 
KLF6 is a member of the Krilppel-like Factors (KLF) gene family which are a 
group of transcription factors that contain three highly conserved Cys2-His2 type 
zinc fingers invariably located in the C-terminus (Schuh et al. 1986; Kaczynski et 
al. 2003). Subsequently, these proteins regulate a vast range of target genes by 
preferentially binding to cognate GC-boxes or CACCC elements. KLF6 was 
originally identified due to its ability to regulate TAT A-less gene promoters that 
can regulate glycoproteins in placental cells (Koritschoner et al, 1997) Since then, 
KLF6 has been found to be expressed in most tissues including neuronal, hindgut, 
heart and limb buds (Matsumoto et al. 2006) and is localized in the nucleus (Shields 
& Yang, 1997). Interestingly, homozygous null KLF6 mice resulted in failure in the 
development of the liver and yolk sac vasculature, resulting in early lethality at (E) 
12.5 (Matsumoto et al. 2006). To date, the most well established target gene of 
KLF6 is TGFP and its receptors (Kojima et al. 2000) and subsequent studies have 
shown a positive feedback loop by which TGFP activation enhances KLF6 
transactivation properties through the formation of a Smad3-Spl-KLF6 protein 
complex (Botella et al. 2009). TGFP and KLF6 cooperatively regulate a wide range 
of cellular processes such as cell differentiation, proliferation and epithelial-to-
mesenchymal transitions (EMT) (Haldar et al. 2000; Holian et al. 2008). Recently 
KLF6 was identified as a MEF2 target gene that is involved in neuronal cell 
230 
survival (Salma & McDermott, 2012). Since TGF~ and MEF2 are two key 
regulators of skeletal myogenesis and since KLF6 was identified in the myogenic 
transcriptome (Blais et al. 2005), we wanted to investigate the role of KLF6 in 
skeletal muscle cells. 
Regulation of skeletal myogenesis is a complex process. Initially paracrine 
factors instigate the migration of designated myotome progenitor cells to the 
dermomyotome region of the somite. These proliferating cells grow and divide until 
cell contact triggers differential gene expression and activation of the myocyte 
enhancer factor 2 (MEF2) proteins and muscle regulatory factors (MRFs). This 
cascade of events causes morphological changes in the progenitor cells that allow 
them to align and fuse to form multinucleated myotubes that can eventually 
spontaneously contract as functional muscle fibers. Transforming growth factor ~ 
(TGF~) antagonizes this process by preventing cells from exiting the cell cycle 
hence maintaining myoblasts in a proliferative state. TGFB ligands bind to a type II 
receptor which becomes activated and autophosphorylated (Luo & Lodish, 1997). 
The activated type II receptor can then phosphorylate and activate a type I receptor 
which in turn phosphorylates receptor mediated Smads(2/3) enabling them to 
dimerize with Smad4 and translocate into the nucleus where they can bind to other 
transcription factors and DNA to repress essential muscle genes and the expression 
of their downstream targets (Liu et al. 2001; Kollias & McDermott, 2008). In 
addition, TGFB also regulates the mitogen-activated protein kinase (MAPK) 
pathway, which involves a cascade of protein kinases (MAPKKK., MAPKK, 
MAPK) which become activated in sequence by G-proteins in response to TGF~ 
231 
binding its receptors (Pelicci et al. 1992; Yue & Mulder, 2000; Derynck & Zhang, 
2003). Upon TGF~ activation, MEKl/2 (MAPKK) can phosphorylate and activate 
ERK.1/2 MAPK at conserved TEY sites, causing it to translocate into the nucleus to 
regulate gene expression. These two TGF~ regulated pathways converge to inhibit 
the function of MEF2 and hence muscle specific genes (Liu et al. 2004) and, 
ultimately result in cell proliferation (Liu et al. 2001; Jungert et al. 2006). 
Not surprisingly inhibition of either or both of these pathways, (either 
pharmacologically or through ectopically expressed Smad7, which can antagonize 
the canonical Smad-pathway), enhances myotube formation (Kollias et al. 2006; 
Miyake et al. 2010). Cross-talk between these pathways is further supported by 
Smad7 antagonizing the repressive effects of MEKl on MyoD (Perry et al. 2001 
Miyake et al. 2010). 
In this report, our goal was to assess the role of KLF6 in myogenic cells based 
on its regulation by both MEF2D and TGF~. We report that TGF~ up-regulates 
KLF6 specifically through a Smad3-dependent pathway which enhances 
proliferation in myoblasts. In addition, we observed that (i) TGF~ enhanced KLF6 
promoter activation in a MEF2 site dependent manner and, (ii) that TGF~ recruited 
MEF2 to the KLF6 promoter region. TGF~ induction coupled with pharmacological 
inhibition of Smad3 repressed KLF6 expression and cell proliferation but, 
importantly did not re-activate the differentiation program which is potently 
repressed by TGF~ signaling. Conversely, TGF~ treatment coupled with 
pharmacological inhibition of MEKl/2, enhanced myotube formation but had no 
effect on KLF6 expression and function. Loss of function assays using siRNA for 
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KLF6 revealed that KLF6 is required for cell proliferation. These experiments tease 
apart two independent functions of TGF~ signaling in myogenic cells. One is a 
repressive effect on differentiation which is mediated by ERK activation; the other 
being an enhancement of proliferation which is dependent on Smad3 and KLF6. 
Methods 
Plasmids 
Expression plasmids for pcDNA3-MEF2D, pCMV ~-galactosidase (Du et al. 
2008; Perry et al. 2009) and, reporter gene constructs for 3TP-lux (Wrana et al. 
1992) MCK-Luc (Donoviel et al. 1996) MEF2-Luc (Quinn et al. 2001) pROM6 
~MEF2 (Salma & McDermott, 2012) have been previously described. KLF6 
reporter constructs pRM06 were generously provided by Dr. Nicolas P. 
Koritschoner (Faculty of Bioquimica y Ciencias Biologicas, Universidad Nacional 
del Litoral, Santa Fe, Argentina). 
Antibodies 
Anti-MEF2A rabbit polyclonal, anti-Myosin heavy chain mouse monoclonal 
and anti-Myogenin mouse monoclonal antibodies were produced with the assistance 
of the York University Animal Care Facility; anti-MEF2D (1:1000; BD 
Biosciences); Smad3, phospho-Smad3 and phospho-ERK.1/2 (1 :1000; Cell 
Signaling); Klf6, actin, ERKl/2 (1: 1000; SantaCruz) were used for immunoblotting 
experiments. IgGs were also purchased from Santacruz Biotechnologies. 
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Cell culture, transfections and drug treatments 
C2C12 cells were maintained in DMEM supplemented with 10% fetal bovine 
serum (HyClone ), 1 % L-glutamine and 1 % penicillin-streptomycin. Cells were 
maintained in a humidified, 37°C incubator with a 5% C02 atmosphere. For 
transfections, cells were seeded on pre-gelatin coated plates 1 day prior to 
transfection and transfected according to the standard calcium phosphate method 
previously described by Perry et al., 2001. A mixture of 50µ12.5M CaCh per 25µg 
DNA with an equal volume of 2x HeBS (2.8M NaCl, 15mM Na2HP04, 50mM 
HEPES, pH=7.15) was used and the cells were and incubated overnight followed by 
washing and addition of fresh media. Drugs treatments were used at the following 
concentrations: 2ng/ml TGF~, 5 µM Sis3 and IOµM UO 126 as indicated. 
siRNA gene silencing 
Small interfering RNAs (siRNA) targeting Klf6, MEF2D and non-specific 
scramble RN A were purchased from Sigma. Transient transfections were performed 
using TurboFect Transfection Reagent (#R0531, Fermentas) according to the 
manufacturer's instructions. TurboFect (Fermentas): A 1:2 mixture ratio of DNA to 
turboFect reagent (including 4ng/ml siRNA) in 200µ1 serum-free DMEM was 
prepared for 19 hours incubation. 
lmmunocytochemistry 
C2C 12 cells were treated as previously described by Salma and McDermott, 
2012 [14] and, incubated overnight with at 4°C with primary MEF2D and Klf6 
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antibodies (1: 100) diluted in 1.5% goat serum. Cells were washed 3X with PBS for 
1 Omin and incubated with the appropriate TRITC/FITC-conjugated secondary 
antibodies (1:500) in 1.5% goat serum (PBS) for 2h at RT following DAPI (4',6-
diaminidino-2-phenylindole) staining for 15min at RT. Cells were washed 3X with 
PBS and cover slips were mounted with DAKO mounting media (Dako) on glass 
slides. The fluorescence images were captured using Fluoview 300 (Olympus). 
Protein extractions, immunoblotting and reporter gene assays 
Cells were harvested using an NP-40 lysis buffer (0.5% NP-40, 50mM Tris-
HCl [pH 8.0], 150mM NaCl, lOmM sodium pyrophosphate, lmM EDTA [pH 8.0], 
O. lM NaF) containing 1 Oµg/ml leupetin and aprotinin, 5µg/ml pepstatin A, 0.2mM 
phenylmethylsulfonyl fluoride and 0.5mM sodium orthovanadate. Protein 
concentrations were determined using the Bradford method (Bio-Rad) with bovine 
serum albumin (BSA) as a standard. 20µg of total protein extracts were used for 
immunoblotting, diluted in sample buffer containing 5% ~-mercaptoethanol and 
boiled. Transcriptional assays were done using luciferase reporter plasmids. The 
cells were harvested for these assays using 20mM Tris, (pH 7.4) and 0.1 % Triton-X 
100 and the values obtained were normalized to ~-galactosidase activity expressed 
from a constitutive SV 40 driven expression vector and represented as relative light 
units (RLU) or in some cases corrected Luciferase values for control, reporter alone 
transfections were arbitrarily set to 1.0, and fold activation values were calculated. 
Bars represent the mean (n=3) and error bars represent the standard error of the 
mean (n=3). 
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Coimmunoprecipitation assays 
Protein extracts were prepared as described above. Immunoprecipitaion was 
performed using the ExactaCruz kit (SantaCruz Biotechnology), as per 
manufacturer's instructions. Precipitated proteins were separated by SDS PAGE 
and immunoblotting of proteins was performed as described above 
Chromatin Immunoprecipitation (ChIP) 
ChIP experiments followed the guidelines set by EZ ChIP™ (Upsate) with 
minor modifications. Approximately 1 x 10 7 C2C 12 cells were fixed with 1 % 
formaldehyde (Sigma) for 15 minutes at 37°C. Fixing was quenched by Glycine 
(Bioshop) at a final concentration of 0.125M. Cells were collected in PBS 
containing PMSF (Sigma) and protease inhibitor cocktail (Roche). Cells were 
pelleted at 5000 rpm for 5 min at 4°C. Nuclei were treated with Wash Buffer I 
(lOmM HEPES pH 6.5, 0.5M EGTA, lOmM EDTA, 0.25% Triton X-100, protease 
inhibitor cocktail, PMSF) for 5 minutes on ice. Nuclei were collected and 
resuspended in Wash Buffer II (lOmM HEPES pH 6.5, 0.5 mM EGTA, 1 mM 
EDTA, 200 mM NaCl, protease inhibitor cocktail, PMSF) for 10 min on ice. Nuclei 
were again collected and then treated with lysis buffer (50mM Tris-HCl pH 8.1, 10 
mM EDT A, 1 % SDS). Chromatin was sheared using Misonix X at 3 x 1 Os (power 
8) to produce 500 bp fragments. Crosslinked sheared chromatin was collected 
following a 15 minute spin at maximum speed. 20% of total chromatin was set 
aside as input. Sheared crosslinked chromatin was diluted 1: 10 with IP dilution 
buffer (0.01% SDS, 1.1% Triton-X 100, 1.2 mM EDTA, 16.7 mM Tris-HCL pH 
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8.1, 167 mM NaCl) and incubated with antibody overnight at 4°C with rocking. 
Protein G Dynabeads (Invitrogen) were blocked with 20 ug salmon sperm DNA in 
IP dilution buffer (15 ul beads + 135 ul IP dilution buffer+ 20 ug salmon sperm 
DNA per IP) overnight at 4°C with rocking. 152 ul of pre-blocked beads were 
incubated with the IP reaction at 4°C for 1 hr. Dynabead-bound antibody:chromatin 
complexes were washed using IP Wash Buffer I (20 mM Tris pH 8.1, 2mM EDTA, 
150 mM NaCl, 1 % Triton-X 100, 0.1 % SDS) and II (20 mM Tris pH 8.1, 2 mM 
EDTA, 500 mM NaCl, 1 % Triton X-100, 0.1 % SDS), each incubated for 10 
minutes at 4°C, and followed with two washes in TE buffer at 4°C. Protein:DNA 
complexes were freed from Dynabeads through the addition of elution buffer (0.1 
M NaHC03, 1 % SDS) for 30 minutes at room temperature. To separate protein 
from DNA samples were treated with 12 ul of 5 M NaCl (BioShop) at 65°C for 4 
hours to overnight. Protein was further degraded by the addition of Proteinase K 
(Sigma), EDTA, Tris pH 6.5 for 1 hr at 45°C. Samples were then purified using a 
PCR clean up kit (Qiagen). 
ChIP-qPCR 
ChIP-qPCR analysis on the KLF6 promoter was done using BioRad Sybr 
Green as per the user manual with a final primer concentration of 0.5 uM. 
Antibodies used in ChIP: MEF2 (Santa Cruz, sc-313X, Dll 12; 5 ug), H3K9ac 
(Abeam, X; 2 ug). Primers flanking the ME2 site on the KLF6 promoter are: 5' -
CTGCAACGTTGGGCTGT A-3' and 5 '-TTGGAAAGACGTCTCACAGG-3'. 
Data were analyzed using percent input or fold enrichment. 
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Results and Discussion 
MEF2D and KLF6 expression and co-localization in the nucleus, in skeletal 
myoblasts. 
Since KLF6 was identified in the skeletal muscle transcriptome (Blais et al. 
2005) and has since been shown to be a MEF2D target gene that is involved in the 
cell survival pathway in primary embryonal hippocampal neurons (Salma & 
McDermott, 2012) and, since MEF2D is also a crucial regulator of skeletal 
myogenesis, we wanted to investigate the role of KLF6 in skeletal myoblasts. We 
determined that KLF6 and MEF2D are indeed both co-expressed in C2C12 
myoblasts and, co-localized in the nucleus using western blot analysis and 
immunocytochemistry respectively (Figures 43A and B). Endogenous expression of 
KLF6 is detected in C2C 12 myoblasts in growth conditions and sustained upon 
serum withdrawal and throughout the course of myogenic differentiation up to 
120h. Interestingly, we observed that KLF6 protein expression is down regulated at 
48h, up regulated at 72h, down regulated at 96h and up-regulated again at 120h in a 
manner that is not easily explainable (Fig. 43A). Immunofluorescence labeling was 
conducted in order to observe the cellular localization of KLF6 with respect to 
MEF2D in proliferating myoblasts and then in differentiated myotubes. The data 
indicated strong nuclear localization of both KLF6 (red) and MEF2D (green) in 
conjunction with nuclear (blue) 4' ,6-diaminidino-2-phenylindole (DAPI) staining in 
myoblasts and, less so in differentiated myotubes (Fig. 43B). Since TGF~ has also 
been shown to regulate KLF6 expression, we tested the effect of TGF~ on 
previously characterized KLF6 promoter constructs (pROM6-Luc and pROM6-Luc 
238 
~MEF2). Serum was withdrawn 24h after transfection and treated with 2ng/ml 
TGF~ for 24h as indicated in the figure. The data indicates a 4-fold increase in 
transcriptional activity of pROM6-Luc in response to TGF~ treatment, but no effect 
on pROM6-Luc ~MEF2, indicating that TGF~ regulates the KLF6 promoter 
through the MEF2 cis element (Figure. 43C). 
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Figure 43: (A) Western blot analysis reveals that KLF6 and MEF2D are co-
expressed in C2C12 myoblasts. Myoblasts were cultured in growth medium (10% 
serum), followed by serum withdrawal (2%) for 144h and harvested at 24h time 
intervals. Cells were then lysed and equal amounts of protein (20µg) were used for 
western blot analysis. The levels of the indicated proteins were assessed by a 
standard immunoblotting technique using specific primary antibodies for each. 
Actin was used as a loading control. (B) Immunocytochemistry reveals that KLF6 
and MEF2D are co-localized in the nucleus at the myoblast stage but to a lesser 
extent in differentiated myotubes. C2C 12 cells were treated as previously described 
by Salma and McDermott, 2012. DAPI staining was used for nuclear staining, green 
and red were used for MEF2D and KLF6 respectively and then merged. (C) TGF~ 
treatment potentiates KLF6 promoter region through MEF2. KLF6 promoter 
constructs (pROM6 Luc and pROM6 ~MEF2 Luc) were used, and luciferase 
activities were analyzed upon serum withdrawal, with and without 2ng/ml TGF~ 
treatment as indicated 
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MEF2A/D expression is not required for KLF6 protein expression in skeletal 
myoblasts 
Since we had already observed that TGFP regulates the KLF6 promoter 
through MEF2 we wanted to assess the effect of MEF2A/D knock down using RNA 
silencing and observed an overall effect on KLF6 protein expression levels (Figure. 
44A). Although siRNA2 for MEF2A appears to affect KLF6 expression slightly, 
this observation did not indicate a strong and consistent effect. On the other hand, 
siMEF2D appears to de-repress KLF6 expression. Since MEF2D is a potent 
HDAC4 co-factor, siMEF2D might be preventing the recruitment of HDAC4 to the 
promoter and hence de-repressing KLF6. Contrary to our initial hypothesis, these 
data indicate that MEF2 is not necessarily required for KLF6 expression, or that its 
requirement is only at the myoblast stage when the cells are responsive to TGFP 
signaling. To further corroborate this observation, we looked at MEF2 recruitment 
on the KLF6 promoter with or without TGFP treatment (Figure 44B). The data 
indicates that whilst MEF2 is indeed recruited to the KLF6 promoter in C2C 12 
myoblasts, there is no change in MEF2 recruitment upon TGFP treatment with 
respect to the control, implicating a different mechanism for TGFP activation of 
KLF6. 
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Figure 44: (A) MEF2A/D RNA silencing reveals that MEF2A/D expression is not 
required for endogenous KLF6 protein expression. In contrast siMEF2D appears to 
de-repress endogenous KLF6 protein levels. (B) Chromatin immunoprecipitation 
analysis of MEF2 recruitment onto the KLF6 promoter revealed no change upon 
TGF~ treatment. 
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TGFP regulates KLF6 through a Smad3 specific pathway and inhibits skeletal 
myogenesis through MEK/ERK specific pathway 
Since Smad3 is activated in proliferating myoblasts and is also regulated by 
TGF~, we observed that Smad3, along with MEF2 and KLF6 are co-expressed in 
skeletal myoblasts (Figure. 45A). To further investigate the effect of TGF~ on 
KLF6 we used well documented pharmacological inhibitors of the Smad and ERK 
MAPK pathways. We tested the effect of TGF~ on KLF6 protein expression in 
C2C12 myoblasts in the presence and absence of a Smad3 inhibitor, Sis3 (Figure. 
45B). The data in Fig. 45B reveal that indeed TGF~ treatment increases KLF6 
protein levels and this corresponded with a decrease in myogenin as an indicator of 
myogenic differentiation. Interestingly, pharmacological inhibition of Smad3 with 
5 µM Sis3 reduced TGF~ induced KLF6 protein expression but had no effect on 
myogenin. This indicates that TGF~ regulates KLF6 and myogenin through two 
distinct pathways. Smad2/3 and phospho-Smad2/3 antibodies were used as positive 
controls for Sis3 treatment since Sis3 inhibits Smad3 phosphorylation and hence its 
translocation into the nucleus (Jinnin et al. 2006). Since TGF~ also regulates the 
MEK/ERK (1/2) MAPK pathway we wanted to test the effect of pharmacological 
inhibition of that pathway on KLF6 using 1 OµM UO 126. The data summarized in 
Figure. 45C confirms that TGF~ induces KLF6 protein expression while inhibiting 
myotube formation (using sarcomeric myosin heavy chain expression as an 
indicator). In this experiment Smad3 inhibition repressed TGF~ induction of KLF6 
but did not reverse the effects on MyHC (Figure. 45C). Strikingly, pharmacological 
inhibition of ERKl/2 had no effect on KLF6 levels but instead rescued myotube 
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formation and MyHC expression, hence supporting the idea that TGFP regulates 
KLF6 and myogenic differentiation through Smad3 and ERKl/2 distinctively. 
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Figure 45: (A) Western blot analysis revealed that Smad3 and KLF6 are co-
expressed in C2C12 myoblasts. Myogenin was used as a protein marker for 
differentiation and actin was used as a loading control. Pharmacological 
manipulation of TGFP signaling pathway reveals that TGFP regulates KLF6 protein 
expression through Smad3 but not MEK/ERK MAPK. (B) Western blot analysis 
indicates that 2ng/ml TGFP treatment elevates KLF6 protein expression and that 
this effect is abrogated in the presence of 5 µM specific inhibitor of Samd3, Sis3. 
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TGFB treatment also inhibited myogenic differentiation marker, myogenin protein 
expression levels and, this effect was not abrogated by Sis3. (C) Western blot 
analysis revealed that TGFB treatment enhances KLF6 expression through Smad3 
but not ERKl/2 MAPK and that TGFB treatment repressed myogenic 
differentiation through ERKl/2 MAPK but not Smad3. lOµM U0126 was used as 
an inhibitor of the MEK/ERK MAPK pathway, 5 µM Sis3 was used for Smad3 
inhibition and 2ng/ml TGFB were all used as indicated. Actin was used as a loading 
control. 
TGFP induces cell proliferation in C2C12 myoblasts through KLF6 
Since TGFB represses skeletal myogenesis by retaining cells in a proliferative 
state, we wanted to test the effect of KLF6 mRNA silencing using siRNA mediated 
gene silencing. siRNA3 was chosen as the most efficient in knocking down KLF6 
expression based on Fig. 46 A. Subsequent KLF6 silencing resulted in increased 
MyoD and myogenin protein expression (Figure. 46B; upper panel) and this 
corresponded with a 2.5 fold increase in muscle creatine kinase (MCK) promoter 
activity indicating, as predicted, that KLF6 is anti-myogenic (Figure. 46B; lower 
panel). Furthermore, an MTT cell proliferation assay was performed, and the data 
showed that a 24h, 2ng/ml TGFB treatment doubles the number of proliferating 
cells (Figure. 46C). This effect is negated upon KLF6 gene silencing thus 
implicating KLF6 in the proliferative response to TGFB signaling. In support of 
this, siKLF6 on its own reduced the number of proliferating cells indicating a 
functional role in proliferation of skeletal myoblasts (Figure. 46C). 
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Figure 46: KLF6 RNA silencing reveals that (A) KLF6 protein expression was 
successfully repressed, particularly by siRNA3 which was used in subsequent 
experiments. (B) KLF6 RNA silencing resulted in (i) increased MyoD and 
myogenin protein levels, (ii) enhanced MCK Luciferase activity and, (iii) reduced 
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TGF~ induced cell proliferation. (C) Cell proliferation was measured using the 
MTT cell proliferation assay kit. The number of proliferating cells is directly 
proportional to the absorbance at 570nm. TGF~ treatment doubled the number of 
proliferating cells and this effect was repressed with KLF6 silencing. (D) A 
schematic summary of the data presented, in which TGFp!ERK signaling represses 
myogenic differentiation while TGFp!Smad signaling regulates KLF6 gene 
expression and myoblast proliferation. 
Conclusions 
In this study we report a novel role for KLF6 in skeletal myoblasts. Based on 
our data we propose that KLF6 is a downstream effector of the TGFp!Smad3 
pathway that regulates cell proliferation in skeletal myoblasts. We identify Smad3 
as a key regulator of KLF6 expression, through TGF~. In addition we were able to 
functionally distinguish between the TGFp!Smad and TGFp!MAPK pathways in 
that TGF~ inhibits skeletal myogenesis through the MEK/ERK (1/2) MAPK 
pathway and concomitantly enhances cell proliferation through Smad3 mediated 
induction of KLF6 expression. Our findings are summarized in figure 46 D. Many 
myopathies and muscle loss disorders have been linked with increased TGF~ 
signaling (Burks & Cohn, 2011) and hence, our findings identify KLF6 as a 
potential therapeutic target for such pathological conditions as well as for cancers 
such as embryonal rhabdomyosarcoma where TGF~ promotes cell proliferation 
(Bouche et al. 2000). 
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Chapter VI: Summary 
Collectively, the goal of these studies was to further define the role of MEF2 
in myogenic and neurogenic cells. MEF2s are tightly regulated via posttranslational 
modifications, directly targeted by phosphorylation or through association with 
particular co-activators/repressors. Dissecting components of key posttranslational 
modifications is an essential step in further understanding the complex role of 
MEF2 in developmental processes and phenotypes. Here our investigations 
highlight the complex and redundant mechanisms that regulate MEF2 proteins in 
myogenic and neurogenic cells, as presented in chapter Ill, IV, and V. 
MEF2 family members (MEF2 A, C, and D) are highly expressed in neurons 
and exhibit distinct patterns of expression in different regions of the brain. MEF2 
expression level is highest in the cerebral cortex, cerebellum and hippocampus and 
is required to regulate neuronal development and synaptic plasticity. In the 
mammalian nervous system, regulation of MEF2 is a crucial determinant of 
neuronal cell survival, and death. Phosphorylation by kinases is an important 
process through which the activity of MEF2 is up or down-regulated in various cell 
types. Several kinases have been linked to muscle and neuronal development in part 
due to their modulation of MEF2 function. In Chapter III, we demonstrated that 
MEF2D is localized in the nuclear compartment of primary hippocampal neurons. 
Previous studies from our lab and others reported that MEF2D is directly targeted 
by PKA (Belfield et al. 2006; Du et al. 2008). Here, we assessed whether cAMP 
signaling converges on the pro-survival role of MEF2D in hippocampal neurons. 
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We observed that experimental induction of cAMP /PKA signaling promotes 
apoptosis in primary hippocampal neurons as indicated by TUNEL and F ACS 
analysis. MEF2 protects neurons from apoptotic cell death, which contrasts with its 
pro-apoptotic function in other cell types such as T-cells. The ability of MEF2 to 
regulate neuronal specific transcriptional programs occurs through activation of 
MEF2 survival genes. In this study we identified that cAMP-dependent protein 
kinase (cAMP/PKA) signaling negatively regulates MEF2D function in neuronal 
cells suggesting the importance of MEF2D in neuronal gene expression. Luciferase 
reporter gene assays revealed that PKA potently represses MEF2D trans-activation 
properties in neurons. This effect was largely reversed by engineered neutralizing 
mutations of PKA phospho-acceptor sites on MEF2D (S121/190A). For the first 
time we characterised a MEF2D target gene named Knippel-like factor 6 (KLF6) as 
a critical survival gene. siRNA mediated of suppression KLF6 expression promotes 
neuronal cell death and antagonizes the pro-survival role of MEF2D in primary 
hippocampal neurons. In addition, we observed nucleo-cytoplasmic shuttling of 
HDAC4 in the presence of activated protein kinase A and PKA signaling prevents 
HDAC4 export from the nucleus resulting in suppression of MEF2 mediated gene 
transcription. In this study, we found that PKA signaling promotes the formation of 
HDAC4/MEF2 repressor complexes by increasing the levels of HDAC4 in the 
nuclear compartment leading to downstream repression of key MEF2 target genes 
involved in neuronal survival such as KLF6. Based on our current observations and 
experimentations, we suggest that there is a bi-partite mechanism regulating MEF2 
mediated gene expression: by direct phosphorylation; and increased physical 
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association with HDAC4 which together contribute to PKA-mediated inhibition of 
MEF2 activity and numerous biological processes. Overall, this chapter 
demonstrated that cAMP/PKA signaling events modulate gene expression by post-
translationally modifying MEF2 to control neuronal development in hippocampal 
neurons suggesting an important role for these proteins in the mammalian nervous 
system. 
In chapter IV, we tested ideas concerning how MEF2 controls diverse cellular 
processes in muscle development in the presence or absence of cofactors. 
Therefore, we initiated experiments to identify MEF2 interacting proteins by using 
Tandem affinity purification combined with mass spectrometry analysis. This 
approach has proven to be a useful proteomics tool to identify novel co-factor 
interactions of physiological relevance. These studies identified Strawberry notch 
1(Sbno1) as a novel interacting partner of MEF2D which is a previously 
documented downstream effecter of Notch signaling. Notch signaling regulates the 
balance between differentiation and maintenance of progenitor cells by inhibition of 
differentiation. Notch signaling is involved in blocking the expression and activity 
of the myogenic factors such as MEF2. Here we utilized C2C12 myoblasts which 
provide a useful in vitro model to study skeletal muscle differentiation to 
understand the role played by the Sbnol-MEF2 interaction. Western blot analysis 
indicated that exogenous Sbnol expression inhibits expression of myogenic 
markers. Sbno I also represses MEF2 trans-activation properties suggesting Sbno I 
plays a role in inhibition of skeletal muscle differentiation through targeting 
MEF2D. Since Sbnol is known as downstream effector of Notch signaling, we 
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focused on the detailed mechanism of myogenic inhibition by Notch-Sbno 1 
signaling. Here we report ectopic expression of Sbno 1 in C2C 12 myoblasts blocks 
terminal differentiation in myogenic cells and decreases expression of myogenic 
factors such as myogenin and Myosine heavy chain. Immunocytochemistry analysis 
revealed that Notch-Sbnol might be involved in maintaining "reserve" population 
in a differentiated muscle culture. Our data indicate that protein-protein interactions 
between Sbno 1 and MEF2D results in interference with the function of myogenic 
factors that repress skeletal muscle differentiation. Thus, we propose that Sbno 1 
serves as an important MEF2 cofactor, functioning to maintain a balance between 
committed myogenic differentiated cells and "reserve" progenitor population. 
Lastly, Chapter V documents a role of MEF2D target gene, KLF6, in skeletal 
muscle development. In the previous study (chapter III) we documented that KLF6 
is involved in hippocampal neuronal survival and is a MEF2 target gene. TGFp, a 
potent inhibitor of myogenic differentiation, maintains myoblasts in a proliferative 
undifferentiated state. Previous studies documented that together TGFP and KLF6 
regulate each other's expression in other cell types. Therefore we sought to 
investigate the possible role of KLF6 in a myogenic context and assessed whether 
TGFP activation regulates KLF6 protein expression and function through MEF2 in 
C2C 12 myoblasts. We observed that TGFP enhanced KLF6 protein expression 
levels in myogenic cells and this effect was repressed by pharmacological inhibition 
of Smad3. Collectively these results illustrated that TGFP enhances skeletal muscle 
cell proliferation and survival through KLF6 in response to TGF p. 
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Figure 4 7. A schematic summary of regulation of MEF2 in Myogenic and 
neurogenic cells. 
In conclusion, we report that differential activation of signaling cascades and 
co-factors regulate the MEF2 transcriptional complex and subsequently MEF2 
dependent gene expression in myogenic and neurogenic cells (Figure 4 7). It is 
established now that cAMP/PKA signaling pathway regulates diverse cellular 
functions and biological processes including muscle differentiation and neuronal 
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survival. This pathway may also represent a mechanism by which cAMP/PKA 
signaling modulates human diseases such as cardiac hypertrophy. Since KLF6 is 
identified as a pro-survival MEF2 target gene in neurons, future work will focus on 
characterizing whether KLF6 plays a corresponding role in development of skeletal 
or cardiac muscle. Here, we speculate that cAMP /PKA could be involved in 
regulation of the MEF2 mediated gene expression in cardiac tissues. Thus, 
understanding the cAMP /PKA signaling and its role in MEF2 function in cardiac 
cell survival and death will be useful to the field of cardiac biology. It will also be 
of interest to examine the role of Notch-Sbno 1 signaling in other cell types such as 
neurons and cardiac cells. Notch signalling pathway plays an important role in the 
development and maintenance of the nervous system at many different levels. 
Notch is required for normal neurites morphology, synaptic plasticity, and memory 
processing. Further analysis of the exact role that Notch-Sbno 1 plays in neural 
development will not only provide insights into neurobiology and underlying 
mechanisms regulating these cells but also provide potential pharmacological 
targets with implications for neurodegenerative diseases. 
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Appendix: Materials and Methods 
Cell Culture 
The following cell lines were utilized in the aforementioned studies, C2C 12, Cos7 
and rat hippocampal neuronal primary cultures. What follows are general cell culture 
guidelines, recommendations by A TCC were also adhered to. 
Reagents: 
1. IX Dulbecco's PBS (without Ca2+) 
NaCl 8 g 
KCl 0.2 g 
Na2HP04 7H20 I.44 g 
KH2P04 0.24g 
Add 800 mL ddH20 
pH to 7.4 with HCl 
take to volume 1 L 
2. Versene 
EDTA 0.2 g 
IX Dulbecco's PBS (without Ca2+) I L 
3. O.I25% Trypsin-EDTA 
4. 1 % penicillin/streptomycin 
5. 10% FBS (GM= Growth Medium) 
Fetal bovine serum (FBS), heat inactivated at 56° for 30 minutes. 
DMEM 
Penicillin/streptomycin 
6. 5% HS (DM=Differentiation Medium) 
Horse serum (HS), heat inactivated at 56° for 30 minutes. 
DMEM 
Penicillin/streptomycin 
Freezing medium: 
Growth media (10%FBS) in which the cells are normally cultured, 
supplemented with 10% DMSO; sterilize the freezing medium by passing 
thr_ough a 0.2um filter. 
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Thawing Frozen Cells 
Materials 
1. Vial of frozen cell stock 
2. 10% FBS (Growth Medium) 
Method 
1. Remove the vial from -80°C freezer/ liquid-nitrogen and thaw in 3 7 °C 
2. Dissociate clumps of cells using a sterile glass pasteur pipette. 
3. Transfer the cell suspension to a centrifuge tube containing 5 ml of 10% 
FBS medium. 
4. Centrifuge for 10 minutes at 1500 x g. 
5. Aspirate the supernatant and agitate tube vigorously to remove cell clumps 
6. Resuspend cells in 1 Oml of 10% FBS (Growth medium). 
7. Count cells in haemocytometer 
8. Seed cells at appropriate dilution (106 cells/100 mm dish in 10 ml of growth 
medium). 
Passaging of Adherent Cells 
1. Remove medium from established cell stock. 
2. Rinse the cell monolayer with 5ml Versene to remove any traces of serum. 
3. Add 1.0 ml of0.125% Trypsin-EDTA to 100 mm dish. 
4. Incubate at 3 7°C for 1-4 minutes. 
5. Inactivate the trypsin by adding 9 mL of 10% FBS (GM) and triturate cells 
several times (pipette the cells up and down) to ensure complete removal of 
the cells from the dish and to dissociate clumps of cells. 
6. Count cells in a haemocytometer and seed the cells at the appropriate 
dilution in GM. 
Freezing Cells 
Materials 
1. dimethylsulfoxide (DMSO) 
2. freezing vials 
3. freezing chamber- polystyrene foam box 
4. freezing medium 
Method 
1. Prepare a cell suspension and pellet the cells by centrifugation at 1500 x g. 
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2. Resuspend the cells in freezing medium at a concentration of 1x106 - 8x 106 
cells/ml 
3. Dispense 1 ml of cell suspension into each freezing vial. 
4. Place the vials in the polystyrene box. 
5. Place the box into a -80°C freezer and freeze overnight. 
6. Store vials in -80°C freezer for short term (1-3 months) 
7. Store vials under liquid nitrogen for long term cell stock storage. 
Preparation of primary hippocampal neuron culture 
Materials 
1. Pregnant female rats (Sprague-Dawley) at gestational day 18 (E18) 
2. 95% ethanol 
3. HBSS (Hanks balance salt solution) 
4. Neurobasal Medium 
5. B-27(2ml/100 ml) 
6. L-Glutamine (lml/100 ml) 
7. High-glucose MEM/10% (v/v) FBS 
8. Trypsin solution 
9. Poly-D-lysine coated coverslips 
10. Poly-D-lysine coated 6 well dishes/1 Ocm cell culture plates 
11. 0.04% (w/v) trypan blue 
12. Hemacytometer for cell counting 
13. Dissecting tools, sterile: 
14. Stainless steel scissors 
15. Curved forceps (2 pairs) 
16. Dumont forceps, 
1 7. Dissecting microscope 
18. Anesthetizing chamber connected to a C02 tank 
Embryo Isolation Protocol 
(Approved by Animal Care and Use Committee, York University) 
1. Anesthetize the pregnant rat in an anesthetizing chamber filled with C02. 
2. Sacrifice a pregnant female rat (E 18) by cervical dislocation. 
3. Place rat, ventral side up and sterilize the abdomen with 95% ethanol. 
4. Rinse forceps and scissor in 95% ethanol. 
5. Make an incision down the midsection to expose uterine horns. 
6. Gently grasp uterine horns at one of the constrictions and remove horns. 
7. Pull embryos and uterine horns away from amniotic sac. 
8. Place embryos in a 100-mm Petri dish filled with HBSS. 
9. Working under the dissecting microscope, gently isolate hippocampi. 
10. Add trypsin solution, shake gently and incubate for 5 min at 37°C. 
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11. Inactivate the trypsin by adding 5 mL HBSS and triturate several times 
12. Gently shake and allow the cells to pellet at the bottom of the tube. 
13. Determine the total cell number and viability with a haemocytometer and an 
inverted phase contrast microscope. 
14. Trypan blue is used to distinguish viable from dead cells. Viable cells 
exclude trypan blue while dead or damaged cells are stained (dark blue). 
15. Plate and incubate hipppocampal neurons culture in neurobasal medium at 
37°C humidified incubator with a 5% C02 in air. 
16. After 24 h replenish media. 
Transfection of Mammalian Cells with DNA 
Reagents: 
2X HEBS (2.8 M NaCl, 15mM Na2HP04, 50mM HEP ES) 
8.18 gNaCl 
5.95 g HEPES 
0.1065 g Na2HP04 (MW=142) or 0.201 g Na2HP04-7H20 
Add 400 ml ddH20, pH to 7.15, bring volume up to 500 ml, filter sterilize, 
store at -20 °C. 
2.5 M CaCI 2 
2.78 g CaCh (MW=l 11) 
Add ddH20 up to 10 ml, filter sterilize, store at -20 °C. 
Transient transfection of adherent cells with Calcium-phosphate 
Methods 
1. Seed cells 24 h prior to transfection (30-50% confluent at time of 
transfection). 
2. Refeed cells 2-3 hrs (C2C12) prior transfection with growth media. 
3. Calcium-phosphate-DNA precipitate (for 100 mm plate): 
label 15 mL sterile polystyrene tubes and add 500 µl 2 x HEBS to each tube. 
4. Prepare DNA-CaCh solution containing 50 µl 2.5 M CaCh and 20-30 µg 
total DNA in label sterile eppendorf (Total volume 500 µl), mix gently. 
5. While vortexing 2x HEBS at low speed add DNA-CaCh solution drop by 
drop. 
6. Incubate for 25-30 minutes at room temperature. 
7. Triturate the DNA precipitate and add DNA mix drop by drop to cell 
cultures. 
8. Incubate cells with DNA precipitate for up to 16 hours. 
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9. Wash cells 2X with PBS and re-feed with 10% FBS (growth media) 
10. Incubate cells in growth media for at least 8 h before experimentally 
treating cells. · 
11. For differentiation: remove GM and wash cells 2X with PBS and re-feed 
with 5% HS (DM) ( ....,80% confluent cells at time of change media to DM). 
12. Harvest Cells according to experimental time points. 
Transfection with Lipofectamine 
1. Seed cells at 80% confluence in 10 cm plates. 
2. Dilute 8 µg of DNA in 800 µl serum- and antibiotic-free media. 
3. Mix 20 µl of Lipofectamine reagent in 800 µl serum- and antibiotic-free 
media. 
4. Combine above, mix and incubate for 15 minutes (up to 45 minutes). 
5. Add 1.6 ml of serum- and antibiotic-free media to the mix. 
6. Re-feed cells in 3.2 ml of serum- and antibiotic-free media. 
7. Add the DNA/Lipo mix and gently rock. 
8. Incubate of 2 hours. 
9. Wash 2X in PBS and re-feed in growth media. 
Luc if erase assay. 
Reagents: 
Methods 
Luciferase assay Lysis buffer (20 mMTris, pH 7.4, 0.1% Triton-X 100), 
Luciferase substrate (Promega). 
1. Wash adherent cells 3X with ice-cold lXPBS. 
2. Add 300 µl oflysis buffer per well/dish (35mm). 
3. Incubate 15 minutes at 4 °C while rocking. 
4. Scrape cells with rubber policeman and collect into labelled eppendrof 
tubes. 
5. Spin-down cell debris at 15000rmp for lOmin. 
6. Transfer cell lysate into new tubes. 
7. Transfer 50/100 µl lysate to Luciferase assay tube. 
8. Use the Berthold luminometer to detect light units 
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P-Galactosidase Assay 
Reagents: 
ONPG (4 mg/ml in ddH20) 
Z buffer 
16.1 g Na2HP04-7H20 (60 mM) 
5.5 g NaH2P04-H20 (40 mM 
0.75 g KCl (10 mM) 
0.246 g MgS04-7H20 (1 mM) 
Add 800 ml ddH20, pH to 7, bring volume up to 1 L, filter sterilize, store at RT 
Reaction mix 
500 µl Z buffer/sample 
100 µl ONPG/sample 
2.74 µl ~-mercaptoethanol/sample 
Prepare fresh and mix well 
Prepare volume which is sufficient for all samples and blank to be read 
Methods 
1. Prepare reaction mixture (per sample (500 µl Z buffer, 100 µl ONPG, 2.74 
µl ~- mercaptoethanol)). 
2. Mix 600 µI of reaction mix with 100 µl of cell lysate 
2. Incubate tubes at 37 °C until a color change is apparent (yellow). 
3. Add 300 µl of lM Na2C03 to each tube to stop reaction. 
4. Measure absorbance of samples at 420 nm using spectrophotometer. 
Protein Extracts 
Reagents: 
Lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM Sodium vanadate, 1 
mM PMSF (add fresh) 
Protease inhibitor cocktail (add fresh, Sigma, P-8340), 
ice-cold lXPBS, 
2X SDS sample buffer (BioRad) (supplemented with ~-mercaptoethanol) 
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Methods: 
(Keep protein samples on ice at all times). 
1. Remove media and wash cells twice with ice-cold IXPBS. 
2. Add 700 µl PBS and gently scrape cells and transfer to a new tube. 
3. Centrifuge at 1500 xg for 5min. 
4. Remove PBS, and re-suspend the pellet with five times (vol/vol) lysis 
buffer. 
5. Vortex cells briefly every 10 min for 30 min on ice. 
6. Centrifuge cell lysate at 10,000 xg for 15 min, and transfer supernatant to 
new tube. 
7. Determine protein concentration by Bradford assay 
8. Dilute protein samples to equal concentration (0.5 µg/µ1- 2.0 µg/µl), with 
equal amounts 2 X SDS sample buffer added. 
9. Boil samples for 3-5 min, chill on ice for five minutes, store at - 80 °C. 
SDS-PAGE 
Reagents: 
10% Resolving gel (l 5ml) 
(5.9 ml ddH20; 3.8 ml I.SM Tris pH 8.8; 5 ml 30% acrylamide; 
O.I5 ml IO% SDS; O.I5 ml IO% APS; 0.006 ml TEMED) 
Stacking gel (4ml) 
(2. 7 ml ddH20; 0.5 ml I .O M Tris pH 6.8; 0.67 ml 30% acrylamide; 
0.04 ml IO% SDS; 0.04 ml IO% APS; 0.004 ml TEMED) 
JOX Laemmli (JL) 
ddH20 800 ml 
Tris 30.3g 
Glycine I44.2 g 
SDS IOg 
pH to 8.3; bring volume up to IL with ddH20 
JXPBS 
Methods: 
I. Prepare resolving gel and then top with stacking gel in Hoefer gel apparatus 
2. Fill bottom and centre well of mini-gel apparatus with IX Laemmli buffer. 
3. Load wells with equal amount of protein samples on a gel. 
4. Run a gel at 100 V through stacking and I20 V through running gel. 
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Western blotting 
Reagents: 
Transfer buffer (JOOml) Methanol 20ml; IX Laemmli 80ml 
(Prepare blocking buffer, washing solutions, ECL, and antibody diluent as per 
manufacturer's instruction). 
1. Soak Whatman paper and Immobilon-P (Millipore) membrane in transfer 
buffer for 5-15 min. 
2. After SDS PAGE, transfer protein from gel to Immobilon-P membrane by 
wet- transfer at 20 V for 16-18 hrs. 
3. Block membrane with 5 % (w/v) skim milk powder in lXPBS/TBS 
(blocking solution) for 1 hours at room temperature (RT) 
4. Incubate membrane with primary antibody (1: 1000 or 1: 10 000) in blocking 
solution for 1-16 hrs at 4 °C. 
5. Wash membrane with lXPBS/TBST (3X for 5 min each). 
6. Incubate membrane with secondary antibody (1 :2000 or 1: 100 000) in 
blocking solution for 1-2 hrs at RT. 
7. Wash membrane with PBS/TB ST (3 X 5 min each). 
8. Use chemiluminescence reagent (Amersham), and expose blot to film and 
develop. 
Co-lmmunoprecipitation 
1. Prepare cell lysates as described in protein extracts section. 
2. Prepare IP antibody-IP matrix complex: add 40-50 µl of suspended (25% 
v/v) IP matrix (ImmunoCruz™ IP/WB kit), 1-5 µg of primary antibody (IP 
antibody) and 500 µ1 of PBS. 
3. Incubate the complex at 4 °C for 1 h with gently agitation. 
4. Pellet immuno-complex by centrifugation at lOOOx g for 30 sec and discard 
supernatant. 
5. Wash pelleted matrix 2X with 500 µl of PBS. 
6. After the final wash, add lysis buffer and protein sample (250-500 µg of 
total cellular protein) to the palleted matrix and incubate at 4 °C on a rotator 
for O/N. 
7. After incubation, microcentrifuge at 1 OOOx g for 30 seconds at 4 ° C to pellet 
IP matrix, aspirate and discard supernatant. 
8. Repeat wahing step 2-4X with either RIPA buffer/PBS. 
9. Re-suspend pellet in 40 µl of 2 X SDS sample buffer and boil for 3 min. 
10. Sample analyze by westernblot analysis. 
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Immunofluorescence 
1. Wash cells 3X with cold PBS. 
2. Fix cells with 4 % paraformaldehyde in PBS for 10 min at RT. 
3. Wash cells 3X with PBS. 
4. Permeabilize cells with 0.3 % Triton-X in PBS. 
5. Block cells with 10 % goat serum in PBS at 37 °C for 30 min 
6. Incubate cells with primary antibody (1: 100 - 1 :500) at 4 °C for O/N. 
7. Wash cells 3X with PBS. 
8. Incubate cells with appropriate TRITC/FITC-conjugated secondary antibody 
(1 :500) directed against IgG from species the primary antibody was raised 
in, for 2 hours at RT. 
9. DAPI (4, 6-diamidino-2-phenylindole) staining for 15 min at RT. 
10. Wash cells 3X with PBS, add a drop of appropriate mounting media 
(DAKO), and cover slip. The fluorescence images are captured using a 
Fluoview 300 (Olympus) 
TAP Protocol for Mammalian Cells 
Reagents: 
Lysis buffer 
10 mM Tris-HCI, pH 8.0 
150 mMNaCl 
Protease inhibitor cocktail (Sigma) 
1 mMPMSF 
IPP150 
10 mM Tris-HCI, pH 8.0 
150 mMNaCl 
0.1% NP40 
TEV cleavage buffer 
10 mM Tris-HCl, pH 8.0 
150 mMNaCl 
0.1%NP40 
0.5mMEDTA 
lmMDTT 
IPP150 Calmodulin binding buffer 
69.4 µLI 100 ml ~-mercaptoethanol (add fresh) 
10 mM Tris-HCl, pH 8.0 
150mMNaCl 
1 mM Mg acetate 
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1 mM imidazole 
2mMCaCh 
0.1% NP40 
IPP150 Calmodulin elution buffer 
69.4 µLI 100 ml P-mercaptoethanol 
10 mM Tris-HCl, pH 8.0 
150 mMNaCl 
1 mM Mg acetate 
lmM imidazole 
2mMEGTA 
0.1% NP40 
lgG beads from Sigma (A2909): Washed with IPP150 buffer 
Calmodulin Beads from Stratagene (#214303): Washed with Calmodulin binding 
buffer (without P-mercaptoethanol) 
Methods: 
1. Transfect cells with TAP-protein expression vector. C2C12 (15= 100 mm 
plates) 
2. Harvest cells as directed in Preparing protein extracts. 
3. Add 40 µl of 50% IgG beads for every 1 ml oflysate (5 plates), rotate at 4 
°C for 2 h. 
4. Remove supernatant and wash beads 1 ml of IPPl 50 (all spins involving 
beads should be at 2000 g). Repeat. 
5. Wash beads in lml of TEV buffer. 
6. A~d 100 µl ofTEV buffer +2 µl (10 U) TEV protease (Gibco). 
7. Incubate at 16°C for 1.5 hours, mix occasionally. 
8. Briefly spin and transfer supernatant to new tube. 
9. Add 200 µl of TEV buffer to beads, spin, and combine this supernatant with 
the supernatant from the previous step. 
10. Add 900 µl of Calmodulin binding buffer+ 1 µl CaCh (2M) to supernatant. 
11. Add 20-40µ1of50% Calmodulin beads, rotate for lhour at 4 °C. 
12. Briefly spin and wash beads with 1 ml of CBB. Repeat twice. 
13. Add 25 µl of 2x SDS sample buffer to beads to recover protein complex. 
14. In-solution digestion of proteins for Mass spectrometry analysis 
Coomassie Stain: 
1. wash 3 x 5 min H20. 
2. stain 5-60 min in Gel Code Blue (Pierce). 
3. destain 1-24 hours in H20. 
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RNA Isolation 
1. Add 1 ml of Trizol to 100 - 35 mm dish, agitate for 5 min and then transfer 
solution to microfuge tube. 
2. Add 200 µl chloroform to cell suspension, vortex for 15 sec, and leave at RT 
for 2-3 min. 
3. Centrifuge samples at 12 OOOx g for 15 min at 4 °C. 
4. Transfer the aqueous phase to a fresh tube. 
5. Add 500µ1 of isopropanol to the aqueous phase and incubate at RT for 
10 min. 
6. Centrifuge samples at 12 OOOx g for 10 min at 4 °C. 
7. Following centrifugation, remove the supernatant and leave pellet. 
8. Wash RNA pellet with 70% ethanol. 
9. Centrifuge samples at 7500x g for 5 min at 4 °C. 
10. Remove supernatant and air dry for 5-10 min. 
11. Dissolve the pellet in 25-50 µl of DEPC-treated water by heating at 70°C 
for 5 minutes 
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